He	O
moved	O
to	O
London	location-GPE
where	O
he	O
became	O
a	O
surgeon	O
,	O
specialising	O
in	O
abdominal	other-medical
surgery	other-medical
,	O
at	O
the	O
London	building-hospital
Hospital	building-hospital
in	O
the	O
late	O
19th	O
and	O
early	O
20th	O
century	O
.	O

Dialysis	other-medical
is	O
seen	O
only	O
as	O
a	O
temporary	O
measure	O
for	O
children	O
compared	O
with	O
renal	other-medical
transplantation	other-medical
because	O
this	O
enables	O
the	O
best	O
chance	O
of	O
rehabilitation	O
in	O
terms	O
of	O
educational	O
and	O
psychosocial	O
functioning	O
.	O

The	O
authors	O
of	O
the	O
American	art-writtenart
College	art-writtenart
of	art-writtenart
Chest	art-writtenart
Physicians	art-writtenart
Updates	art-writtenart
on	art-writtenart
Cough	art-writtenart
Guidelines	art-writtenart
(	art-writtenart
2006	art-writtenart
)	art-writtenart
recommend	O
that	O
,	O
for	O
cough	O
associated	O
with	O
the	O
common	O
cold	O
,	O
first-generation	O
antihistamine-decongestants	other-medical
are	O
more	O
effective	O
than	O
newer	O
,	O
non-sedating	other-medical
antihistamines	other-medical
.	O

Radiography	O
and	O
NMR	other-medical
imaging	O
of	O
the	O
skull	O
can	O
also	O
be	O
utilised	O
.	O

One	O
issue	O
with	O
opioid	other-medical
rotation	O
is	O
that	O
an	O
opioid	other-medical
therapy	O
failure	O
poorly	O
predicts	O
whether	O
other	O
opioids	other-medical
would	O
be	O
effective	O
.	O

The	O
impact	O
of	O
postural	O
yoga	O
on	O
physical	O
and	O
mental	O
health	O
has	O
been	O
a	O
topic	O
of	O
systematic	O
studies	O
,	O
with	O
evidence	O
that	O
regular	O
yoga	O
practice	O
yields	O
benefits	O
for	O
low	O
back	other-medical
pain	other-medical
and	O
stress	other-medical
.	O

Discontinuation	other-chemicalthing
syndrome	other-chemicalthing
has	O
been	O
reported	O
to	O
be	O
markedly	O
worse	O
for	O
venlafaxine	other-medical
when	O
compared	O
to	O
other	O
SNRIs	other-medical
.	O

Pfizer	organization-company
UK	organization-company
was	O
presented	O
with	O
the	O
Queen	other-award
's	other-award
Award	other-award
for	other-award
Technological	other-award
Achievement	other-award
in	O
1979	O
,	O
in	O
recognition	O
of	O
the	O
outstanding	O
contribution	O
made	O
to	O
tropical	O
medicine	O
by	O
the	O
medicine	O
Mansil	other-medical
(	O
oxamniquine	O
)	O
,	O
which	O
had	O
been	O
developed	O
at	O
the	O
Sandwich	building-other
site	building-other
.	O

The	O
High	other-medical
Runner	other-medical
lines	O
have	O
been	O
proposed	O
as	O
a	O
model	O
to	O
study	O
human	O
attention-deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
,	O
and	O
administration	O
of	O
Ritalin	other-biologything
reduces	O
their	O
wheel	O
running	O
approximately	O
to	O
the	O
levels	O
of	O
control	O
mice	O
.	O

ART	other-medical
for	O
mothers	O
both	O
before	O
and	O
during	O
delivery	O
and	O
to	O
mothers	O
and	O
infants	O
after	O
delivery	O
are	O
recommended	O
to	O
substantially	O
reduce	O
the	O
risk	O
of	O
transmission	O
.	O

Some	O
of	O
the	O
newer	O
psychiatric	O
medications	O
,	O
such	O
as	O
Zyprexa	other-medical
(	O
Olanzapine	other-medical
)	O
and	O
Cymbalta	other-medical
(	O
Duloxetine	other-medical
)	O
,	O
can	O
also	O
cause	O
significant	O
hyperglycemia	O
.	O

According	O
to	O
William	person-scholar
Clarence-Smith	person-scholar
,	O
Islamic	organization-religion
Southeast	O
Asia	location-GPE
``	O
overwhelmingly	O
''	O
follows	O
the	O
Shafi	organization-education
`	organization-education
i	organization-education
school	O
of	O
law	O
,	O
the	O
only	O
one	O
to	O
make	O
FGM	other-medical
obligatory	O
.	O

It	O
is	O
closely	O
related	O
on	O
a	O
structural	O
level	O
to	O
a	O
number	O
of	O
other	O
stimulants	O
,	O
such	O
as	O
MDPV	other-medical
and	O
prolintane	other-medical
(	O
Promotil	other-medical
,	O
Katovit	other-medical
)	O
.	O

ACC	other-medical
is	O
roughly	O
40	O
%	O
more	O
bioavailable	O
than	O
crystalline	other-chemicalthing
calcium	other-chemicalthing
carbonate	other-chemicalthing
.	O

Prior	O
to	O
joining	O
City	organization-other
of	organization-other
Hope	organization-other
,	O
he	O
served	O
as	O
tenured	O
Professor	O
of	O
Medicine	O
,	O
Pathology	other-medical
and	O
Dermatology	other-medical
,	O
Director	O
of	O
the	O
Thoracic	other-medical
Oncology	other-medical
Program	O
and	O
the	O
Aerodigestive	organization-other
Tract	organization-other
Program	organization-other
Translational	organization-other
Research	organization-other
Lab	organization-other
in	O
the	O
section	O
of	O
Hematology	other-medical
/	O
Oncology	other-medical
,	O
Vice	O
Chair	O
for	O
Translational	O
Research	O
in	O
the	O
Department	organization-religion
of	organization-religion
Medicine	organization-religion
and	O
Associate	O
Director	O
for	O
Translational	O
Science	O
at	O
the	O
University	organization-other
of	organization-other
Chicago	organization-other
Comprehensive	organization-other
Cancer	organization-other
Center	organization-other
in	O
Chicago	location-GPE
.	O

Trimecaine	other-medical
must	O
not	O
be	O
used	O
at	O
hypersensitivity	O
on	O
amide	other-medical
anesthetics	other-medical
,	O
hypervolemia	other-disease
,	O
hypotension	other-disease
,	O
cardial	other-disease
conduction	other-disease
defects	other-disease
,	O
asystole	other-disease
,	O
cardiogenic	other-disease
shock	other-disease
and	O
malignant	other-disease
hyperthermia	other-disease
in	other-disease
anamnesis	other-disease
.	O

In	O
May	O
2004	O
,	O
at	O
the	O
conclusion	O
of	O
MPP	organization-other
's	O
intensive	O
,	O
three-year	O
lobbying	O
campaign	O
,	O
Vermont	location-GPE
became	O
the	O
ninth	O
state	O
to	O
enact	O
a	O
medical	O
marijuana	other-medical
law	O
—	O
and	O
only	O
the	O
second	O
state	O
(	O
after	O
Hawaii	location-GPE
)	O
to	O
do	O
so	O
through	O
its	O
legislature	O
,	O
rather	O
than	O
through	O
a	O
ballot	O
initiative	O
.	O

Triptans	other-medical
is	O
a	O
word	O
commonly	O
used	O
for	O
a	O
class	O
of	O
anti-migraine	O
drugs	O
that	O
are	O
selective	other-chemicalthing
5-hydroxytryptamine/serotonin1B/1D	other-chemicalthing
(	O
5-HT1B/1D	other-chemicalthing
)	O
agonists	O
.	O

The	O
center	O
is	O
for	O
adults	O
with	O
neurodevelopmental	other-medical
disorders	other-medical
complicated	O
by	O
cognitive	other-medical
dysfunction	other-medical
.	O

The	O
results	O
of	O
a	O
preliminary	O
study	O
of	O
40	O
people	O
diagnosed	O
with	O
Major	O
Depressive	O
Disorder	O
suggests	O
that	O
routinely	O
engaging	O
in	O
expressive	O
writing	O
may	O
be	O
effective	O
in	O
reducing	O
symptoms	O
of	O
depression	other-medical
.	O

Carbamazepine	other-medical
is	O
most	O
commonly	O
prescribed	O
to	O
treat	O
trigeminal	other-disease
neuralgia	other-disease
due	O
to	O
clinical	O
experience	O
and	O
early	O
clinical	O
trials	O
showing	O
strong	O
efficacy	O
.	O

Metoclopramide	other-medical
has	O
long	O
been	O
used	O
in	O
all	O
stages	O
of	O
pregnancy	O
with	O
no	O
evidence	O
of	O
harm	O
to	O
the	O
mother	O
or	O
unborn	O
baby	O
.	O

Levomethorphan	other-medical
is	O
a	O
prodrug	O
to	O
levorphanol	other-medical
,	O
analogously	O
to	O
DXM	other-medical
acting	O
as	O
a	O
prodrug	O
to	O
dextrorphan	other-medical
or	O
codeine	O
behaving	O
as	O
a	O
prodrug	O
to	O
morphine	other-medical
.	O

The	O
use	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
such	O
as	O
Ibuprofen	other-medical
may	O
help	O
some	O
athletes	O
ski	O
through	O
the	O
discomfort	O
,	O
but	O
rest	O
is	O
ultimately	O
the	O
most	O
effective	O
remedy	O
.	O

Nelfinavir	other-medical
is	O
an	O
orally	O
bioavailable	O
human	O
immunodeficiency	O
virus	O
HIV-1	other-biologything
protease	O
inhibitor	O
(	O
Ki=2nM	O
)	O
and	O
is	O
widely	O
prescribed	O
in	O
combination	O
with	O
HIV	other-biologything
reverse	O
transcriptase	O
inhibitors	O
for	O
the	O
treatment	O
of	O
HIV	other-biologything
infection	O
.	O

Amlodipine	other-medical
-association	O
edema	O
can	O
be	O
avoided	O
by	O
adding	O
[	O
[	O
ACE	other-medical
inhibitors	other-medical
]	O
]	O
or	O
angiotensin	other-medical
II	other-medical
receptor	other-medical
antagonist	other-medical
.	O

In	O
the	O
1940s	O
and	O
1950s	O
,	O
reports	O
began	O
to	O
emerge	O
about	O
the	O
recreational	O
use	O
of	O
Benzedrine	other-medical
inhalers	other-medical
,	O
and	O
in	O
1949	O
,	O
doctors	O
began	O
to	O
move	O
away	O
from	O
prescribing	O
Benzedrine	other-medical
as	O
a	O
bronchodilator	other-medical
and	O
appetite	O
suppressant	O
.	O

Pralidoxime	other-medical
is	O
intended	O
to	O
reactivate	O
acetylcholinesterase	O
,	O
but	O
the	O
benefit	O
of	O
oxime	O
treatment	O
is	O
questioned	O
.	O

In	O
general	O
,	O
cytotoxic	other-medical
chemotherapy	other-medical
for	O
ALL	other-disease
combines	O
multiple	O
antileukemic	other-medical
drugs	O
tailored	O
to	O
each	O
person	O
.	O

In	O
Bangladesh	location-GPE
,	O
the	O
combination	O
of	O
triamcinolone	other-medical
acetonide	other-medical
and	O
econazole	other-medical
nitrate	other-medical
is	O
branded	O
as	O
Pevisone	other-medical
by	O
Janssen	person-scholar
Pharmaceutica	person-scholar
.	O

Use	O
is	O
widespread	O
among	O
amphetamine	O
users	O
,	O
with	O
those	O
that	O
use	O
amphetamines	other-medical
and	O
benzodiazepines	other-medical
having	O
greater	O
levels	O
of	O
mental	O
health	O
problems	O
and	O
social	O
deterioration	O
.	O

The	O
usefulness	O
of	O
5-ARIs	other-medical
for	O
the	O
potential	O
treatment	O
of	O
acne	O
is	O
uncertain	O
.	O

Metenolone	other-medical
acetate	O
is	O
or	O
has	O
been	O
marketed	O
under	O
a	O
number	O
of	O
brand	O
names	O
including	O
Primobolan	other-medical
,	O
Primobolan	other-medical
S	other-medical
,	O
Primonabol	other-medical
,	O
and	O
Nibal	other-medical
.	O

When	O
compared	O
with	O
just	O
5-fluorouracil	other-medical
and	O
folinic	other-medical
acid	other-medical
administered	O
according	O
to	O
the	O
de	other-medical
Gramont	other-medical
regimen	other-medical
,	O
a	O
FOLFOX4	other-medical
regime	other-medical
produced	O
no	O
significant	O
increase	O
in	O
overall	O
survival	O
,	O
but	O
did	O
produce	O
an	O
improvement	O
in	O
progression-free	O
survival	O
,	O
the	O
primary	O
end-point	O
of	O
the	O
phase	O
III	O
randomized	O
trial	O
.	O

It	O
was	O
one	O
of	O
the	O
earlier	O
bacteria	O
in	O
which	O
penicillin	other-medical
resistance	O
was	O
found—in	O
1947	O
,	O
just	O
four	O
years	O
after	O
the	O
drug	O
started	O
being	O
mass-produced	O
.	O

Clinical	O
vignettes	O
from	O
Green	person-scholar
's	O
work	O
on	O
gender	other-medical
identity	other-medical
disorder	other-medical
appear	O
in	O
widely	O
used	O
textbooks	O
,	O
such	O
as	O
``	O
Kaplan	art-writtenart
and	art-writtenart
Sadock	art-writtenart
's	art-writtenart
Synopsis	art-writtenart
of	art-writtenart
Psychiatry	art-writtenart
``	O
(	O
10th	O
ed	O
.	O
)	O

It	O
is	O
the	O
only	O
TCA	other-medical
with	O
a	O
dibenzoxepin	other-chemicalthing
ring	other-chemicalthing
system	other-chemicalthing
to	O
have	O
been	O
marketed	O
.	O

Metronidazole	other-medical
began	O
to	O
be	O
commercially	O
used	O
in	O
1960	O
in	O
France	location-GPE
.	O

In	O
cases	O
of	O
meningitis	other-disease
caused	O
by	O
Herpes	other-biologything
simplex	other-biologything
virus	other-biologything
,	O
antiviral	O
therapy	O
with	O
(	O
acyclovir	other-medical
or	O
vidarabine	other-medical
)	O
must	O
be	O
started	O
immediately	O
for	O
a	O
favorable	O
outcome	O
.	O

Pilocarpine	other-medical
drops	other-medical
may	O
be	O
administered	O
as	O
a	O
treatment	O
as	O
well	O
as	O
a	O
diagnostic	O
measure	O
.	O

5-APDI	other-medical
acts	O
as	O
a	O
potent	O
and	O
weakly	O
selective	other-medical
serotonin	other-medical
releasing	other-medical
agent	other-medical
(	O
SSRA	other-medical
)	O
with	O
IC50	other-chemicalthing
values	O
of	O
82	O
nM	O
,	O
1,848	O
nM	O
,	O
and	O
849	O
nM	O
for	O
inhibiting	O
the	O
reuptake	O
of	O
serotonin	other-biologything
,	O
dopamine	other-biologything
,	O
and	O
norepinephrine	other-biologything
,	O
respectively	O
.	O

On	O
15	O
October	O
2010	O
,	O
the	O
multi-national	O
Reckitt	organization-company
Benckiser	organization-company
was	O
fined	O
£	other-currency
10	O
million	O
for	O
rigging	O
the	O
market	O
for	O
Gaviscon	other-medical
following	O
an	O
investigation	O
by	O
Jones	person-other
and	O
Martin	person-other
Shankleman	person-other
.	O

The	O
Clinical	organization-other
Pharmacogenetics	organization-other
Implementation	organization-other
Consortium	organization-other
recommends	O
avoiding	O
amitriptyline	other-medical
in	O
patients	O
who	O
are	O
CYP2D6	other-biologything
ultrarapid	O
or	O
poor	O
metabolizers	O
,	O
due	O
to	O
the	O
risk	O
for	O
a	O
lack	O
of	O
efficacy	O
and	O
side	O
effects	O
,	O
respectively	O
.	O

Established	O
diagnoses	O
include	O
Down	other-medical
syndrome	other-medical
,	O
Fragile	other-medical
X	other-medical
syndrome	other-medical
,	O
Trisomy	other-medical
8	other-medical
mosaic	other-medical
syndrome	other-medical
,	O
Trisomy	other-medical
13	other-medical
syndrome	other-medical
,	O
Williams	other-medical
syndrome	other-medical
,	O
Angelman	other-medical
syndrome	other-medical
,	O
Smith–Magenis	other-medical
syndrome	other-medical
,	O
PKU	other-medical
,	O
Tuberous	other-medical
sclerosis	other-medical
,	O
Neurofibromatosis	other-medical
,	O
Sturge–Weber	other-medical
syndrome	other-medical
,	O
Congenital	other-medical
rubella	other-medical
syndrome	other-medical
,	O
the	O
syndrome	O
of	O
hypoxic	other-medical
/	O
ischemic	other-medical
perinatal	other-medical
brain	other-medical
injury	other-medical
,	O
lead	other-medical
encephalopathy	other-medical
,	O
hydrocephalus	other-medical
,	O
prosencephaly	other-medical
,	O
schizencephaly	other-medical
,	O
and	O
other	O
diagnoses	O
.	O

Opioid	other-medical
medications	other-medical
are	O
not	O
utilized	O
to	O
treat	O
ETTH	other-medical
.	O

It	O
has	O
been	O
posited	O
that	O
Lavrenty	person-politician
Beria	person-politician
,	O
Nikita	person-politician
Khrushchev	person-politician
,	O
and	O
others	O
conspired	O
to	O
use	O
warfarin	other-medical
to	O
poison	O
Soviet	location-GPE
leader	O
Joseph	person-politician
Stalin	person-politician
.	O

ADHD	other-disease
,	O
which	O
affects	O
the	O
majority	O
of	O
boys	O
and	O
30	O
%	O
of	O
girls	O
with	O
FXS	other-biologything
,	O
is	O
frequently	O
treated	O
using	O
stimulants	other-medical
.	O

Care	O
must	O
be	O
taken	O
when	O
prescribing	O
benzodiazepines	other-medical
due	O
to	O
the	O
risk	O
of	O
the	O
person	O
developing	O
tolerance	O
and	O
dependence	O
.	O

Individuals	O
with	O
coexisting	other-disease
seizure	other-disease
disorder	other-disease
may	O
require	O
treatment	O
with	O
anticonvulsants	other-medical
.	O

Cigarette	O
smokers	O
who	O
have	O
LET	other-disease
may	O
not	O
respond	O
very	O
well	O
to	O
chloroquine	other-medical
.	O

It	O
was	O
developed	O
under	O
contract	O
to	O
Edgewood	organization-company
Arsenal	organization-company
during	O
the	O
1960s	O
as	O
part	O
of	O
the	O
US	location-GPE
military	O
chemical	O
weapons	O
program	O
,	O
during	O
research	O
to	O
improve	O
upon	O
the	O
properties	O
of	O
earlier	O
agents	O
such	O
as	O
QNB	other-medical
.	O

The	O
most	O
potent	O
aphrodisiacs	other-medical
,	O
according	O
to	O
Levine	person-other
,	O
are	O
psychological	O
intimacy	O
and	O
voyeurism	O
:	O
``	O
looking	O
at	O
pictures	O
or	O
movies	O
of	O
people	O
engaged	O
in	O
genital	O
or	O
romantic	O
interplay	O
.	O
''	O

Bumetanide	other-medical
is	O
a	O
loop	other-medical
diuretic	other-medical
(	O
water	O
pill	O
)	O
that	O
prevents	O
your	O
body	O
from	O
absorbing	O
too	O
much	O
salt	O
,	O
allowing	O
the	O
salt	O
to	O
instead	O
be	O
passed	O
in	O
your	O
urine	O
.	O

These	O
secondary	O
ingredients	O
are	O
not	O
mainstream	O
in	O
the	O
United	location-GPE
States	location-GPE
,	O
where	O
nonoxynol-9	other-medical
alone	O
is	O
typical	O
.	O

Other	O
NSAIDS	other-medical
should	O
be	O
used	O
only	O
in	O
cases	O
refractory	O
to	O
aspirin	O
.	O

The	O
players	O
and	O
their	O
attorneys	O
alleged	O
that	O
the	O
League	O
failed	O
to	O
properly	O
treat	O
head	O
injuries	O
in	O
spite	O
of	O
prevailing	O
medical	O
evidence	O
and	O
the	O
prevalent	O
use	O
of	O
Toradol	other-medical
administered	O
by	O
the	O
team	O
to	O
the	O
players	O
as	O
a	O
pain-masking	O
agent	O
,	O
leading	O
the	O
players	O
to	O
develop	O
effects	O
of	O
brain	O
injury	O
.	O

It	O
is	O
also	O
available	O
in	O
combination	O
with	O
pseudoephedrine	other-medical
,	O
a	O
decongestant	other-medical
,	O
known	O
as	O
loratadine	other-medical
/	O
pseudoephedrine	other-medical
.	O

In	O
2018	O
and	O
in	O
2019	O
,	O
the	O
U.S	organization-government,governmentagency
Food	organization-government,governmentagency
and	organization-government,governmentagency
Drug	organization-government,governmentagency
Administration	organization-government,governmentagency
(	O
FDA	organization-government,governmentagency
)	O
found	O
traces	O
of	O
NDMA	other-chemicalthing
and	O
NDEA	other-chemicalthing
impurities	O
in	O
the	O
angiotensin	O
II	O
receptor	O
blocker	O
(	O
ARB	other-medical
)	O
drug	O
products	O
valsartan	other-medical
,	O
losartan	other-medical
,	O
and	O
irbesartan	other-medical
.	O

Quinine	other-medical
was	O
used	O
in	O
treating	O
malaria	other-disease
.	O

As	O
several	O
HBS	organization-other
case	O
studies	O
point	O
out	O
,	O
Tylenol	other-medical
was	O
the	O
country	O
's	O
best-selling	O
over-the-counter	O
pain	O
reliever	O
at	O
the	O
time	O
of	O
the	O
poisonings	O
,	O
with	O
35	O
percent	O
of	O
the	O
market-more	O
than	O
the	O
next	O
three	O
brands	O
combined	O
.	O

Piracetam	other-medical
is	O
not	O
permitted	O
in	O
compounded	O
drugs	O
or	O
dietary	O
supplements	O
in	O
the	O
United	O
States	O
.	O

This	O
includes	O
methotrexate	other-medical
for	O
juvenile	other-disease
idiopathic	other-disease
arthritis	other-disease
and	O
sumatriptan	other-medical
for	O
treatment	O
of	O
migraines	other-disease
.	O

Tolerance	O
to	O
the	O
anticonvulsant	O
effects	O
of	O
clonazepam	other-medical
occurs	O
in	O
both	O
animals	O
and	O
humans	O
.	O

Proton	O
pump	O
inhibitors	O
(	O
PPI	other-medical
)	O
may	O
reduce	O
mortality	O
in	O
those	O
with	O
severe	O
disease	O
as	O
well	O
as	O
the	O
risk	O
of	O
re-bleeding	O
and	O
the	O
need	O
for	O
surgery	O
among	O
this	O
group	O
.	O

It	O
is	O
used	O
to	O
treat	O
fluid	other-medical
retention	other-medical
(	O
edema	other-medical
)	O
in	O
people	O
with	O
congestive	other-medical
heart	other-medical
failure	other-medical
,	O
liver	other-medical
disease	other-medical
,	O
or	O
a	O
kidney	other-medical
disorder	other-medical
such	O
as	O
nephritic	other-medical
syndrome	other-medical
.	O

The	O
drug	O
is	O
an	O
N-protected	O
dipeptide	other-chemicalthing
and	O
can	O
be	O
written	O
as	O
Pyz-Phe-boroLeu	other-medical
,	O
which	O
stands	O
for	O
pyrazinoic	other-chemicalthing
acid	other-chemicalthing
,	O
phenylalanine	other-chemicalthing
and	O
Leucine	other-chemicalthing
with	O
a	O
boronic	other-chemicalthing
acid	other-chemicalthing
instead	O
of	O
a	O
carboxylic	other-chemicalthing
acid	other-chemicalthing
.	O

A	O
major	O
use	O
of	O
systemic	O
radioisotope	other-medical
therapy	other-medical
is	O
in	O
the	O
treatment	O
of	O
bone	O
metastasis	O
from	O
cancer	O
.	O

Yuri	person-athlete
Larionov	person-athlete
stated	O
the	O
use	O
of	O
the	O
Furosemide	other-medical
was	O
for	O
weight	O
loss	O
but	O
diuretics	O
but	O
it	O
can	O
be	O
used	O
as	O
a	O
masking	O
agent	O
for	O
the	O
use	O
other	O
substances	O
,	O
Though	O
he	O
claims	O
that	O
``	O
during	O
the	O
month	O
of	O
December	O
he	O
had	O
bought	O
and	O
then	O
took	O
a	O
over-the-counter	O
drug	O
which	O
behind	O
his	O
back	O
contained	O
a	O
banned	O
matter	O
''	O

Albendazole	other-medical
was	O
shown	O
to	O
be	O
highly	O
effective	O
and	O
is	O
advocated	O
as	O
the	O
drug	O
of	O
choice	O
.	O

A	O
selective	other-medical
estrogen	other-medical
receptor	other-medical
degrader	other-medical
or	other-medical
downregulator	other-medical
(	O
SERD	other-medical
)	O
is	O
a	O
type	O
of	O
drug	O
which	O
binds	O
to	O
the	O
estrogen	other-biologything
receptor	other-biologything
(	O
ER	other-biologything
)	O
and	O
,	O
in	O
the	O
process	O
of	O
doing	O
so	O
,	O
causes	O
the	O
ER	other-biologything
to	O
be	O
degraded	O
and	O
thus	O
downregulated	O
.	O

In	O
1982	O
,	O
DeLong	person-other
became	O
involved	O
in	O
the	O
investigation	O
of	O
the	O
Chicago	location-GPE
Tylenol	other-medical
murders	O
,	O
in	O
which	O
seven	O
people	O
died	O
from	O
potassium	other-chemicalthing
cyanide	other-chemicalthing
-laced	O
Tylenol	other-medical
capsules	O
.	O

For	O
people	O
who	O
have	O
severe	O
congenital	other-disease
protein	other-disease
C	other-disease
deficiency	other-disease
,	O
protein	other-medical
C	other-medical
replacement	other-medical
therapies	other-medical
are	O
available	O
,	O
which	O
is	O
indicated	O
and	O
approved	O
for	O
use	O
in	O
the	O
United	location-GPE
States	location-GPE
and	O
Europe	location-GPE
for	O
the	O
prevention	O
of	O
purpura	other-disease
fulminans	other-disease
.	O

GGPS	other-biologything
has	O
since	O
been	O
successfully	O
inhibited	O
by	O
a	O
novel	O
bisphosphonate	other-medical
compound	O
with	O
a	O
triazole	other-biologything
group	O
within	O
R2	other-biologything
and	O
a	O
methyl	other-biologything
group	O
in	O
R1	other-biologything
.	O

Active	O
secondary	O
spermicidal	O
ingredients	O
can	O
include	O
octoxynol-9	other-medical
,	O
benzalkonium	other-medical
chloride	other-medical
and	O
menfegol	other-medical
.	O

In	O
some	O
cases	O
,	O
Botox	other-medical
may	O
be	O
used	O
to	O
provide	O
temporary	O
decompression	O
of	O
the	O
nerve	O
.	O

In	O
children	O
,	O
hemodialysis	other-medical
must	O
be	O
individualized	O
and	O
viewed	O
as	O
an	O
``	O
integrated	O
therapy	O
''	O
that	O
considers	O
their	O
long-term	O
exposure	O
to	O
chronic	other-disease
renal	other-disease
failure	other-disease
treatment	O
.	O

As	O
a	O
laxative	other-medical
syrup	other-medical
with	O
a	O
concentration	O
of	O
1.745	O
g	O
of	O
magnesium	other-chemicalthing
citrate	other-chemicalthing
per	O
fluid	O
ounce	O
,	O
a	O
typical	O
dose	O
for	O
adults	O
and	O
children	O
twelve	O
years	O
or	O
older	O
is	O
between	O
,	O
followed	O
immediately	O
with	O
a	O
full	O
glass	O
of	O
water	O
.	O

with	O
a	O
Marfanoid	other-medical
Habitus	other-medical
.	O

The	O
council	O
,	O
who	O
support	O
licensing	O
poppy	O
cultivation	O
in	O
Afghanistan	location-GPE
to	O
create	O
Afghan	location-GPE
morphine	O
,	O
believe	O
the	O
opium	O
supply	O
in	O
this	O
country	O
could	O
go	O
a	O
long	O
way	O
to	O
easing	O
the	O
pain	O
relief	O
needs	O
of	O
sufferers	O
in	O
emerging	O
countries	O
by	O
producing	O
a	O
cheap	O
poppy-based	O
medicine	O
solution	O
(	O
see	O
[	O
The	O
Senlis	organization-other
Council	organization-other
]	O
:	O
``	O
Poppy	other-medical
for	other-medical
Medicine	other-medical
.	O
''	O

Medical	O
management	O
of	O
miscarriage	O
and	O
medical	O
abortion	O
using	O
drugs	O
such	O
as	O
misoprostol	other-medical
and	O
mifepristone	other-medical
are	O
safe	O
,	O
non-invasive	O
and	O
potentially	O
less	O
expensive	O
alternatives	O
to	O
D	other-medical
&	other-medical
amp	other-medical
;	other-medical
C	other-medical
.	O

It	O
is	O
the	O
main	O
road	O
that	O
gives	O
access	O
to	O
the	O
Jodrell	other-medical
Bank	other-medical
Observatory	other-medical
and	O
the	O
Quinta	other-medical
Arboretum	other-medical
,	O
planted	O
by	O
Sir	O
Bernard	person-other
Lovell	person-other
in	O
1948	O
.	O

They	O
are	O
rethinking	O
chemotherapy	other-medical
because	O
of	O
the	O
antiangiogenic	O
effects	O
of	O
low	O
dose	O
chemotherapy	other-medical
given	O
on	O
a	O
more	O
frequent	O
basis	O
than	O
conventional	O
chemotherapy	other-medical
.	O

This	O
meant	O
that	O
in	O
contrast	O
to	O
flumazenil	other-medical
,	O
which	O
is	O
ineffective	O
at	O
treating	O
alcohol	O
overdoses	O
,	O
Ro15-4513	other-medical
showed	O
potential	O
as	O
a	O
useful	O
alcohol	O
antidote	O
.	O

The	O
Knee	organization-media,newspaper
Surgery	organization-media,newspaper
,	organization-media,newspaper
Sports	organization-media,newspaper
Traumatology	organization-media,newspaper
,	organization-media,newspaper
Arthroscopy	organization-media,newspaper
is	O
a	O
monthly	O
peer-reviewed	O
medical	O
journal	O
published	O
in	O
English	other-language
covering	O
orthopaedic	O
surgery	O
,	O
especially	O
related	O
to	O
sports	O
trauma	O
and	O
surgeries	O
,	O
in	O
particular	O
arthroscopies	other-medical
.	O

Turmeric	other-medical
has	O
been	O
used	O
in	O
Asia	location-GPE
for	O
centuries	O
and	O
is	O
a	O
major	O
part	O
of	O
Ayurveda	other-medical
,	O
Siddha	other-medical
medicine	other-medical
,	O
traditional	other-medical
Chinese	other-medical
medicine	other-medical
,	O
Unani	other-medical
,	O
and	O
the	O
animistic	O
rituals	O
of	O
Austronesian	location-GPE
peoples	O
.	O

Rapid	O
partial	O
correction	O
with	O
3	O
%	O
normal	other-medical
saline	other-medical
is	O
only	O
recommended	O
in	O
those	O
with	O
significant	O
symptoms	O
and	O
occasionally	O
those	O
in	O
whom	O
the	O
condition	O
was	O
of	O
rapid	O
onset	O
.	O

A	O
single	O
,	O
modified	O
TEG	other-medical
assay	O
with	O
exogenous	O
tissue	other-medical
plasminogen	other-medical
activator	other-medical
(	O
tPA	other-medical
)	O
demonstrated	O
remarkable	O
efficiency	O
in	O
unmasking	O
patients	O
'	O
impending	O
risk	O
for	O
massive	O
transfusion	O
in	O
trauma	O
patients	O
.	O

However	O
,	O
ketoconazole	other-medical
has	O
largely	O
been	O
replaced	O
as	O
a	O
first-line	O
systemic	O
antifungal	other-medical
medication	O
by	O
other	O
azole	other-disease
antifungal	other-disease
agents	other-disease
,	O
such	O
as	O
itraconazole	other-medical
,	O
because	O
of	O
ketoconazole	other-medical
's	O
greater	O
toxicity	O
,	O
poorer	O
absorption	O
,	O
and	O
more	O
limited	O
spectrum	O
of	O
activity	O
.	O

Benzodiazepines	other-medical
are	O
not	O
without	O
their	O
drawbacks	O
;	O
substance	O
dependence	O
is	O
possible	O
,	O
and	O
deaths	O
from	O
overdoses	O
sometimes	O
occur	O
,	O
especially	O
in	O
combination	O
with	O
alcohol	O
and/or	O
other	O
depressants	O
.	O

Peripheral	other-disease
edema	other-disease
(	O
fluid	O
accumulation	O
in	O
the	O
tissues	O
)	O
occurs	O
at	O
rate	O
of	O
10.8	O
%	O
at	O
a	O
10-mg	O
dose	O
(	O
versus	O
0.6	O
%	O
for	O
placebos	other-medical
)	O
,	O
and	O
is	O
three	O
times	O
more	O
likely	O
in	O
women	O
than	O
in	O
men	O
.	O

Benzedrine	other-medical
was	O
supplied	O
to	O
combat	O
troops	O
in	O
World	event-attack,battle,war,militaryconflict
War	event-attack,battle,war,militaryconflict
2	event-attack,battle,war,militaryconflict
for	O
use	O
in	O
exceptional	O
circumstances	O
(	O
e.g	O
.	O

Lamivudine	other-medical
showed	O
no	O
evidence	O
of	O
carcinogenicity	O
or	O
mutagenicity	O
in	O
``	O
in	O
vivo	O
''	O
studies	O
in	O
mice	O
and	O
rats	O
at	O
doses	O
from	O
10	O
to	O
58	O
times	O
those	O
used	O
in	O
humans	O
.	O

Anti-GM1	other-medical
antibodies	O
are	O
positive	O
in	O
around	O
80	O
%	O
of	O
cases	O
.	O

Metoclopramide	other-medical
is	O
excreted	O
into	O
milk	O
.	O

Chronic	O
users	O
of	O
paracetamol	other-medical
may	O
have	O
a	O
higher	O
risk	O
of	O
developing	O
blood	other-disease
cancer	other-disease
.	O

However	O
,	O
scopolamine	other-medical
has	O
greater	O
effects	O
on	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
than	O
atropine	other-medical
due	O
to	O
its	O
ability	O
to	O
cross	O
the	O
blood–brain	O
barrier	O
.	O

Evidence	O
of	O
the	O
effects	O
of	O
terrestrial	O
forms	O
of	O
ionizing	O
radiation	O
on	O
the	O
CNS	other-medical
has	O
been	O
documented	O
from	O
radiotherapy	O
patients	O
,	O
although	O
the	O
dose	O
is	O
higher	O
for	O
these	O
patients	O
than	O
would	O
be	O
experienced	O
by	O
astronauts	O
in	O
the	O
space	O
environment	O
.	O

As	O
such	O
,	O
levomethorphan	other-medical
has	O
similar	O
effects	O
to	O
levorphanol	other-medical
but	O
is	O
less	O
potent	O
as	O
it	O
must	O
be	O
demethylated	O
to	O
the	O
active	O
form	O
by	O
liver	O
enzymes	O
before	O
being	O
able	O
to	O
produce	O
its	O
effects	O
.	O

At	O
higher-than-therapeutic	O
doses	O
,	O
atropine	other-medical
and	O
scopolamine	other-medical
cause	O
CNS	O
depression	O
characterized	O
by	O
amnesia	O
,	O
fatigue	O
,	O
and	O
reduction	O
in	O
rapid	O
eye	O
movement	O
sleep	O
.	O

Vomiting	other-medical
agents	other-medical
are	O
chemical	O
weapon	O
agents	O
causing	O
vomiting	O
.	O

Recommended	O
antibiotics	O
in	O
those	O
who	O
are	O
young	O
and	O
sexually	O
active	O
are	O
ceftriaxone	other-medical
and	O
doxycycline	other-medical
.	O

In	O
2020	O
,	O
Baszucki	person-other
funded	O
a	O
study	O
on	O
the	O
effect	O
of	O
Hydroxychloroquine	other-medical
on	O
COVID-19	other-disease
,	O
which	O
showed	O
no	O
evidence	O
of	O
it	O
preventing	O
or	O
treating	O
the	O
virus	O
.	O

Because	O
of	O
its	O
increasing	O
popularity	O
with	O
young	other-medical
party	other-medical
goers	other-medical
in	O
Beijing	location-GPE
,	O
Shanghai	location-GPE
,	O
Nanjing	location-GPE
,	O
Guangzhou	location-GPE
,	O
and	O
Shenzhen	location-GPE
,	O
Chinese	location-GPE
law	O
enforcement	O
officials	O
report	O
significant	O
increases	O
in	O
the	O
domestic	O
production	O
of	O
MDMA	other-medical
(	O
``	O
Ecstasy	other-medical
``	O
)	O
.	O

The	O
word	O
dystonia	other-medical
describes	O
abnormal	O
involuntary	O
sustained	O
muscle	other-medical
contractions	other-medical
and	O
spasms	other-medical
.	O

Hemorrhage	other-medical
is	O
rare	O
,	O
but	O
the	O
most	O
likely	O
cause	O
of	O
fatality	O
after	O
a	O
tracheostomy	other-medical
.	O

A	O
D	other-medical
&	other-medical
amp	other-medical
;	other-medical
C	other-medical
may	O
be	O
performed	O
early	O
in	O
pregnancy	O
to	O
remove	O
pregnancy	O
tissue	O
,	O
either	O
in	O
the	O
case	O
of	O
a	O
non-viable	O
pregnancy	O
,	O
such	O
as	O
a	O
missed	O
or	O
incomplete	O
miscarriage	O
,	O
or	O
an	O
undesired	O
pregnancy	O
,	O
as	O
in	O
a	O
surgical	O
abortion	O
.	O

In	O
this	O
capacity	O
he	O
was	O
involved	O
in	O
the	O
very	O
earliest	O
assessment	O
of	O
the	O
use	O
of	O
Penicillin	other-medical
in	O
war	O
wounds	O
.	O

Stents	other-medical
to	O
maintain	O
the	O
arterial	O
widening	O
are	O
often	O
used	O
at	O
the	O
same	O
time	O
.	O

Yuri	person-athlete
Larionov	person-athlete
a	O
male	O
pairs	O
skater	O
Junior	event-sportsevent
World	event-sportsevent
Championships	event-sportsevent
and	O
winner	O
of	O
the	O
2007	event-sportsevent
Junior	event-sportsevent
Grand	event-sportsevent
Prix	event-sportsevent
finals	event-sportsevent
paired	O
with	O
Vera	person-athlete
Bazarova	person-athlete
,	O
was	O
suspended	O
for	O
an	O
anti-doping	O
violation	O
for	O
18	O
months	O
(	O
January	O
2008	O
to	O
July	O
2009	O
)	O
for	O
using	O
Furosemide	other-medical
a	O
powerful	O
diuretic	O
which	O
the	O
World	organization-other
Anti-Doping	organization-other
Agency	organization-other
classifies	O
as	O
“	O
masking	O
”	O
anabolic	O
and	O
steroids	O
.	O

RLS	other-disease
symptoms	O
decrease	O
with	O
the	O
use	O
of	O
drugs	O
that	O
stimulate	O
dopamine	O
receptors	O
and	O
increase	O
dopamine	O
levels	O
,	O
such	O
as	O
dopamine	other-medical
agonists	other-medical
.	O

However	O
,	O
religious	O
and	O
conservative	O
lobbying	O
groups	O
as	O
well	O
as	O
the	O
influence	O
of	O
neo-eugenicscreated	O
push	O
back	O
on	O
some	O
other	O
forms	O
of	O
birth	O
control	O
such	O
as	O
emergency	other-medical
contraception	other-medical
and	O
tubal	other-medical
ligation	other-medical
.	O

Trebananib	other-medical
and	O
tasquinimod	other-medical
are	O
other	O
angiogenesis	O
inhibitors	O
being	O
investigated	O
.	O

Cinqair	other-medical
is	O
approved	O
for	O
patients	O
who	O
have	O
a	O
history	O
of	O
severe	O
asthma	other-disease
attacks	other-disease
(	O
exacerbations	O
)	O
despite	O
receiving	O
their	O
current	O
asthma	other-disease
medicines	O
.	O

It	O
was	O
picked	O
up	O
by	O
Bio-Technology	organization-company
General	organization-company
Corporation	organization-company
,	O
which	O
changed	O
its	O
name	O
to	O
Savient	other-medical
Pharmaceuticals	other-medical
,	O
which	O
following	O
successful	O
clinical	O
trials	O
in	O
1995	O
,	O
released	O
it	O
under	O
the	O
brand	O
name	O
Oxandrin	other-medical
.	O

In	O
an	O
early	O
report	O
on	O
inhibition	O
of	O
snake	O
venom	O
toxicities	O
,	O
Varespladib	other-medical
,	O
and	O
its	O
orally	other-medical
bioavailable	other-medical
prodrug	other-medical
methyl-varespladib	other-medical
(	O
LY333013	other-medical
)	O
showed	O
strong	O
inhibition	O
of	O
28	O
types	O
of	O
svPLA2s	other-biologything
from	O
six	O
continents	O
.	O

While	O
one	O
of	O
the	O
main	O
rationales	O
for	O
the	O
use	O
of	O
this	O
class	O
is	O
the	O
avoidance	O
of	O
a	O
persistent	O
dry	other-disease
cough	other-disease
and/or	O
angioedema	other-disease
associated	O
with	O
ACE	other-medical
inhibitor	other-medical
therapy	O
,	O
rarely	O
they	O
may	O
still	O
occur	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
explore	O
which	O
opioid	other-medical
drugs	O
are	O
most	O
effective	O
in	O
implementing	O
in	O
an	O
opioid	other-medical
rotation	O
,	O
but	O
have	O
so	O
far	O
found	O
no	O
difference	O
in	O
efficacy	O
between	O
opioid	other-medical
drugs	O
like	O
methadone	other-medical
and	O
fentanyl	other-medical
in	O
cancer	O
patients	O
.	O

2001	O
–	O
Pegylated	other-medical
interferon	other-medical
was	O
approved	O
.	O

Most	O
MDMA	other-medical
production	O
in	O
China	location-GPE
is	O
for	O
domestic	O
consumption	O
.	O

It	O
may	O
also	O
cause	O
interactions	O
with	O
anesthetics	O
,	O
so	O
its	O
use	O
should	O
be	O
related	O
to	O
the	O
veterinarian	O
if	O
the	O
animal	O
is	O
going	O
into	O
surgery	O
,	O
and	O
it	O
decreases	O
the	O
kidneys	O
'	O
ability	O
to	O
excrete	O
aspirin	other-medical
,	O
so	O
dosages	O
will	O
need	O
to	O
be	O
adjusted	O
if	O
combined	O
with	O
that	O
drug	O
.	O

Following	O
a	O
2016	O
publication	O
of	O
a	O
flawed	O
paper	O
on	O
HPV	other-medical
vaccine	O
in	O
Japan	location-GPE
,	O
which	O
was	O
later	O
retracted	O
,	O
the	O
Board	O
responded	O
with	O
a	O
letter	O
,	O
signed	O
by	O
20	O
of	O
its	O
Board	O
members	O
,	O
criticising	O
both	O
the	O
research	O
and	O
the	O
time	O
to	O
retract	O
it	O
.	O

The	O
binding	O
affinity	O
(	O
K	O
)	O
and	O
inhibitory	O
potency	O
(	O
i.e.	O
,	O
the	O
half	O
maximal	O
inhibitory	O
concentration	O
or	O
IC	O
)	O
of	O
bupropion	other-medical
at	O
the	O
human	O
dopamine	other-biologything
transporter	O
are	O
526	O
nanomolar	O
(	O
nM	O
)	O
and	O
443	O
nM	O
,	O
respectively	O
.	O

Anthelmintic	other-medical
medicines	O
are	O
made	O
from	O
extracts	O
of	O
``	O
Leucaena	other-livingthing
``	O
seeds	O
in	O
Sumatra	location-island
,	O
Indonesia	location-GPE
.	O

Methicillin	other-medical
was	O
then	O
the	O
antibiotic	O
of	O
choice	O
,	O
but	O
has	O
since	O
been	O
replaced	O
by	O
oxacillin	other-medical
because	O
of	O
significant	O
kidney	O
toxicity	O
.	O

There	O
is	O
evidence	O
that	O
spironolactone	other-medical
may	O
block	O
voltage-dependent	O
Ca2+	other-chemicalthing
channels	O
.	O

Other	O
biomedical	O
companies	O
also	O
produce	O
brands	O
of	O
hyaluronan	other-chemicalthing
for	O
ophthalmic	other-medical
surgery	other-medical
.	O

The	O
first	O
such	O
compound	O
to	O
be	O
patented	O
was	O
zimelidine	other-medical
in	O
1971	O
,	O
while	O
the	O
first	O
released	O
clinically	O
was	O
indalpine	other-medical
.	O

In	O
2002	O
,	O
Swedish	building-hospital
Covenant	building-hospital
Hospital	building-hospital
completed	O
its	O
hyperbaric	other-medical
oxygen	other-medical
chambers	other-medical
to	O
help	O
wounds	O
heal	O
seven	O
days	O
faster	O
than	O
the	O
national	O
average	O
.	O

Leukotriene	other-medical
antagonists	other-medical
and	O
inhibitors	other-medical
(	O
montelukast	other-medical
,	O
zafirlukast	other-medical
,	O
and	O
zileuton	other-medical
)	O
often	O
are	O
helpful	O
in	O
treating	O
the	O
symptoms	O
of	O
AERD	other-disease
.	O

In	O
the	O
second	O
trial	O
,	O
62	O
%	O
of	O
fluoxetine	other-medical
treated	O
patients	O
were	O
free	O
of	O
panic	O
attacks	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
vs.	O
44	O
%	O
in	O
the	O
placebo	other-medical
arm	O
.	O

CHMP	organization-government,governmentagency
stated	O
that	O
doctors	O
should	O
not	O
prescribe	O
oral	other-medical
norfloxacin	other-medical
for	O
complicated	other-medical
pyelonephritis	other-medical
and	O
should	O
consider	O
switching	O
patients	O
already	O
taking	O
oral	other-medical
norfloxacin	other-medical
for	O
this	O
type	O
of	O
infection	O
to	O
an	O
alternative	O
antibiotic	O
.	O

Desipramine	other-medical
has	O
the	O
weakest	O
antihistamine	O
and	O
anticholinergic	O
effects	O
of	O
the	O
TCAs	other-medical
.	O

Ibuprofen	other-medical
can	O
also	O
worsen	O
asthma	O
.	O

The	O
major	O
active	O
forms	O
of	O
spironolactone	other-medical
include	O
7α-thiomethylspironolactone	other-chemicalthing
(	O
7α-TMS	other-chemicalthing
)	O
and	O
canrenone	other-chemicalthing
(	O
7α-desthioacetyl-δ6-spironolactone	other-chemicalthing
)	O
,	O
while	O
more	O
minor	O
metabolites	O
of	O
spironolactone	other-medical
include	O
7α-thiospironolactone	other-chemicalthing
(	O
7α-TS	other-chemicalthing
)	O
,	O
6β-hydroxy-7α-thiomethylspironolactone	other-chemicalthing
(	O
6β-OH-7α-TMS	other-chemicalthing
)	O
,	O
and	O
a	O
number	O
of	O
others	O
.	O

This	O
is	O
much	O
more	O
invasive	O
than	O
angioplasty	other-medical
.	O

Chronic	other-disease
kidney	other-disease
disease	other-disease
is	O
defined	O
as	O
prolonged	O
kidney	other-medical
abnormalities	other-medical
(	O
functional	O
and/or	O
structural	O
in	O
nature	O
)	O
that	O
last	O
for	O
more	O
than	O
three	O
weeks	O
.	O

25I-NBOH	other-medical
acts	O
as	O
a	O
potent	O
agonist	O
for	O
the	O
5HT2A	other-medical
receptor	other-medical
,	O
with	O
a	O
Ki	O
of	O
0.061	O
nM	O
at	O
the	O
human	O
5HT2A	other-medical
receptor	other-medical
,	O
similar	O
to	O
the	O
better-known	O
compound	O
25I-NBOMe	other-chemicalthing
,	O
making	O
it	O
some	O
twelve	O
times	O
the	O
potency	O
of	O
2C-I	other-medical
itself	O
.	O

Kanuma	other-medical
is	O
a	O
recombinant	O
form	O
of	O
the	O
natural	O
human	O
LAL	other-chemicalthing
enzyme	other-chemicalthing
and	O
an	O
enzyme	other-chemicalthing
replacement	O
therapy	O
being	O
developed	O
for	O
patients	O
with	O
LAL	other-disease
Deficiency	other-disease
.	O

They	O
may	O
be	O
hyperplastic	other-medical
or	O
tumorous	other-medical
,	O
but	O
only	O
a	O
small	O
percentage	O
of	O
thyroid	other-medical
tumors	other-medical
are	O
malignant	O
.	O

In	O
2011	O
,	O
after	O
pressure	O
by	O
activist	O
organizations	O
,	O
the	O
manufacturers	O
of	O
pentobarbital	other-medical
and	O
sodium	other-medical
thiopental	other-medical
halted	O
the	O
supply	O
of	O
the	O
drugs	O
to	O
U.S	location-GPE
.	location-GPE
prisons	O
performing	O
lethal	O
injections	O
and	O
required	O
all	O
resellers	O
to	O
do	O
the	O
same	O
.	O

In	O
animal	O
models	O
of	O
depression	O
,	O
aticaprant	O
has	O
been	O
found	O
to	O
have	O
potent	O
synergistic	O
efficacy	O
in	O
combination	O
with	O
other	O
antidepressants	O
such	O
as	O
citalopram	other-medical
and	O
imipramine	other-medical
.	O

In	O
genioglossus	other-medical
advancement	other-medical
and	other-medical
hyoid	other-medical
myotomy	other-medical
(	O
GAHM	other-medical
)	O
,	O
a	O
genioglossus	O
advancement	O
is	O
performed	O
at	O
the	O
same	O
time	O
as	O
either	O
a	O
hyo-mandibular	O
or	O
hyo-thyroid	O
suspension	O
.	O

Like	O
NSAIDs	other-medical
and	O
unlike	O
opioid	O
analgesics	O
,	O
paracetamol	other-medical
has	O
not	O
been	O
found	O
to	O
cause	O
euphoria	O
or	O
alter	O
mood	O
although	O
recent	O
research	O
shows	O
some	O
evidence	O
that	O
paracetamol	other-medical
can	O
ease	O
psychological	O
pain	O
.	O

Naltrexone	other-medical
monthly	O
IM	O
injections	O
received	O
FDA	organization-other
approval	O
in	O
2010	O
,	O
for	O
the	O
treatment	O
of	O
opioid	other-medical
dependence	O
in	O
abstinent	O
opioid	other-medical
users	O
.	O

Pentobarbital	other-medical
-induced	O
coma	O
has	O
been	O
advocated	O
in	O
patients	O
with	O
acute	other-disease
liver	other-disease
failure	other-disease
refractory	O
to	O
mannitol	other-medical
.	O

It	O
is	O
native	O
to	O
northern	O
Nigeria	location-GPE
,	O
where	O
local	O
farmers	O
extract	O
its	O
latex	O
for	O
use	O
as	O
a	O
pesticide	other-medical
.	O

Charlotte	other-livingthing
's	other-livingthing
Web	other-livingthing
was	O
developed	O
in	O
2011	O
by	O
the	O
Stanley	organization-showorganization
brothers	organization-showorganization
(	O
Joel	person-artist,author
,	O
Jesse	person-artist,author
,	O
Jon	person-artist,author
,	O
Jordan	person-artist,author
,	O
Jared	person-artist,author
and	O
Josh	person-artist,author
)	O
through	O
crossbreeding	O
a	O
strain	O
of	O
marijuana	other-medical
with	O
industrial	O
hemp	other-livingthing
.	O

It	O
is	O
a	O
component	O
of	O
the	O
PCDAI	other-medical
(	O
Pediatric	other-disease
Crohn	other-disease
's	other-disease
Disease	other-disease
Activity	O
Index	O
)	O
,	O
an	O
index	O
for	O
assessment	O
of	O
the	O
severity	O
of	O
inflammatory	O
bowel	O
disease	O
in	O
children	O
.	O

He	O
and	O
his	O
colleagues	O
often	O
served	O
as	O
their	O
own	O
lab	O
rats	O
,	O
voluntarily	O
undergoing	O
such	O
procedures	O
as	O
self-induced	O
iron	other-medical
deficiency	other-medical
anemia	other-medical
,	O
sub-dermal	other-medical
bone	other-medical
transplantation	other-medical
,	O
and	O
consumption	O
of	O
radio-labeled	other-medical
iron	other-medical
.	O

This	O
antigen	O
is	O
recognized	O
by	O
the	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
OKM5	other-medical
and	O
OKM8	other-medical
.	O

He	O
survived	O
the	O
initial	O
surgery	O
,	O
but	O
after	O
a-five-and-a-half-month	O
battle	O
with	O
cancer	other-medical
,	O
he	O
died	O
in	O
Los	location-GPE
Angeles	location-GPE
on	O
July	O
31	O
,	O
1980	O
,	O
and	O
is	O
interred	O
at	O
Mount	location-other
Sinai	location-other
Memorial	location-other
Park	location-other
Cemetery	location-other
,	O
a	O
Jewish	location-GPE
cemetery	O
in	O
Los	location-GPE
Angeles	location-GPE
.	O

Along	O
with	O
other	O
brands	O
,	O
Anadin	other-medical
's	other-medical
paracetamol	other-medical
tablets	other-medical
have	O
been	O
criticised	O
for	O
being	O
overpriced	O
compared	O
to	O
non-branded	O
versions	O
(	O
e.g	O
.	O

As	O
with	O
SSRIs	other-medical
,	O
the	O
abrupt	O
discontinuation	O
of	O
an	O
SNRI	other-medical
usually	O
leads	O
to	O
withdrawal	O
,	O
or	O
``	O
discontinuation	other-disease
syndrome	other-disease
``	O
,	O
which	O
could	O
include	O
states	O
of	O
anxiety	O
and	O
other	O
symptoms	O
.	O

Elway	person-other
had	O
LASIK	other-medical
eye	O
surgery	O
and	O
endorsed	O
Icon	organization-other
LASIK	organization-other
in	O
the	O
Denver	location-GPE
area	O
in	O
November	O
2008	O
.	O

Triclabendazole	other-medical
is	O
the	O
drug	O
of	O
choice	O
in	O
fasciolosis	other-disease
,	O
as	O
it	O
is	O
highly	O
effective	O
against	O
both	O
mature	O
and	O
immature	O
flukes	O
.	O

It	O
is	O
a	O
common	O
protecting	O
group	O
for	O
sugars	O
and	O
sugar	O
alcohols	O
,	O
a	O
simple	O
example	O
being	O
solketal	other-medical
.	O

Its	O
most	O
major	O
brand	O
names	O
are	O
Provera	other-medical
as	O
oral	O
tablets	O
and	O
Depo-Provera	other-medical
as	O
an	O
aqueous	O
suspension	O
for	O
intramuscular	O
injection	O
.	O

In	O
particular	O
,	O
immunization	O
with	O
P28GST	other-medical
,	O
a	O
schistosome	O
glutathione	O
``	O
S	O
''	O
-transferase	O
enzyme	O
in	O
rats	O
has	O
been	O
shown	O
to	O
reduce	O
colitis	other-disease
lesions	O
and	O
expression	O
of	O
pro-inflammatory	O
cytokines	O
by	O
eosinophil	O
responses	O
to	O
inflammation	O
.	O

Others	O
have	O
found	O
it	O
to	O
be	O
less	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	O
constipation	O
than	O
psyllium	other-medical
.	O

Warfarin	other-medical
is	O
tasteless	O
and	O
colourless	O
,	O
and	O
produces	O
symptoms	O
similar	O
to	O
those	O
that	O
Stalin	person-politician
exhibited	O
.	O

Lamivudine	other-medical
is	O
administered	O
by	O
mouth	O
,	O
and	O
it	O
is	O
rapidly	O
absorbed	O
with	O
a	O
bio-availability	O
of	O
over	O
80	O
%	O
.	O

Piperazine	other-medical
containing	O
designer	O
drugs	O
have	O
effects	O
similar	O
to	O
MDMA	other-medical
(	O
ecstasy	other-medical
)	O
.	O

More	O
heart	other-medical
transplants	other-medical
are	O
performed	O
at	O
Texas	location-other
Medical	location-other
Center	location-other
than	O
anywhere	O
else	O
in	O
the	O
world	O
.	O

It	O
is	O
almost	O
always	O
combined	O
with	O
an	O
estrogen	other-biologything
,	O
such	O
as	O
ethinylestradiol	other-medical
,	O
when	O
it	O
is	O
used	O
in	O
the	O
treatment	O
of	O
PCOS	other-disease
in	O
women	O
.	O

Since	O
the	O
components	O
of	O
myelin	other-medical
are	O
stoichiometrically	O
set	O
,	O
any	O
irregular	O
expression	O
of	O
a	O
component	O
can	O
cause	O
destabilization	other-medical
of	other-medical
myelin	other-medical
and	O
neuropathic	other-medical
disorders	other-medical
.	O

Hydralazine	other-medical
is	O
a	O
medication	O
used	O
to	O
treat	O
high	O
blood	O
pressure	O
.	O

The	O
drug	O
was	O
originally	O
thought	O
to	O
function	O
as	O
a	O
kinase	other-medical
inhibitor	other-medical
but	O
was	O
subsequently	O
shown	O
to	O
be	O
an	O
Hsp90	other-medical
inhibitor	other-medical
where	O
it	O
uses	O
a	O
compact	O
conformation	O
to	O
insert	O
itself	O
into	O
the	O
ATP	other-chemicalthing
binding	O
site	O
.	O

When	O
using	O
over-the-counter	O
drug	O
clotrimazole	other-medical
products	O
,	O
use	O
should	O
be	O
discontinued	O
if	O
condition	O
does	O
not	O
improve	O
after	O
treatment	O
for	O
2	O
weeks	O
for	O
jock	O
itch	O
or	O
after	O
4	O
weeks	O
for	O
athlete	O
's	O
foot	O
or	O
ringworm	O
.	O

Cryosurgery	other-medical
is	O
the	O
application	O
of	O
extremely	O
low	O
temperatures	O
to	O
destroy	O
abnormal	O
or	O
diseased	O
tissue	O
and	O
is	O
used	O
most	O
commonly	O
to	O
treat	O
skin	O
conditions	O
.	O

Feldene	other-medical
(	O
piroxicam	O
)	O
,	O
a	O
non-steroidal	O
anti-inflammatory	O
drug	O
developed	O
jointly	O
by	O
the	O
Sandwich	organization-company
site	organization-company
and	O
Pfizer	organization-company
's	organization-company
R	organization-company
&	organization-company
amp	organization-company
;	organization-company
D	organization-company
facility	organization-company
in	O
Groton	location-GPE
,	O
United	location-GPE
States	location-GPE
,	location-GPE
was	O
launched	O
in	O
1980	O
.	O

Protein	other-medical
C	other-medical
replacement	other-medical
is	O
often	O
in	O
combination	O
with	O
anticoagulation	other-medical
therapy	other-medical
of	O
injectable	O
low	O
molecular	other-medical
weight	other-medical
heparin	other-medical
or	O
oral	other-medical
warfarin	other-medical
.	O

Acute	other-disease
kidney	other-disease
disease	other-disease
is	O
now	O
termed	O
acute	other-medical
kidney	other-medical
injury	other-medical
and	O
is	O
marked	O
by	O
the	O
sudden	O
reduction	O
in	O
kidney	O
function	O
over	O
seven	O
days	O
.	O

Cambodia	location-GPE
remains	O
a	O
major	O
supplier	O
of	O
cannabis	other-medical
to	O
countries	O
in	O
East	location-GPE
and	location-GPE
Southeast	location-GPE
Asia	location-GPE
and	O
other	O
parts	O
of	O
the	O
world	O
.	O

Furosemide	other-medical
also	O
can	O
lead	O
to	O
gout	O
caused	O
by	O
hyperuricemia	other-disease
.	O

Pertaining	O
to	O
the	O
(	O
online	O
)	O
drug	O
market/trade	O
which	O
exists	O
in	O
Cambodia	location-GPE
,	O
more	O
recently	O
the	O
trade	O
took	O
on	O
its	O
international	O
intervention	O
in	O
which	O
officials	O
were	O
able	O
to	O
prevent	O
10,000	O
tablets	O
of	O
Codeine	other-medical
and	O
Valium	other-medical
being	O
sent	O
out	O
of	O
Cambodia	location-GPE
to	O
the	O
United	location-GPE
States	location-GPE
and	O
United	location-GPE
Kingdom	location-GPE
.	O

Some	O
drugs	O
,	O
like	O
tolcapone	other-medical
(	O
a	O
central	O
COMT-inhibitor	other-medical
)	O
,	O
raise	O
the	O
levels	O
of	O
all	O
the	O
catecholamines	other-biologything
.	O

It	O
is	O
a	O
less	O
profitable	O
plant	O
with	O
``	O
close	O
to	O
no	O
value	O
to	O
traditional	O
marijuana	other-medical
consumers	O
.	O
''	O

For	O
people	O
who	O
have	O
already	O
had	O
a	O
single	O
DVT	other-disease
event	O
,	O
the	O
best	O
way	O
to	O
prevent	O
a	O
second	O
DVT	other-disease
is	O
appropriate	O
anticoagulation	other-medical
therapy	other-medical
.	O

Carbapenem-resistant	other-medical
Enterobacteriaceae	other-medical
(	O
CRE	other-medical
)	O
have	O
been	O
defined	O
as	O
carbapenem	other-biologything
-nonsusceptible	O
and	O
extended-spectrum	other-biologything
cephalosporin-resistant	O
``	O
Escherichia	other-biologything
coli	other-biologything
,	O
Enterobacter	other-biologything
aerogenes	other-biologything
,	O
Enterobacter	other-biologything
cloacae	other-biologything
``	O
complex	O
,	O
``	O
Klebsiella	other-biologything
pneumoniae	other-biologything
``	O
,	O
or	O
``	O
Klebsiella	other-biologything
oxytoca	other-biologything
``	O
.	O

Penicillins	other-medical
may	O
decrease	O
the	O
elimination	O
of	O
methotrexate	other-biologything
,	O
so	O
increase	O
the	O
risk	O
of	O
toxicity	O
.	O

CAR-302,196	other-medical
(	O
also	O
known	O
as	O
PCMG	other-medical
or	O
just	O
by	O
its	O
code	O
number	O
302196	other-medical
)	O
is	O
a	O
moderately	O
potent	O
and	O
relatively	O
short	O
lasting	O
anticholinergic	O
deliriant	O
drug	O
,	O
related	O
to	O
the	O
chemical	O
warfare	O
agent	O
3-	O
Quinuclidinyl	other-chemicalthing
benzilate	other-chemicalthing
(	O
QNB	other-chemicalthing
)	O
.	O

One	O
advantage	O
is	O
a	O
well-defined	O
margin	O
between	O
therapeutic	O
and	O
toxic	O
doses	O
,	O
which	O
means	O
one	O
would	O
lose	O
consciousness	O
before	O
dangerous	O
levels	O
of	O
dissolved	O
ether	other-medical
in	O
blood	O
would	O
be	O
reached	O
.	O

Many	O
studies	O
have	O
found	O
that	O
tolerance	O
develops	O
to	O
the	O
anticonvulsant	O
properties	O
of	O
clonazepam	other-medical
with	O
chronic	O
use	O
,	O
which	O
limits	O
its	O
long-term	O
effectiveness	O
as	O
an	O
anticonvulsant	O
.	O

Chemotherapy	other-medical
can	O
be	O
given	O
as	O
cycles	O
of	O
treatment	O
.	O

Adalimumab	other-medical
has	O
been	O
shown	O
to	O
reduce	O
the	O
signs	O
and	O
symptoms	O
of	O
moderate	O
to	O
severe	O
Crohn	other-disease
's	other-disease
disease	other-disease
.	O

For	O
vulvovaginal	other-disease
candidiasis	other-disease
,	O
clotrimazole	other-medical
tablets	other-medical
and	O
creams	O
are	O
inserted	O
into	O
the	O
vagina	O
.	O

If	O
pH	O
is	O
also	O
less	O
than	O
7.35	O
this	O
is	O
respiratory	other-medical
acidosis	other-medical
.	O

Melatonin	other-medical
has	O
been	O
claimed	O
to	O
be	O
an	O
endogenous	O
ligand	O
for	O
ROR-α	other-chemicalthing
while	O
CGP	other-chemicalthing
52608	other-chemicalthing
has	O
been	O
identified	O
as	O
a	O
ROR-α	other-chemicalthing
selective	O
synthetic	O
ligand	O
.	O

For	O
the	O
less	O
aggressive	O
allergic	other-disease
bronchopulmonary	other-disease
aspergillosis	other-disease
,	O
findings	O
suggest	O
the	O
use	O
of	O
oral	O
steroids	other-medical
for	O
a	O
prolonged	O
period	O
of	O
time	O
,	O
preferably	O
for	O
6–9	O
months	O
in	O
allergic	other-disease
aspergillosis	other-disease
of	O
the	O
lungs	O
.	O

A	O
brand	O
name	O
for	O
bumetanide	other-medical
is	O
Bumex	other-medical
.	O

In	O
2001	O
,	O
Merck	O
commenced	O
the	O
APPROVe	O
(	O
Adenomatous	other-disease
Polyp	other-disease
PRevention	O
On	O
Vioxx	other-medical
)	O
study	O
,	O
a	O
three-year	O
trial	O
with	O
the	O
primary	O
aim	O
of	O
evaluating	O
the	O
efficacy	O
of	O
rofecoxib	other-medical
for	O
the	O
prophylaxis	O
of	O
colorectal	other-disease
polyps	other-disease
.	O

Topical	other-medical
clotrimazole	other-medical
is	O
usually	O
not	O
effective	O
in	O
treatment	O
of	O
fungal	other-disease
infections	other-disease
of	O
the	O
scalp	O
or	O
nails	O
.	O

In	O
May	O
2011	O
,	O
the	O
Vermont	organization-government,governmentagency
Legislature	organization-government,governmentagency
approved	O
S.	other-law
17	other-law
,	O
which	O
added	O
four	O
non-profit	O
marijuana	other-medical
dispensaries	O
to	O
the	O
existing	O
law	O
.	O

Subsequent	O
analysis	O
demonstrated	O
that	O
patients	O
treated	O
with	O
Ribociclib	other-medical
and	O
letrozole	other-medical
showed	O
a	O
median	O
progression-free	O
survival	O
of	O
25.3	O
months	O
.	O

Sodium	other-medical
docusate	other-medical
is	O
recommended	O
as	O
a	O
stool	O
softener	O
for	O
children	O
.	O

Triptans	other-medical
are	O
therefore	O
often	O
preferred	O
treatment	O
in	O
migraine	other-disease
.	O

His	O
widow	O
,	O
Elaine	person-other
Joyce	person-other
,	O
stated	O
on	O
the	O
Sally	art-broadcastprogram
Jessy	art-broadcastprogram
Raphael	art-broadcastprogram
talk	O
show	O
that	O
Van	person-other
suffered	O
13	O
days	O
of	O
headaches	O
and	O
went	O
to	O
the	O
hospital	O
where	O
they	O
made	O
a	O
small	O
incision	O
and	O
tested	O
the	O
tumor	other-medical
.	O

The	O
gel	O
typically	O
contains	O
potassium	other-chemicalthing
chloride	other-chemicalthing
–	O
sometimes	O
silver	other-chemicalthing
chloride	other-chemicalthing
as	O
well	O
–	O
to	O
permit	O
electron	O
conduction	O
from	O
the	O
skin	O
to	O
the	O
wire	O
and	O
to	O
the	O
electrocardiogram	other-medical
.	O

The	O
association	O
offers	O
education	O
and	O
advocacy	O
services	O
to	O
improve	O
the	O
lives	O
of	O
sleep	other-medical
apnea	other-medical
patients	O
.	O

Milloy	person-other
has	O
campaigned	O
against	O
the	O
1972	O
ban	O
on	O
non-public-health	O
uses	O
of	O
DDT	other-medical
in	O
the	O
United	location-GPE
States	location-GPE
and	O
in	O
favour	O
of	O
wider	O
use	O
of	O
DDT	other-medical
against	O
malaria	other-disease
,	O
which	O
he	O
claims	O
could	O
be	O
largely	O
eliminated	O
if	O
DDT	other-medical
were	O
used	O
more	O
aggressively	O
.	O

Treatments	O
(	O
both	O
preventive	O
and	O
therapeutic	O
)	O
available	O
are	O
pressure	other-medical
therapy	other-medical
,	O
silicone	other-medical
gel	other-medical
sheeting	other-medical
,	O
intra-lesional	other-medical
triamcinolone	other-medical
acetonide	other-medical
(	O
TAC	other-medical
)	O
,	O
cryosurgery	other-medical
(	O
freezing	other-medical
)	O
,	O
radiation	other-medical
,	O
laser	other-medical
therapy	other-medical
(	O
PDL	other-medical
)	O
,	O
IFN	other-medical
,	O
5-FU	other-medical
and	O
surgical	other-medical
excision	other-medical
as	O
well	O
as	O
a	O
multitude	other-medical
of	other-medical
extracts	other-medical
and	O
topical	other-medical
agents	other-medical
.	O

Artemether	other-medical
has	O
been	O
demonstrated	O
``	O
in	O
vitro	O
''	O
to	O
be	O
equally	O
effective	O
.	O

Deforolimus	other-medical
(	O
Ridaforolimus	other-medical
)	O
has	O
C43	O
secondary	O
alcohol	O
moiety	O
of	O
the	O
cyclohexyl	other-chemicalthing
group	O
of	O
Rapamycin	other-medical
that	O
was	O
substituted	O
with	O
phosphonate	other-chemicalthing
and	O
phosphinate	other-chemicalthing
groups	O
,	O
preventing	O
the	O
high-affinity	O
binding	O
to	O
mTOR	other-biologything
and	O
FKBP	other-biologything
.	O

Applied	other-medical
Behavior	other-medical
Analysis	other-medical
is	O
the	O
only	O
empirically	O
proven	O
method	O
of	O
treatment	O
.	O

The	O
typical	O
course	O
of	O
isotretinoin	other-medical
treatment	O
will	O
last	O
4–5	O
months	O
,	O
and	O
is	O
generally	O
considered	O
to	O
be	O
an	O
option	O
when	O
nothing	O
else	O
has	O
worked	O
.	O

Brand	O
names	O
of	O
MPA	other-medical
in	O
combination	O
with	O
estradiol	O
as	O
oral	O
tablets	O
include	O
Indivina	other-medical
and	O
Tridestra	other-medical
.	O

Ketamine	other-medical
is	O
likely	O
to	O
be	O
most	O
beneficial	O
for	O
surgical	O
patients	O
when	O
severe	O
post-operative	O
pain	O
is	O
expected	O
and	O
for	O
opioid-tolerant	O
patients	O
.	O

Psychoactive	O
drugs	O
,	O
such	O
as	O
caffeine	other-medical
,	O
amphetamine	other-medical
,	O
mescaline	other-medical
,	O
lysergic	other-medical
acid	other-medical
diethylamide	other-medical
(	O
LSD	other-medical
)	O
,	O
marijuana	other-medical
,	O
chloral	other-medical
hydrate	other-medical
,	O
theophylline	other-medical
,	O
IBMX	other-medical
and	O
others	O
,	O
can	O
have	O
strong	O
effects	O
on	O
certain	O
animals	O
.	O

The	O
rate	O
of	O
hypothyroidism	other-disease
is	O
around	O
six	O
times	O
higher	O
in	O
people	O
who	O
take	O
lithium	other-medical
.	O

Dermatologic	other-disease
conditions	other-disease
cause	O
about	O
75	O
%	O
of	O
cases	O
of	O
desquamative	other-disease
gingivitis	other-disease
,	O
and	O
over	O
95	O
%	O
of	O
the	O
dermatologic	other-disease
cases	other-disease
are	O
accounted	O
for	O
by	O
either	O
oral	other-medical
lichen	other-medical
planus	other-medical
or	O
cicatricial	other-medical
pemphigoid	other-medical
.	O

Type	other-disease
2	other-disease
diabetes	other-disease
is	O
a	O
progressive	O
condition	O
in	O
which	O
the	O
body	O
becomes	O
resistant	O
to	O
the	O
normal	O
effects	O
of	O
insulin	other-medical
and/or	O
gradually	O
loses	O
the	O
capacity	O
to	O
produce	O
enough	O
insulin	other-medical
in	O
the	O
pancreas	O
.	O

Medical	other-medical
diagnosis	other-medical
(	O
abbreviated	O
Dx	other-medical
or	O
DS	other-medical
)	O
is	O
the	O
process	O
of	O
determining	O
which	O
disease	O
or	O
condition	O
explains	O
a	O
person	O
's	O
symptoms	O
and	O
signs	O
.	O

A	O
high	O
proportion	O
of	O
bites—five	O
out	O
of	O
eight	O
recorded	O
cases—from	O
the	O
northern	other-livingthing
tree-dwelling	other-livingthing
funnel-web	other-livingthing
spider	other-livingthing
result	O
in	O
severe	O
symptoms	O
of	O
envenomation	other-medical
.	O

Third-line	O
medications	O
include	O
phenytoin	other-medical
for	O
children	O
and	O
phenobarbital	other-medical
for	O
adults	O
.	O

Oxacillin	other-medical
(	O
trade	O
name	O
Bactocill	other-medical
)	O
is	O
a	O
narrow-spectrum	other-medical
beta-lactam	other-medical
antibiotic	other-medical
of	other-medical
the	other-medical
penicillin	other-medical
class	O
developed	O
by	O
Beecham	organization-other
.	O

The	O
efficacy	O
of	O
fluoxetine	other-medical
in	O
the	O
treatment	O
of	O
panic	other-disease
disorder	other-disease
was	O
demonstrated	O
in	O
two	O
12-week	O
randomized	O
multicenter	O
phase	O
III	O
clinical	O
trials	O
that	O
enrolled	O
patients	O
diagnosed	O
with	O
panic	O
disorder	O
,	O
with	O
or	O
without	O
agoraphobia	other-disease
.	O

Nevertheless	O
,	O
if	O
the	O
mechanism	O
of	O
action	O
of	O
imatinib	other-medical
on	O
melanocyte	other-biologything
stem	other-biologything
cells	other-biologything
can	O
be	O
discovered	O
,	O
it	O
is	O
possible	O
that	O
a	O
safer	O
and	O
less	O
expensive	O
substitute	O
drug	O
might	O
someday	O
be	O
developed	O
.	O

However	O
,	O
atropine	other-medical
does	O
not	O
affect	O
acetylcholine	O
at	O
nicotinic	O
receptors	O
and	O
thus	O
is	O
a	O
partial	O
treatment	O
.	O

It	O
is	O
both	O
a	O
cranial	O
and	O
a	O
focal	O
dystonia	other-medical
.	O

Since	O
serotonin	other-medical
deficiency	other-medical
has	O
been	O
recognized	O
as	O
a	O
possible	O
cause	O
of	O
depression	O
,	O
it	O
has	O
been	O
suggested	O
that	O
consumption	O
of	O
tryptophan	other-biologything
or	O
5-HTP	other-biologything
may	O
therefore	O
improve	O
depression	O
symptoms	O
by	O
increasing	O
the	O
level	O
of	O
serotonin	other-biologything
in	O
the	O
brain	O
.	O

In	O
December	O
1927	O
,	O
Frank	person-other
M.	person-other
Dillard	person-other
and	O
William	person-other
C.	person-other
Nalle	person-other
formed	O
the	O
Dillard-Nalle	organization-company
company	O
and	O
sought	O
U.S	location-GPE
.	location-GPE
trademark	O
protection	O
for	O
Aspergum	other-medical
.	O

Varespladib	other-medical
treatment	O
exerted	O
a	O
significant	O
inhibitory	O
effect	O
on	O
snake	O
venom	O
PLA₂	other-biologything
both	O
``	O
in	O
vitro	O
''	O
and	O
in	O
``	O
vivo	O
''	O
.	O

Celecoxib	other-medical
had	O
already	O
been	O
approved	O
for	O
this	O
indication	O
,	O
and	O
it	O
was	O
hoped	O
to	O
add	O
this	O
to	O
the	O
indications	O
for	O
rofecoxib	other-medical
as	O
well	O
.	O

Individuals	O
diagnosed	O
with	O
PD	other-disease
often	O
exhibit	O
similar	O
movement	other-medical
dysfunction	other-medical
as	O
those	O
diagnosed	O
with	O
CBD	other-disease
,	O
which	O
adds	O
complexity	O
to	O
its	O
diagnosis	O
.	O

Fistulas	O
can	O
result	O
from	O
incorrectly	O
positioned	O
equipment	O
,	O
high	O
cuff	O
pressures	O
causing	O
pressure	O
sores	O
or	O
mucosal	O
damage	O
,	O
a	O
low	O
surgical	O
trachea	O
site	O
,	O
repetitive	O
neck	O
movement	O
,	O
radiotherapy	other-medical
,	O
or	O
prolonged	O
intubation	O
.	O

Chest	other-medical
X-rays	other-medical
are	O
frequently	O
used	O
to	O
aid	O
in	O
the	O
diagnosis	O
of	O
CHF	other-disease
.	O

Constipation	other-medical
is	O
common	O
.	O

Conservative	O
lobbyist	O
groups	O
with	O
ties	O
to	O
various	O
religious	O
powers	O
such	O
as	O
the	O
Vatican	organization-religion
,	O
originally	O
were	O
promoting	O
limiting	O
healthcare	O
coverage	O
of	O
items	O
such	O
as	O
birth	other-medical
control	other-medical
,	O
and	O
once	O
RU-486	other-medical
was	O
made	O
public	O
knowledge	O
these	O
groups	O
actively	O
worked	O
to	O
threaten	O
Hoechst	person-scholar
by	O
claiming	O
they	O
would	O
cause	O
the	O
company	O
financial	O
hardship	O
if	O
they	O
did	O
not	O
cease	O
all	O
activity	O
pertaining	O
to	O
RU-486	other-medical
.	O

Although	O
gabapentin	other-medical
and	O
pregabalin	other-medical
possess	O
low	O
abuse	O
potential	O
,	O
these	O
drugs	O
can	O
cause	O
physical	O
dependence	O
over	O
the	O
course	O
of	O
normal	O
treatment	O
,	O
and	O
certain	O
patients	O
may	O
become	O
psychologically	O
dependent	O
as	O
well	O
.	O

Chemotherapy	other-medical
(	O
drug	O
treatment	O
for	O
cancer	other-disease
)	O
may	O
be	O
used	O
before	O
surgery	O
,	O
after	O
surgery	O
,	O
or	O
instead	O
of	O
surgery	O
for	O
those	O
cases	O
in	O
which	O
surgery	O
is	O
considered	O
unsuitable	O
.	O

In	O
breast	other-disease
cancer	other-disease
,	O
the	O
acquisition	O
of	O
tamoxifen	other-medical
resistance	O
is	O
another	O
major	O
therapeutic	O
problem	O
.	O

The	O
Dutch	organization-other
Pharmacogenetics	organization-other
Working	organization-other
Group	organization-other
also	O
recommends	O
selecting	O
an	O
alternative	O
drug	O
or	O
monitoring	O
plasma	O
concentrations	O
of	O
amitriptyline	other-medical
in	O
patients	O
who	O
are	O
CYP2D6	other-biologything
poor	O
or	O
ultrarapid	O
metabolizers	O
,	O
and	O
selecting	O
an	O
alternative	O
drug	O
or	O
reducing	O
initial	O
dose	O
in	O
patients	O
who	O
are	O
CYP2D6	other-biologything
intermediate	O
metabolizers	O
.	O

Postradioembolization	other-disease
syndrome	other-disease
(	O
PRS	other-disease
)	O
includes	O
fatigue	other-medical
,	O
nausea	other-medical
,	O
vomiting	other-medical
,	O
abdominal	other-medical
discomfort	other-medical
or	O
pain	other-medical
,	O
and	O
cachexia	other-medical
,	O
occurring	O
in	O
20-70	O
%	O
of	O
patients	O
.	O

Air	O
under	O
moderately	O
high	O
pressure	O
,	O
such	O
as	O
is	O
used	O
when	O
diving	O
below	O
about	O
,	O
has	O
an	O
increasing	O
narcotic	other-medical
effect	O
on	O
the	O
nervous	O
system	O
.	O

A	O
palpable	O
spleen	O
is	O
not	O
always	O
a	O
clinical	O
significance	O
,	O
therefore	O
CT	other-medical
scan	O
,	O
MRI	other-medical
,	O
or	O
ultrasound	O
can	O
be	O
administered	O
in	O
order	O
to	O
help	O
diagnose	O
the	O
condition	O
.	O

The	O
WHO	organization-other
stated	O
that	O
a	O
coronavirus	other-medical
vaccine	other-medical
could	O
be	O
ready	O
in	O
approximately	O
18	O
months	O
.	O

Pentobarbital	other-medical
also	O
has	O
an	O
application	O
in	O
reducing	O
intracranial	O
pressure	O
in	O
Reye	other-disease
's	other-disease
syndrome	other-disease
,	O
traumatic	other-disease
brain	other-disease
injury	other-disease
and	O
induction	O
of	O
coma	O
in	O
cerebral	other-disease
ischemia	other-disease
patients	O
.	O

Attempts	O
to	O
actively	O
expel	O
water	O
from	O
the	O
airway	O
by	O
abdominal	O
thrusts	O
,	O
Heimlich	other-medical
maneuver	other-medical
or	O
positioning	O
head	O
downwards	O
should	O
be	O
avoided	O
as	O
there	O
is	O
no	O
obstruction	O
by	O
solids	O
,	O
and	O
they	O
delay	O
the	O
start	O
of	O
ventilation	O
and	O
increase	O
the	O
risk	O
of	O
vomiting	O
,	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
death	O
,	O
as	O
the	O
a	O
spiration	other-disease
of	other-disease
stomach	other-disease
contents	other-disease
is	O
a	O
common	O
complication	O
of	O
resuscitation	O
efforts	O
.	O

Isolated	O
situations	O
like	O
pregnancy	other-medical
,	O
thyroid	other-disease
disease	other-disease
or	O
ones	O
occupation	O
(	O
desk	O
work	O
or	O
intense	O
physical	O
labour	O
)	O
can	O
lead	O
to	O
mononeuropathy	other-disease
as	O
a	O
result	O
entrapped	O
nerve	O
sites	O
.	O

The	O
Jiajing	person-politician
Emperor	person-politician
in	O
the	O
Ming	location-GPE
Dynasty	location-GPE
died	O
from	O
ingesting	O
a	O
lethal	O
dosage	O
of	O
mercury	other-chemicalthing
in	O
the	O
supposed	O
``	O
Elixir	other-medical
of	other-medical
Life	other-medical
``	O
conjured	O
by	O
alchemists	O
.	O

CHMP	organization-government,governmentagency
had	O
concluded	O
that	O
the	O
marketing	O
authorizations	O
for	O
norfloxacin	other-medical
,	O
when	O
used	O
in	O
the	O
treatment	O
of	O
acute	O
or	O
chronic	other-disease
complicated	other-disease
pyelonephritis	other-disease
,	O
should	O
be	O
withdrawn	O
because	O
the	O
benefits	O
do	O
not	O
outweigh	O
their	O
risks	O
in	O
this	O
indication	O
.	O

A	O
randomized	O
controlled	O
trial	O
(	O
RCT	product-other
)	O
supported	O
the	O
use	O
of	O
higher	O
doses	O
of	O
pralidoxime	other-medical
rather	O
than	O
lower	O
doses	O
.	O

Pharmacological	O
treatment	O
using	O
a	O
highly-specific	O
ALK	other-chemicalthing
inhibitor	O
corrected	O
all	O
these	O
defects	O
in	O
flies	O
and	O
this	O
therapeutic	O
approach	O
was	O
later	O
successfully	O
validated	O
in	O
a	O
preclinical	O
mouse	O
model	O
of	O
NF1	other-disease
by	O
treating	O
mice	O
with	O
Alectinib	other-medical
,	O
suggesting	O
it	O
represents	O
a	O
promising	O
therapeutic	O
target	O
.	O

Desquamation	other-medical
(	O
skin	O
peeling	O
)	O
can	O
occur	O
with	O
severe	O
mercury	other-chemicalthing
poisoning	O
acquired	O
by	O
handling	O
elemental	O
mercury	other-chemicalthing
.	O

Thus	O
,	O
a	O
significantly	O
depressed	O
MA	O
could	O
be	O
treated	O
with	O
platelet	O
transfusion	O
or	O
medications	O
that	O
improve	O
platelet	O
function	O
,	O
such	O
as	O
DDAVP	other-medical
.	O

Hypopigmented	other-medical
skin	other-medical
macules	other-medical
have	O
occasionally	O
been	O
reported	O
.	O

Bufotalin	other-biologything
is	O
part	O
of	O
Ch'an	other-medical
Su	other-medical
,	O
a	O
traditional	O
Chinese	location-GPE
medicine	O
used	O
for	O
cancer	O
.	O

However	O
,	O
there	O
is	O
little	O
evidence	O
for	O
a	O
specific	O
diagnosable	O
MDMA	other-medical
dependence	O
syndrome	O
because	O
MDMA	other-medical
is	O
typically	O
used	O
relatively	O
infrequently	O
.	O

Even	O
patients	O
desensitized	O
to	O
aspirin	other-medical
may	O
continue	O
to	O
need	O
other	O
medications	O
including	O
nasal	other-medical
steroids	other-medical
,	O
inhaled	other-medical
steroids	other-medical
,	O
and	O
leukotriene	other-medical
antagonists	other-medical
.	O

Several	O
popular	O
products	O
sold	O
by	O
SKF	organization-company
contained	O
amphetamine	other-medical
,	O
including	O
Benzedrine	other-medical
pills	O
and	O
inhalers	O
,	O
Dexedrine	other-medical
pills	O
and	O
Dexamyl	other-medical
tablets	O
.	O

Hunt	person-other
and	O
Liddy	person-other
met	O
with	O
a	O
CIA	organization-other
operative	O
and	O
discussed	O
methods	O
of	O
assassinating	O
Anderson	organization-other
,	O
which	O
included	O
covering	O
Anderson	organization-other
's	O
car	O
steering	O
wheel	O
with	O
LSD	other-medical
to	O
drug	O
him	O
and	O
cause	O
a	O
fatal	O
accident	O
,	O
poisoning	O
his	O
aspirin	O
bottle	O
,	O
and	O
staging	O
a	O
fatal	O
robbery	O
.	O

Lysergic	other-medical
acid	other-medical
diethylamide	other-medical
(	O
LSD	other-medical
)	O
,	O
also	O
known	O
colloquially	O
as	O
acid	O
,	O
is	O
a	O
hallucinogenic	O
drug	O
.	O

Three	O
years	O
later	O
Merck	organization-company
pulled	O
Vioxx	other-medical
from	O
the	O
market	O
when	O
additional	O
studies	O
confirmed	O
that	O
daily	O
,	O
long-term	O
use	O
of	O
the	O
drug	O
could	O
increase	O
the	O
risk	O
of	O
heart	O
attacks	O
and	O
strokes	O
.	O

To	O
demonstrate	O
,	O
the	O
serotonin	O
:	O
norepinephrine	O
ratios	O
of	O
SNRIs	other-medical
are	O
as	O
follows	O
:	O
venlafaxine	other-medical
=	O
30:1	O
,	O
duloxetine	other-medical
=	O
10:1	O
,	O
desvenlafaxine	other-medical
=	O
14:1	O
,	O
milnacipran	other-medical
=	O
1.6:1	O
,	O
and	O
levomilnacipran	other-medical
=	O
1:2	O
.	O

If	O
antibiotics	O
are	O
used	O
,	O
a	O
narrow-spectrum	O
antibiotic	O
like	O
amoxicillin	other-medical
is	O
generally	O
recommended	O
,	O
as	O
broad-spectrum	O
antibiotics	O
may	O
be	O
associated	O
with	O
more	O
adverse	O
events	O
.	O

It	O
has	O
been	O
concluded	O
in	O
various	O
studies	O
that	O
benzodiazepine	other-medical
use	O
causes	O
greater	O
levels	O
of	O
risk	O
and	O
psycho-social	O
dysfunction	O
among	O
drug	O
misusers	O
.	O

Dexlansoprazole	other-medical
is	O
used	O
to	O
heal	O
and	O
maintain	O
healing	O
of	O
erosive	O
esophagitis	O
and	O
to	O
treat	O
heartburn	O
associated	O
with	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	other-disease
)	O
.	O

Unlike	O
other	O
racetams	O
,	O
nefiracetam	other-medical
shows	O
high	O
affinity	O
for	O
the	O
GABAA	other-biologything
receptor	O
(	O
IC50	O
)	O
=	O
8.5	O
nM	O
)	O
,	O
where	O
it	O
is	O
presumed	O
to	O
be	O
an	O
agonist	O
.	O

The	O
Boston	O
Diagnostic	other-medical
Aphasia	other-medical
Examination	other-medical
(	O
BDAE	other-medical
)	O
and	O
the	O
Western	other-medical
Aphasia	other-medical
Battery	other-medical
(	O
WAB	other-medical
)	O
are	O
two	O
commonly	O
used	O
test	O
batteries	O
for	O
diagnosing	O
conduction	O
aphasia	other-disease
.	O

Most	O
of	O
these	O
cases	O
are	O
now	O
thought	O
to	O
be	O
manifestation	O
of	O
tuberculosis	other-disease
and	O
indeed	O
they	O
respond	O
well	O
to	O
anti-tuberculous	other-medical
treatment	other-medical
.	O

More	O
severe	O
eruptions	O
usually	O
clear	O
up	O
after	O
treatment	O
for	O
one	O
to	O
three	O
months	O
with	O
Accutane	other-medical
or	O
tetracycline	other-medical
.	O

As	O
a	O
prodrug	O
of	O
levorphanol	other-medical
,	O
levomethorphan	other-medical
functions	O
as	O
a	O
potent	O
agonist	O
of	O
all	O
three	O
of	O
the	O
opioid	O
receptors	O
,	O
μ	O
,	O
κ	O
(	O
κ1	O
and	O
κ3	O
but	O
notably	O
not	O
κ2	O
)	O
,	O
and	O
δ	O
,	O
as	O
an	O
NMDA	O
receptor	O
antagonist	O
,	O
and	O
as	O
a	O
serotonin-norepinephrine	O
reuptake	O
inhibitor	O
.	O

25	O
%	O
of	O
ingested	O
seletracetam	other-medical
is	O
metabolized	O
and	O
excreted	O
unchanged	O
and	O
about	O
53	O
%	O
is	O
excreted	O
in	O
the	O
form	O
of	O
an	O
inactive	O
carboxylic	other-chemicalthing
acid	other-chemicalthing
metabolite	O
.	O

Naturally	O
infected	O
hens	O
were	O
dewormed	O
completely	O
in	O
24	O
hours	O
using	O
mebendazole	other-medical
orally	O
at	O
doses	O
25	O
mg/kg	O
body	O
weight	O
and	O
higher	O
,	O
without	O
apparent	O
sideeffect	O
.	O

In	O
the	O
European	organization-government,governmentagency
Union	organization-government,governmentagency
pioglitazone	other-medical
/	O
glimepiride	other-medical
is	O
indicated	O
for	O
the	O
treatment	O
of	O
people	O
with	O
type	other-disease
2	other-disease
diabetes	other-disease
mellitus	other-disease
who	O
show	O
intolerance	O
to	O
metformin	other-medical
or	O
for	O
whom	O
metformin	other-medical
is	O
contraindicated	O
and	O
who	O
are	O
already	O
treated	O
with	O
a	O
combination	O
of	O
pioglitazone	other-medical
and	O
glimepiride	other-medical
.	O

Immune-mediated	O
HIT	other-disease
most	O
commonly	O
arises	O
five	O
to	O
ten	O
days	O
after	O
exposure	O
to	O
heparin	other-medical
.	O

It	O
has	O
less	O
activity	O
against	O
factor	other-biologything
IIa	other-biologything
(	O
thrombin	other-biologything
)	O
compared	O
to	O
unfractionated	other-medical
heparin	other-medical
(	O
UFH	other-medical
)	O
due	O
to	O
its	O
low	O
molecular	O
weight	O
.	O

SERMs	other-medical
like	O
tamoxifen	other-medical
and	O
raloxifene	other-medical
can	O
also	O
be	O
considered	O
to	O
be	O
nonsteroidal	other-biologything
estrogens	other-biologything
in	O
some	O
tissues	O
.	O

In	O
the	O
2000	O
European	location-GPE
APL	organization-other
study	O
,	O
the	O
2-year	O
relapse	O
rate	O
for	O
those	O
that	O
did	O
not	O
receive	O
consolidation	O
chemotherapy	O
(	O
ATRA	other-medical
not	O
included	O
)	O
therapy	O
was	O
27	O
%	O
compared	O
to	O
11	O
%	O
in	O
those	O
that	O
did	O
receive	O
consolidation	O
therapy	O
(	O
p	O
&	O
lt	O
;	O
0.01	O
)	O
.	O

Methylene	other-medical
blue	other-medical
is	O
used	O
in	O
endoscopic	O
polypectomy	O
as	O
an	O
adjunct	O
to	O
saline	O
or	O
epinephrine	O
,	O
and	O
is	O
used	O
for	O
injection	O
into	O
the	O
submucosa	O
around	O
the	O
polyp	O
to	O
be	O
removed	O
.	O

There	O
are	O
no	O
studies	O
suggesting	O
that	O
H2	other-medical
antagonists	other-medical
improve	O
the	O
healing	O
of	O
ulcers	O
already	O
present	O
.	O

Fame	O
was	O
gained	O
by	O
the	O
resident	O
of	O
the	O
house	O
,	O
doctor	O
Gurari	person-other
Fabian	person-other
Natanovich	person-other
who	O
treated	O
skin	O
and	O
internal	O
diseases	O
X-rays	other-medical
.	O

Her	O
struggle	O
with	O
PPP	other-disease
was	O
brought	O
on	O
by	O
the	O
prescription	O
drug	O
Zoloft	other-medical
which	O
resulted	O
in	O
an	O
SSRI	other-disease
syndrome	other-disease
.	O

If	O
symptoms	O
are	O
detected	O
early	O
enough	O
and	O
the	O
patient	O
is	O
injected	O
with	O
this	O
compound	O
,	O
levels	O
of	O
severe	O
mental	O
retardation	O
can	O
be	O
slightly	O
lessened	O
,	O
but	O
brain	other-medical
damage	other-medical
is	O
irreversible	O
.	O

Stereotactic	other-medical
radiation	other-medical
therapy	other-medical
is	O
used	O
to	O
treat	O
brain	O
tumors	O
and	O
other	O
brain	O
disorders	O
.	O

Cetuximab	other-medical
and	O
other	O
EGFR	other-medical
inhibitors	other-medical
only	O
work	O
on	O
tumors	O
in	O
which	O
KRAS	other-biologything
is	O
not	O
mutated	O
.	O

He	O
is	O
the	O
first	O
person	O
to	O
have	O
prepared	O
amphetamine	other-medical
sulfate	other-medical
,	O
although	O
not	O
the	O
amphetamine	other-medical
molecule	O
.	O

In	O
Canada	location-GPE
,	O
2C-B	other-medical
is	O
classified	O
under	O
Controlled	other-law
Drugs	other-law
and	other-law
Substances	other-law
Act	other-law
as	O
Schedule	O
III	O
as	O
``	O
4-bromo-2,5-dimethoxybenzeneethanamine	other-chemicalthing
and	O
any	O
salt	O
,	O
isomer	O
or	O
salt	O
of	O
isomer	O
thereof	O
''	O
.	O

It	O
is	O
a	O
combination	O
of	O
lisinopril	other-medical
an	O
ACE	O
inhibitor	O
with	O
amlodipine	other-medical
a	O
calcium	other-chemicalthing
channel	O
blocker	O
.	O

These	O
mutants	O
also	O
demonstrated	O
diminished	O
dopamine	other-chemicalthing
binding	O
affinity	O
,	O
reduced	O
cell	O
surface	O
transporter	O
,	O
loss	O
of	O
post-translational	O
dopamine	other-chemicalthing
transporter	O
glycosylation	O
,	O
and	O
failure	O
of	O
amphetamine	other-medical
-mediated	O
dopamine	other-chemicalthing
efflux	O
.	O

It	O
was	O
developed	O
in	O
the	O
late	O
1960s	O
and	O
has	O
since	O
been	O
used	O
in	O
France	location-GPE
and	O
several	O
other	O
European	location-GPE
countries	O
,	O
and	O
although	O
pyrovalerone	other-medical
is	O
still	O
occasionally	O
prescribed	O
,	O
it	O
is	O
used	O
infrequently	O
due	O
to	O
problems	O
with	O
abuse	O
and	O
dependence	O
.	O

GFAP	other-medical
has	O
also	O
been	O
shown	O
to	O
be	O
important	O
in	O
repair	O
after	O
CNS	O
injury	O
.	O

Only	O
a	O
small	O
subset	O
of	O
dementia	other-disease
cases	O
have	O
been	O
found	O
to	O
be	O
reversible	O
with	O
vitamin	other-medical
B12	other-medical
therapy	O
.	O

In	O
a	O
large	O
survey	O
of	O
AERD	other-disease
patients	O
,	O
it	O
was	O
reported	O
that	O
Zyflo	other-medical
(	other-medical
zileuton	other-medical
)	other-medical
was	O
significantly	O
more	O
effective	O
at	O
controlling	O
the	O
symptoms	O
of	O
the	O
disease	O
than	O
Singulair	other-medical
(	other-medical
montelukast	other-medical
)	other-medical
.	O

The	O
adverse	O
effects	O
of	O
mechlorethamine	other-medical
depend	O
on	O
the	O
formulation	O
.	O

Precious	building-hospital
Blood	building-hospital
Hospital	building-hospital
offers	O
specialist	O
outpatient	O
and	O
inpatient	O
services	O
in	O
General	other-medical
medicine	other-medical
,	O
Surgery	other-medical
,	O
Obstetrics	other-medical
and	O
Gynaecology	other-medical
,	O
Orthopaedics	other-medical
and	O
Ophthalmology	other-medical
.	O

Topical	O
corticosteroids	other-medical
are	O
not	O
effective	O
as	O
treatment	O
for	O
LET	other-disease
,	O
but	O
many	O
will	O
respond	O
to	O
chloroquine	other-medical
.	O

A	O
solution	O
of	O
1	O
%	O
potassium	other-chemicalthing
permanganate	other-chemicalthing
dissolved	O
in	O
hot	O
water	O
is	O
an	O
alternative	O
to	O
antifungal	other-medical
drugs	other-medical
.	O

As	O
such	O
,	O
antibodies	O
against	O
HER2/neu	other-biologything
have	O
been	O
FDA	organization-government,governmentagency
approved	O
for	O
clinical	O
treatment	O
of	O
cancer	O
under	O
the	O
drug	O
name	O
``	O
Herceptin	other-medical
``	O
.	O

The	O
release	O
of	O
OxyContin	other-medical
in	O
1996	O
was	O
accompanied	O
by	O
an	O
aggressive	O
marketing	O
campaign	O
promoting	O
the	O
use	O
of	O
opioids	other-medical
for	O
pain	O
relief	O
.	O

The	O
biosynthesis	O
of	O
tacrolimus	other-medical
is	O
hybrid	O
synthesis	O
of	O
both	O
type	other-biologything
1	other-biologything
polyketide	other-biologything
synthases	other-biologything
(	O
PKS	other-biologything
1	other-biologything
)	O
and	O
nonribosomal	other-biologything
peptide	other-biologything
synthases	other-biologything
(	O
NRPS	other-biologything
)	O
.	O

Clonazepam	other-medical
(	O
Klonopin	other-medical
,	O
Rivotril	other-medical
)	O
is	O
effective	O
in	O
the	O
short	O
term	O
but	O
is	O
not	O
generally	O
recommended	O
for	O
treatment	O
of	O
absence	O
seizure	other-disease
because	O
of	O
the	O
rapid	O
development	O
of	O
tolerance	O
and	O
high	O
frequency	O
of	O
side	O
effects	O
.	O

Birth	O
defects	O
have	O
been	O
associated	O
with	O
use	O
of	O
lisinopril	other-medical
in	O
any	O
trimester	O
.	O

Telmisartan	other-medical
was	O
patented	O
in	O
1991	O
and	O
came	O
into	O
medical	O
use	O
in	O
1999	O
.	O

MPP	organization-other
played	O
an	O
instrumental	O
role	O
in	O
passing	O
this	O
legislation	O
,	O
by	O
funding	O
a	O
two-year	O
lobbying	O
effort	O
and	O
helping	O
elect	O
a	O
governor	O
who	O
supports	O
sensible	O
marijuana	other-medical
policies	O
.	O

Gaetano	person-other
Badalamenti	person-other
would	O
become	O
one	O
of	O
the	O
major	O
heroin	other-medical
traffickers	O
of	O
the	O
Sicilian	organization-other
Mafia	organization-other
.	O

As	O
of	O
2006	O
,	O
quinine	other-medical
is	O
no	O
longer	O
recommended	O
by	O
the	O
World	organization-other
Health	organization-other
Organization	organization-other
(	O
WHO	organization-other
)	O
as	O
a	O
first-line	O
treatment	O
for	O
malaria	other-disease
,	O
because	O
there	O
are	O
other	O
substances	O
that	O
are	O
equally	O
effective	O
with	O
fewer	O
side	O
effects	O
.	O

Pajer	person-other
lobbied	O
against	O
Washington	other-law
State	other-law
HB1638	other-law
,	O
a	O
bill	O
that	O
banned	O
personal	O
exemptions	O
to	O
the	O
MMR	other-medical
vaccine	O
in	O
the	O
state	O
.	O

Traditionally	O
quinquinas	product-other
contain	O
cinchona	O
bark	O
,	O
which	O
provides	O
quinine	other-medical
.	O

However	O
,	O
because	O
this	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
the	O
effect	O
of	O
omeprazole	other-medical
and	O
esomeprazole	other-medical
on	O
CYP2C19	other-biologything
,	O
the	O
enzyme	O
that	O
activates	O
clopidogrel	O
,	O
this	O
drug	O
interaction	O
is	O
not	O
expected	O
to	O
occur	O
as	O
strongly	O
with	O
rabeprazole	other-medical
.	O

Several	O
internal	O
documents	O
,	O
which	O
were	O
released	O
by	O
the	O
British	art-other
Medical	art-other
Journal	art-other
,	O
indicated	O
a	O
link	O
between	O
use	O
of	O
Prozac	other-medical
and	O
suicidal	O
or	O
violent	O
behavior	O
.	O

Since	O
the	O
introduction	O
of	O
adjuvant	O
chemotherapy	O
,	O
chiefly	O
platinum-based	O
drugs	O
like	O
cisplatin	other-medical
and	O
carboplatin	other-medical
,	O
the	O
outlook	O
has	O
improved	O
substantially	O
.	O

Therefore	O
,	O
it	O
is	O
recommended	O
that	O
users	O
seeking	O
to	O
discontinue	O
an	O
SNRI	other-medical
slowly	O
taper	O
the	O
dose	O
under	O
the	O
supervision	O
of	O
a	O
professional	O
.	O

Because	O
it	O
contains	O
pseudoephedrine	other-medical
,	O
its	O
purchase	O
in	O
the	O
United	location-GPE
States	location-GPE
was	O
severely	O
restricted	O
by	O
the	O
Combat	other-law
Methamphetamine	other-law
Epidemic	other-law
Act	other-law
of	other-law
2005	other-law
over	O
fears	O
that	O
any	O
product	O
containing	O
pseudoephedrine	other-medical
can	O
be	O
used	O
to	O
make	O
methamphetamine	other-medical
.	O

These	O
findings	O
show	O
that	O
fluoxetine	other-medical
as	O
well	O
as	O
other	O
antidepressants	O
that	O
act	O
through	O
the	O
same	O
mechanisms	O
as	O
fluoxetine	other-medical
enhance	O
neurorecovery	O
and	O
neurotransmission	O
to	O
reduce	O
the	O
risk	O
of	O
depression	other-disease
.	O

Three	O
tests	O
that	O
are	O
commonly	O
used	O
in	O
diagnosing	O
narcolepsy	other-disease
are	O
polysomnography	other-medical
(	O
PSG	other-medical
)	O
,	O
the	O
multiple	O
sleep	O
latency	O
test	O
(	O
MSLT	other-medical
)	O
,	O
and	O
the	O
Epworth	other-medical
Sleepiness	other-medical
Scale	other-medical
(	O
ESS	other-medical
)	O
.	O

Home	other-medical
hemodialysis	other-medical
has	O
become	O
rare	O
because	O
of	O
its	O
disadvantages	O
.	O

According	O
to	O
the	O
American	organization-other
Cancer	organization-other
Society	organization-other
and	O
the	O
Memorial	organization-other
Sloan-Kettering	organization-other
Cancer	organization-other
Center	organization-other
,	O
there	O
is	O
no	O
evidence	O
that	O
Ukrain	other-medical
is	O
an	O
effective	O
cancer	O
treatment	O
.	O

Its	O
plasma	O
half-life	O
is	O
about	O
30	O
hours	O
when	O
it	O
is	O
given	O
as	O
single	O
dose	O
,	O
but	O
it	O
is	O
a	O
strong	O
inducer	other-medical
of	other-medical
hepatic	other-medical
enzymes	other-medical
and	O
the	O
plasma	O
half-life	O
shortens	O
to	O
about	O
15	O
hours	O
when	O
it	O
is	O
given	O
repeatedly	O
.	O

The	O
Philadelphia	other-medical
chromosome	other-medical
was	O
first	O
discovered	O
and	O
described	O
in	O
1959	O
by	O
David	person-scholar
Hungerford	person-scholar
from	O
Fox	organization-other
Chase	organization-other
Cancer	organization-other
Center	organization-other
(	O
then	O
the	organization-education
Institute	organization-education
for	organization-education
Cancer	organization-education
Research	organization-education
)	O
and	O
Peter	person-scholar
Nowell	person-scholar
from	O
the	O
University	organization-education
of	organization-education
Pennsylvania	organization-education
School	organization-education
of	organization-education
Medicine	organization-education
,	O
and	O
was	O
named	O
after	O
the	O
city	O
in	O
which	O
both	O
facilities	O
are	O
located	O
.	O

Couples	O
without	O
children	O
can	O
receive	O
funding	O
for	O
IVF	other-medical
for	O
up	O
to	O
two	O
children	O
.	O

Spirorenone	other-medical
(	O
INN	other-medical
)	O
(	O
developmental	O
code	O
name	O
ZK-35973	other-medical
)	O
is	O
a	O
steroidal	other-chemicalthing
antimineralocorticoid	other-chemicalthing
of	O
the	O
spirolactone	O
group	O
that	O
was	O
never	O
marketed	O
.	O

Abemaciclib	other-medical
(	O
LY2835219	other-medical
)	O
(	O
trade	O
name	O
Verzenio	other-medical
)	O
acts	O
as	O
a	O
selective	O
inhibitor	O
for	O
CDK4	other-biologything
and	O
CDK6	other-biologything
.	O

Patients	O
should	O
therefore	O
always	O
be	O
screened	O
for	O
G6PD	other-biologything
deficiency	O
prior	O
to	O
being	O
prescribed	O
pamaquine	other-medical
.	O

The	O
most	O
common	O
side	O
effects	O
for	O
montelukast	other-medical
are	O
,	O
for	O
example	O
,	O
respiratory	O
infection	O
,	O
fever	O
,	O
headache	O
,	O
cough	O
,	O
abdominal	O
pain	O
,	O
otitis	O
media	O
,	O
rhinorrhea	O
,	O
sinusitis	O
and	O
more	O
.	O

Clinical	O
trials	O
began	O
in	O
Europe	location-GPE
in	O
November	O
1998	O
for	O
the	O
MicroMed	other-medical
DeBakey	other-medical
VAD	other-medical
.	O

Caffeine	other-medical
has	O
also	O
been	O
shown	O
to	O
reduce	O
errors	O
made	O
by	O
shift	O
workers	O
.	O

Neuromuscular	other-medical
medicine	other-medical
is	O
subspecialty	O
of	O
neurology	O
and	O
physiatry	O
that	O
focuses	O
the	O
diagnosis	O
and	O
treatment	O
of	O
neuromuscular	other-disease
diseases	other-disease
.	O

Taking	O
amoxicillin	other-medical
once	O
a	O
day	O
may	O
be	O
as	O
effective	O
as	O
twice	O
or	O
three	O
times	O
a	O
day	O
.	O

In	O
some	O
cases	O
,	O
switching	O
from	O
venlafaxine	other-medical
to	O
fluoxetine	other-medical
,	O
a	O
long-acting	O
SSRI	other-medical
,	O
and	O
then	O
tapering	O
off	O
fluoxetine	other-medical
,	O
may	O
be	O
recommended	O
to	O
reduce	O
discontinuation	other-disease
symptoms	other-disease
.	O

See	O
the	O
latest	O
package	O
insert	O
for	O
ofloxacin	other-medical
for	O
additional	O
details	O
.	O

Moreover	O
,	O
spirorenone	other-medical
itself	O
has	O
virtually	O
no	O
affinity	O
for	O
the	O
androgen	other-biologything
receptor	other-biologything
while	O
its	O
progestogenic	other-biologything
activity	O
shows	O
species	O
differences	O
,	O
being	O
somewhat	O
greater	O
than	O
that	O
of	O
spironolactone	other-biologything
in	O
rabbits	other-livingthing
but	O
absent	O
in	O
mice	other-livingthing
and	O
rats	other-livingthing
.	O

Ibuprofen	other-medical
is	O
a	O
weaker	O
anti-inflammatory	O
agent	O
than	O
other	O
NSAIDs	other-medical
.	O

A	O
Cochrane	person-scholar
review	O
of	O
clinical	O
research	O
noted	O
that	O
devil	other-medical
's	other-medical
claw	other-medical
seems	O
to	O
reduce	O
low	O
back	O
pain	O
more	O
than	O
placebo	other-medical
,	O
although	O
evidence	O
was	O
of	O
moderate	O
quality	O
at	O
best	O
.	O

However	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
high	O
doses	O
of	O
NSAIDs	other-medical
given	O
over	O
several	O
days	O
can	O
cause	O
kidney	O
damage	O
,	O
as	O
well	O
as	O
ulcers	O
.	O

Prior	O
to	O
the	O
1930s	O
naturally	O
occurring	O
stimulants	O
such	O
as	O
camphor	other-medical
and	O
caffeine	other-medical
were	O
utilized	O
in	O
the	O
treatment	O
of	O
barbiturate	other-medical
overdose	O
.	O

In	O
experiments	O
on	O
mice	O
,	O
eglumegad	other-medical
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
diazepam	other-medical
for	O
treating	O
anxiety	O
symptoms	O
in	O
several	O
standard	O
tests	O
,	O
but	O
without	O
producing	O
any	O
of	O
the	O
negative	O
side	O
effects	O
of	O
diazepam	other-medical
such	O
as	O
sedation	O
and	O
memory	O
impairment	O
.	O

Freudians	person-scholar
claimed	O
that	O
premature	other-disease
ejaculation	other-disease
could	O
be	O
cured	O
using	O
psychoanalysis	other-medical
.	O

5-ARIs	other-medical
are	O
sometimes	O
used	O
as	O
antiandrogens	O
in	O
feminizing	O
hormone	O
therapy	O
for	O
transgender	O
women	O
to	O
help	O
reduce	O
body	O
hair	O
growth	O
and	O
scalp	O
hair	O
loss	O
.	O

Small	O
,	O
asymptomatic	O
nodules	other-medical
are	O
common	O
,	O
and	O
often	O
go	O
unnoticed	O
.	O

Hsp90	other-medical
inhibitors	other-medical
are	O
another	O
possible	O
treatment	O
for	O
autoimmunity	O
,	O
because	O
hsp90	other-medical
is	O
necessary	O
for	O
proper	O
folding	O
of	O
many	O
pro-inflammatory	O
proteins	O
(	O
components	O
of	O
PI3K	other-biologything
,	O
MAPK	other-biologything
and	O
NF-kB	other-biologything
cascades	O
)	O
.	O

Adjunctive	O
to	O
morphine	other-medical
or	O
on	O
its	O
own	O
,	O
ketamine	other-medical
reduces	O
morphine	other-medical
use	O
,	O
pain	O
level	O
,	O
nausea	O
,	O
and	O
vomiting	O
after	O
surgery	O
.	O

The	O
thiolactone	other-chemicalthing
functional	O
group	O
is	O
also	O
present	O
in	O
some	O
pharmaceutical	O
drugs	O
such	O
as	O
citiolone	other-medical
and	O
erdosteine	other-medical
.	O

Anthelmintics	other-medical
should	O
generally	O
be	O
paired	O
with	O
corticosteroids	other-biologything
in	O
severe	O
infections	O
to	O
limit	O
the	O
inflammatory	O
reaction	O
to	O
the	O
dying	O
parasites	O
.	O

Emodepside	other-medical
is	O
an	O
anthelmintic	O
drug	O
that	O
is	O
effective	O
against	O
a	O
number	O
of	O
gastrointestinal	other-livingthing
nematodes	other-livingthing
,	O
is	O
licensed	O
for	O
use	O
in	O
cats	other-livingthing
and	O
belongs	O
to	O
the	O
class	O
of	O
drugs	O
known	O
as	O
the	O
``	O
octadepsipeptides	other-medical
``	O
,	O
a	O
relatively	O
new	O
class	O
of	O
anthelmintic	O
(	O
research	O
into	O
these	O
compounds	O
began	O
in	O
the	O
early	O
1990s	O
)	O
,	O
which	O
are	O
suspected	O
to	O
achieve	O
their	O
anti-parasitic	other-medical
effect	O
by	O
a	O
novel	O
mechanism	O
of	O
action	O
due	O
to	O
their	O
ability	O
to	O
kill	O
nematodes	other-livingthing
resistant	O
to	O
other	O
anthelmintics	other-medical
.	O

Growth	other-medical
hormone	other-medical
secretagogues	other-medical
or	other-medical
GH	other-medical
secretagogues	other-medical
(	O
GHSs	other-medical
)	O
are	O
a	O
class	O
of	O
drugs	O
which	O
act	O
as	O
secretagogues	O
(	O
i.e.	O
,	O
induce	O
the	O
secretion	O
)	O
of	O
growth	other-chemicalthing
hormone	other-chemicalthing
(	O
GH	other-chemicalthing
)	O
.	O

The	O
European	organization-government,governmentagency
Medicines	organization-government,governmentagency
Agency	organization-government,governmentagency
,	O
also	O
in	O
2008	O
,	O
had	O
recommended	O
restricting	O
the	O
use	O
of	O
oral	other-medical
norfloxacin	other-medical
to	O
treat	O
urinary	other-disease
infections	other-disease
.	O

All	O
GH	other-medical
prescribed	O
in	O
North	location-GPE
America	location-GPE
,	O
Europe	location-GPE
,	O
and	O
most	O
of	O
the	O
rest	O
of	O
the	O
world	O
is	O
a	O
human	O
GH	other-medical
,	O
manufactured	O
by	O
recombinant	O
DNA	other-biologything
technology	O
.	O

Tyrosine	other-biologything
kinases	other-biologything
play	O
a	O
particularly	O
important	O
role	O
in	O
cancer	O
,	O
and	O
several	O
agents	O
that	O
block	O
their	O
activity	O
are	O
now	O
used	O
as	O
anti-cancer	O
drugs	O
,	O
such	O
as	O
Imatinib	other-medical
or	O
Gleevec	other-medical
.	O

It	O
acts	O
as	O
a	O
potent	O
serotonin	other-medical
receptor	O
agonist	O
with	O
similar	O
affinity	O
to	O
the	O
better-known	O
compound	O
25B-NBOMe	other-chemicalthing
at	O
5-HT2A	other-chemicalthing
and	O
5-HT2C	other-chemicalthing
receptors	O
with	O
pKis	other-chemicalthing
values	O
of	O
8.3	O
and	O
9.4	O
,	O
respectively	O
.	O

The	O
physician	O
will	O
provide	O
you	O
a	O
course	O
of	O
2	O
weeks	O
of	O
antibiotics	other-medical
to	O
eliminate	O
any	O
possible	O
bacterial	O
overgrowth	O
and	O
repeat	O
the	O
test	O
to	O
check	O
whether	O
radio-labeled	O
Vitamin	other-chemicalthing
B12	other-chemicalthing
would	O
be	O
found	O
in	O
urine	O
or	O
not	O
.	O

Self-catheterization	other-medical
is	O
an	O
option	O
in	O
BPH	other-medical
when	O
it	O
is	O
difficult	O
or	O
impossible	O
to	O
completely	O
empty	O
the	O
bladder	O
.	O

Methotrexate	other-medical
is	O
teratogenic	O
and	O
hence	O
is	O
not	O
advised	O
for	O
either	O
the	O
prospective	O
father	O
to	O
take	O
it	O
before	O
or	O
for	O
the	O
mother	O
to	O
take	O
it	O
before	O
or	O
during	O
pregnancy	O
(	O
pregnancy	O
category	O
X	O
)	O
and	O
for	O
a	O
period	O
after	O
birth	O
.	O

His	O
apparent	O
ADHD	other-disease
affected	O
his	O
play	O
in	O
high	O
school	O
,	O
and	O
he	O
took	O
Ritalin	other-medical
to	O
treat	O
the	O
condition	O
.	O

All	O
PPIs	other-medical
react	O
with	O
cysteine	other-chemicalthing
813	other-chemicalthing
in	O
the	O
loop	O
between	O
TM5	other-chemicalthing
and	O
TM6	other-chemicalthing
on	O
the	O
H+	other-chemicalthing
/	O
K+	other-chemicalthing
ATPase	other-chemicalthing
,	O
fixing	O
the	O
enzyme	O
in	O
the	O
E2	O
configuration	O
.	O

some	O
published	O
information	O
for	O
comparing	O
rosuvastatin	other-medical
,	O
atorvastatin	other-medical
,	O
and	O
ezetimibe	other-medical
/	O
simvastatin	other-medical
results	O
is	O
available	O
,	O
but	O
many	O
of	O
the	O
relevant	O
studies	O
are	O
still	O
in	O
progress	O
.	O

Ectrodactyly	other-disease
,	O
or	O
Split	other-disease
hand/split	other-disease
foot	other-disease
malformation	other-disease
(	O
SHFM	other-disease
)	O
type	O
1	O
is	O
the	O
only	O
form	O
of	O
split	O
hand/	O
malformation	O
associated	O
with	O
sensorineural	other-medical
hearing	other-medical
loss	other-medical
.	O

It	O
was	O
formerly	O
used	O
as	O
an	O
antidepressant	other-medical
in	O
the	O
1960s	O
,	O
but	O
has	O
since	O
been	O
discontinued	O
.	O

In	O
overdose	O
propranolol	other-medical
is	O
associated	O
with	O
seizures	other-disease
.	O

SSRI	other-medical
s	O
became	O
known	O
as	O
``	O
novel	other-livingthing
antidepressants	other-livingthing
``	O
along	O
with	O
other	O
newer	O
drugs	O
such	O
as	O
SNRIs	other-medical
and	O
NRIs	other-medical
with	O
various	O
selective	O
effects	O
.	O

A	O
landmark	O
study	O
found	O
that	O
fluoxetine	other-biologything
(	O
Prozac	other-medical
)	O
was	O
more	O
likely	O
to	O
increase	O
overall	O
suicidal	O
behavior	O
.	O

The	O
boxed	O
warning	O
about	O
heart	other-medical
attack	other-medical
was	O
removed	O
;	O
the	O
warning	O
about	O
heart	other-medical
failure	other-medical
remained	O
in	O
place	O
.	O

Estrogen	other-medical
treatment	other-medical
upregulates	O
TRPV6	other-biologything
transcripts	O
by	O
8-fold	O
in	O
VDR	other-livingthing
KO	other-livingthing
mice	other-livingthing
and	O
by	O
4-fold	O
in	O
ovariectomized	other-livingthing
mice	other-livingthing
.	O

The	O
anticonvulsants	other-medical
carbamazepine	other-medical
and	O
oxcarbazepine	other-medical
are	O
especially	O
effective	O
in	O
trigeminal	other-disease
neuralgia	other-disease
.	O

The	O
precise	O
mechanism	O
of	O
action	O
of	O
niacin	other-medical
therapeutic	other-medical
effects	O
has	O
not	O
been	O
fully	O
elucidated	O
,	O
but	O
appears	O
to	O
work	O
in	O
part	O
through	O
activation	O
of	O
HCA2	other-biologything
which	O
reduces	O
the	O
levels	O
of	O
intracellular	O
cAMP	other-medical
thereby	other-medical
inhibiting	O
lipolysis	O
in	O
adipocytes	other-biologything
.	O

For	O
his	O
suggestions	O
on	O
the	O
cure	O
of	O
varicocele	other-disease
and	O
on	O
the	O
operation	O
of	O
urethroplasty	other-medical
he	O
received	O
in	O
1842	O
one	O
of	O
the	O
Montyon	other-award
prizes	O
.	O

Sibutramine	other-medical
is	O
not	O
listed	O
on	O
the	O
product	O
label	O
.	O
''	O

It	O
is	O
also	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
chemotherapeutic	O
drugs	O
5-fluorouracil	other-medical
and	O
tegafur	other-medical
.	O

Steroids	other-medical
and	O
anti-emetic	other-medical
agents	other-medical
may	O
decrease	O
the	O
incidence	O
of	O
PRS	other-disease
.	O

Anxiety	O
,	O
as	O
well	O
as	O
mood	O
and	O
obsessive-compulsive	O
symptoms	O
,	O
may	O
be	O
treated	O
using	O
SSRIs	other-medical
,	O
although	O
these	O
can	O
also	O
aggravate	O
hyperactivity	O
and	O
cause	O
disinhibited	O
behavior	O
.	O

The	O
condition	O
can	O
be	O
prevented	O
by	O
using	O
chloramphenicol	other-medical
at	O
the	O
recommended	O
doses	O
and	O
monitoring	O
blood	O
levels	O
,	O
or	O
alternatively	O
,	O
third	O
generation	O
cephalosporins	other-medical
can	O
be	O
effectively	O
substituted	O
for	O
the	O
drug	O
,	O
without	O
the	O
associated	O
toxicity	O
.	O

Adam	person-scholar
Dicker	person-scholar
,	O
an	O
associate	O
professor	O
at	O
Jefferson	organization-education
Medical	organization-education
College	organization-education
of	organization-education
Thomas	organization-education
Jefferson	organization-education
University	organization-education
in	O
Philadelphia	location-GPE
,	O
supports	O
that	O
chemotherapy	other-medical
is	O
often	O
used	O
in	O
the	O
highest	O
possible	O
doses	O
.	O

For	O
example	O
,	O
the	O
Hsp90	other-medical
inhibitor	other-medical
geldanamycin	other-medical
has	O
been	O
used	O
as	O
an	O
anti-	O
tumor	other-disease
agent	O
.	O

They	O
and	O
their	O
parents	O
sued	O
Merrell	organization-company
Dow	organization-company
Pharmaceuticals	organization-company
Inc	organization-company
.	organization-company
,	O
a	O
subsidiary	O
of	O
Dow	organization-company
Chemical	organization-company
Company	organization-company
,	O
in	O
a	O
California	organization-other
District	organization-other
Court	organization-other
,	O
claiming	O
that	O
the	O
drug	O
Bendectin	other-medical
had	O
caused	O
the	O
birth	O
defects	O
.	O

Rheumatic	other-disease
fever	other-disease
,	O
since	O
the	O
advent	O
of	O
routine	O
penicillin	other-medical
administration	O
for	O
Strep	other-disease
throat	other-disease
,	other-disease
has	O
become	O
less	O
common	O
in	O
developed	O
countries	O
.	O

Diabetic	other-disease
ketoacidosis	other-disease
may	O
be	O
diagnosed	O
when	O
the	O
combination	O
of	O
hyperglycemia	other-medical
(	O
high	other-medical
blood	other-medical
sugars	other-medical
)	O
,	O
ketones	other-biologything
in	O
the	O
blood	O
or	O
on	O
urinalysis	O
and	O
acidosis	other-medical
are	O
demonstrated	O
.	O

Patients	organization-other
Out	organization-other
of	organization-other
Time	organization-other
(	O
POT	organization-other
)	O
is	O
an	O
American	location-GPE
medical	O
cannabis	other-medical
nonprofit	O
organization	O
and	O
patients	O
rights	O
group	O
,	O
established	O
in	O
1995	O
.	O

H2	other-medical
antagonists	other-medical
are	O
cheaper	O
and	O
will	O
decrease	O
stomach	O
acid	O
production	O
but	O
require	O
more	O
frequent	O
administration	O
compared	O
to	O
PPIs	other-medical
,	O
usually	O
every	O
eight	O
hours	O
.	O

In	O
May	O
2015	O
the	O
restaurant	O
manager	O
,	O
a	O
North	location-GPE
Korean	location-GPE
National	O
was	O
arrested	O
for	O
selling	O
illegal	O
Viagra	other-medical
and	O
Alcohol	other-chemicalthing
out	O
of	O
the	O
restaurant	O
.	O

Fluoxetine	other-medical
was	O
approved	O
for	O
commercial	O
use	O
by	O
the	O
US	organization-other
Food	organization-other
and	organization-other
Drug	organization-other
Administration	organization-other
(	organization-other
FDA	organization-other
)	organization-other
in	O
1988	O
,	O
becoming	O
the	O
first	O
blockbuster	O
SSRI	other-medical
.	O

Research	O
continued	O
,	O
further	O
fueled	O
by	O
knowledge	O
gained	O
from	O
other	O
techniques	O
like	O
TMS	other-medical
and	O
fMRI	other-medical
.	O

For	O
the	O
treatment	O
of	O
yeast	O
keratitis	O
,	O
``	O
topical	O
amphotericin	other-medical
B	other-medical
is	O
usually	O
the	O
first	O
choice	O
.	O
''	O

The	O
neuraminidase	O
inhibitors	O
oseltamivir	other-medical
and	O
zanamivir	other-medical
were	O
approved	O
in	O
the	O
US	location-GPE
and	O
Europe	location-GPE
for	O
treatment	O
and	O
prevention	O
of	O
influenza	other-disease
A	other-disease
and	O
B.	O
Peramivir	O
acts	O
by	O
strongly	O
binding	O
to	O
the	O
neuraminidase	O
of	O
the	O
influenza	O
viruses	O
and	O
inhibits	O
activation	O
of	O
neuraminidase	O
much	O
longer	O
than	O
Oseltamivir	other-medical
or	O
Zanamivir	other-medical
.	O

Symptoms	O
of	O
an	O
allergic	other-medical
reaction	other-medical
include	O
rash	other-medical
,	O
itching	other-medical
,	O
swelling	other-medical
,	other-medical
severe	other-medical
dizziness	other-medical
,	O
and	O
trouble	O
breathing	O
.	O

In	O
2016	O
Israel	location-GPE
's	O
State	O
Comptroller	O
concluded	O
his	O
inquiry	O
into	O
the	O
affair	O
by	O
claiming	O
that	O
injections	O
of	O
Depo-Provera	other-medical
had	O
not	O
been	O
forced	O
on	O
the	O
women	O
by	O
the	O
State	location-GPE
of	location-GPE
Israel	location-GPE
.	O

Although	O
the	O
success	O
of	O
Sulphetrone	other-medical
drugs	O
in	O
treating	O
Hansen	other-disease
's	O
disease	O
led	O
to	O
hopes	O
in	O
the	O
early	O
1950s	O
that	O
Fantome	location-island
Island	location-island
could	O
close	O
,	O
this	O
did	O
not	O
occur	O
until	O
1973	O
.	O

Her	O
work	O
was	O
instrumental	O
in	O
the	O
introduction	O
of	O
vaccine	O
programmes	O
for	O
Haemophilus	other-medical
influenzae	other-medical
type	other-medical
b	other-medical
and	O
meningococcal	other-medical
A	other-medical
and	other-medical
B	other-medical
.	O

The	O
law	O
enforcement	O
duties	O
involve	O
counter-	O
narcotic	other-medical
operations	O
,	O
fisheries	O
,	O
and	O
environmental	O
protection	O
.	O

In	O
1978	O
,	O
the	O
Eye	O
and	O
Ear	O
was	O
the	O
site	O
of	O
a	O
pioneering	O
operation	O
to	O
install	O
the	O
world	O
's	O
first	O
multi-channel	other-medical
cochlear	other-medical
implant	other-medical
(	O
Bionic	other-medical
Ear	other-medical
)	O
,	O
developed	O
by	O
Graeme	person-scholar
Clark	person-scholar
.	O

This	O
process	O
created	O
a	O
variety	O
with	O
less	O
tetrahydrocannabinol	other-chemicalthing
(	O
THC	other-chemicalthing
)	O
and	O
more	O
cannabidiol	other-chemicalthing
(	O
CBD	other-chemicalthing
)	O
than	O
typical	O
varieties	O
of	O
marijuana	other-medical
.	O

The	O
FDA	organization-government,governmentagency
stated	O
``	O
In	O
June	O
2018	O
,	O
FDA	organization-government,governmentagency
was	O
informed	O
of	O
the	O
presence	O
of	O
an	O
impurity	O
,	O
identified	O
as	O
N-Nitrosodimethylamine	other-chemicalthing
(	O
NDMA	other-chemicalthing
)	O
,	O
from	O
one	O
valsartan	other-medical
API	other-medical
producer	O
.	O

Tamoxifen	other-medical
is	O
useful	O
in	O
the	O
treatment	O
of	O
peripheral	other-disease
precocious	other-disease
puberty	other-disease
,	O
for	O
instance	O
due	O
to	O
McCune–Albright	other-disease
syndrome	other-disease
,	O
in	O
both	O
girls	O
and	O
boys	O
.	O

These	O
two	O
drugs	O
,	O
in	O
combination	O
with	O
other	O
drugs	O
like	O
Nyquil	other-medical
and	O
Theraflu	other-medical
,	O
can	O
cause	O
death	O
by	O
multiple	O
drug	O
intake	O
and/or	O
drug	O
overdose	O
.	O

Serotonin-norepinephrine	other-medical
reuptake	other-medical
inhibitors	other-medical
(	O
SNRIs	other-medical
)	O
such	O
as	O
venlafaxine	other-medical
have	O
shown	O
similar	O
effectiveness	O
to	O
the	O
SSRIs	other-disease
.	O

Rates	O
of	O
sexual	other-disease
dysfunction	other-disease
in	O
MDD	other-disease
patients	O
treated	O
with	O
duloxetine	other-medical
vs	O
escitalopram	other-medical
did	O
not	O
differ	O
significantly	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
of	O
treatment	O
,	O
although	O
the	O
trend	O
favored	O
duloxetine	other-medical
(	O
33.3	O
%	O
of	O
duloxetine	other-medical
patients	O
experienced	O
sexual	O
side	O
effects	O
compared	O
to	O
43.6	O
%	O
of	O
those	O
receiving	O
escitalopram	other-medical
and	O
25	O
%	O
of	O
those	O
receiving	O
placebo	other-medical
)	O
.	O

Benzopyrone	other-medical
may	O
refer	O
to	O
either	O
of	O
two	O
ketone	O
derivatives	O
of	O
benzopyran	O
which	O
constitute	O
the	O
core	O
skeleton	O
of	O
many	O
flavonoid	O
compounds	O
:	O

Treatment	O
options	O
include	O
eye	O
exercises	O
,	O
wearing	O
an	O
eye	O
patch	O
on	O
alternative	O
eyes	O
,	O
prism	O
correction	O
,	O
and	O
in	O
more	O
extreme	O
situations	O
,	O
surgery	O
or	O
botulinum	other-medical
toxin	other-medical
.	O

A	O
Chem-7	other-medical
is	O
thus	O
a	O
vital	O
tool	O
when	O
attempting	O
to	O
stabilize	O
a	O
patient	O
.	O

First	O
made	O
in	O
1977	O
,	O
ketoconazole	other-medical
was	O
the	O
first	O
orally-active	O
azole	other-medical
antifungal	other-medical
medication	O
.	O

A	O
landmark	O
study	O
found	O
that	O
fluoxetine	other-medical
(	O
Prozac	other-medical
)	O
was	O
more	O
likely	O
to	O
increase	O
overall	O
suicidal	O
behavior	O
.	O

Minocycline	other-medical
has	O
also	O
been	O
reported	O
to	O
very	O
rarely	O
cause	O
idiopathic	other-medical
intracranial	other-medical
hypertension	other-medical
(	O
pseudotumor	other-medical
cerebri	other-medical
)	O
,	O
a	O
side	O
effect	O
also	O
more	O
common	O
in	O
female	O
patients	O
,	O
potentially	O
leading	O
to	O
permanent	other-medical
vision	other-medical
damage	other-medical
if	O
not	O
recognized	O
early	O
and	O
treated	O
.	O

Hyoscine	other-medical
butylbromide	other-medical
can	O
be	O
taken	O
by	O
mouth	O
,	O
injection	O
into	O
a	O
muscle	O
,	O
or	O
into	O
a	O
vein	O
.	O

This	O
concern	O
is	O
partly	O
due	O
to	O
William	person-scholar
E.	person-scholar
White	person-scholar
,	O
the	O
author	O
of	O
the	O
DXM	other-medical
FAQ	other-medical
,	O
who	O
claimed	O
that	O
dissociatives	O
definitely	O
cause	O
brain	O
damage	O
.	O

Individuals	O
with	O
hemodynamically	other-disease
``	other-disease
unstable	other-disease
''	other-disease
ventricular	other-disease
tachycardia	other-disease
``	O
should	O
not	O
''	O
initially	O
receive	O
amiodarone	other-medical
.	O

Snakebite	other-disease
envenomation	other-disease
can	O
cause	O
local	O
tissue	O
damage	O
,	O
with	O
edema	other-medical
,	O
hemorrhage	other-medical
,	O
myonecrosis	other-medical
,	O
and	O
systemic	other-medical
toxic	other-medical
responses	other-medical
,	O
including	O
organ	O
failure	O
.	O

Rehabilitation	other-medical
robotics	other-medical
is	O
a	O
new	O
frontier	O
for	O
neurological	O
rehabilitation	O
treatments	O
.	O

Spironolactone	other-medical
has	O
a	O
very	O
short	O
biological	O
half-life	O
and	O
is	O
considered	O
to	O
be	O
a	O
prodrug	O
;	O
hence	O
,	O
its	O
active	O
metabolites	O
are	O
responsible	O
for	O
most	O
of	O
its	O
pharmacodynamics	O
.	O

In	O
the	O
current	O
version	O
of	O
the	O
Diagnostic	art-writtenart
and	art-writtenart
Statistical	art-writtenart
Manual	art-writtenart
of	art-writtenart
Mental	art-writtenart
Disorders	art-writtenart
(	O
DSM-IV-TR	art-writtenart
)	O
,	O
a	O
paraphilia	other-medical
is	O
not	O
diagnosable	O
as	O
a	O
psychiatric	O
disorder	O
unless	O
it	O
causes	O
distress	O
to	O
the	O
individual	O
or	O
harm	O
to	O
others	O
.	O

However	O
,	O
most	O
data	O
remain	O
proprietary	O
and	O
thus	O
reviews	O
on	O
the	O
expanded	O
clinical	O
potential	O
for	O
drugs	O
like	O
aprepitant	other-medical
range	O
from	O
optimistic	O
to	O
poor	O
.	O

Botulinum	other-medical
toxin	other-medical
does	O
not	O
appear	O
to	O
be	O
helpful	O
.	O

Carbamazepine	other-medical
is	O
a	O
voltage-gated	O
sodium	O
channel	O
inhibitor	O
,	O
and	O
reduces	O
neuronal	O
excitability	O
by	O
preventing	O
depolarisation	O
.	O

Poisoning	O
is	O
treated	O
with	O
atropine	other-medical
and	O
simultaneously	O
with	O
oximes	O
such	O
as	O
pralidoxime	other-medical
.	O

They	O
can	O
also	O
be	O
found	O
in	O
combination	O
with	O
vasoconstrictor	other-medical
drugs	other-medical
such	O
as	O
pseudoephedrine	other-medical
for	O
sinus-related	O
preparations	O
,	O
or	O
with	O
antihistamine	other-medical
drugs	other-medical
for	O
allergy	O
sufferers	O
.	O

Tamoxifen	other-medical
acts	O
as	O
a	O
selective	O
estrogen	other-medical
receptor	other-medical
modulator	other-medical
(	O
SERM	other-medical
)	O
,	O
or	O
as	O
a	O
partial	O
agonist	O
of	O
the	O
estrogen	other-biologything
receptors	other-biologything
(	O
ER	other-biologything
s	O
)	O
.	O

Scopolamine	other-medical
and	O
atropine	other-medical
have	O
similar	O
effects	O
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Morphine	other-medical
is	O
also	O
available	O
as	O
a	O
slow-release	O
formulation	O
for	O
opiate	other-medical
substitution	other-medical
therapy	other-medical
(	O
OST	other-medical
)	O
in	O
Austria	location-GPE
,	O
Germany	location-GPE
,	O
Bulgaria	location-GPE
,	O
Slovenia	location-GPE
,	O
and	O
Canada	location-GPE
for	O
addicts	O
who	O
can	O
not	O
tolerate	O
either	O
methadone	other-medical
or	O
buprenorphine	other-medical
.	O

Spirorenone	other-medical
possesses	O
5–8	O
times	O
the	O
antimineralocorticoid	O
activity	O
of	O
spironolactone	other-medical
in	O
animal	O
studies	O
.	O

Cyclophosphamide	other-medical
is	O
one	O
of	O
the	O
most	O
potent	O
immunosuppressive	O
substances	O
.	O

Numerous	O
clinical	O
trials	O
have	O
been	O
performed	O
to	O
assess	O
the	O
use	O
of	O
dopamine	other-medical
agonists	other-medical
for	O
the	O
treatment	O
of	O
restless	other-disease
leg	other-disease
syndrome	other-disease
(	O
RLS	other-disease
)	O
.	O

It	O
tends	O
to	O
be	O
slightly	O
activating/stimulating	O
rather	O
than	O
sedating	O
,	O
unlike	O
most	O
others	O
TCAs	other-medical
.	O

It	O
confirmed	O
an	O
association	O
between	O
rosiglitazone	other-medical
and	O
an	O
increased	O
risk	O
of	O
heart	other-medical
failure	other-medical
and	O
fractures	other-medical
,	O
but	O
not	O
of	O
heart	other-medical
attack	other-medical
,	O
and	O
concluded	O
that	O
it	O
``	O
does	O
not	O
increase	O
the	O
risk	O
of	O
overall	O
cardiovascular	O
morbidity	O
or	O
mortality	O
compared	O
with	O
standard	O
glucose-lowering	O
drugs	O
.	O
''	O

MPA	other-medical
is	O
marketed	O
under	O
a	O
large	O
number	O
of	O
brand	O
names	O
throughout	O
the	O
world	O
.	O

Myocet	other-medical
is	O
another	O
non-pegylated	O
liposome	O
encapsulated	O
doxorubicin	O
citrate	O
complex	O
approved	O
for	O
use	O
in	O
combination	O
with	O
cyclophosphamide	O
in	O
metastatic	O
breast	O
cancer	O
patients	O
as	O
first	O
line	O
treatment	O
in	O
Europe	location-GPE
and	O
Canada	location-GPE
.	O

Other	O
tertiary	O
amine	O
TCAs	other-medical
include	O
amitriptyline	other-medical
,	O
imipramine	other-medical
,	O
clomipramine	other-medical
,	O
dosulepin	other-medical
(	O
dothiepin	other-medical
)	O
,	O
and	O
trimipramine	other-medical
.	O

Percodan	other-medical
has	O
largely	O
been	O
replaced	O
by	O
Percocet	other-medical
(	O
which	O
is	O
oxycodone	other-medical
combined	O
with	O
paracetamol	other-medical
(	O
acetaminophen	other-medical
)	O
instead	O
of	O
Percodan	other-medical
's	O
aspirin	other-medical
)	O
and	O
other	O
oxycodone-containing	O
compounds	O
for	O
post-operative	O
pain	O
.	O

However	O
,	O
whether	O
the	O
effect	O
of	O
omeprazole	other-medical
and	O
esomeprazole	other-medical
on	O
clopidogrel	other-medical
's	O
metabolism	O
actually	O
leads	O
to	O
poor	O
clinical	O
outcomes	O
is	O
still	O
a	O
matter	O
of	O
intense	O
debate	O
among	O
healthcare	O
professionals	O
.	O

Very	O
large	O
intakes	O
of	O
fish	other-medical
oil	other-medical
/	O
omega-3	other-medical
fatty	O
acids	O
may	O
increase	O
the	O
risk	O
of	O
hemorrhagic	O
(	O
bleeding	O
)	O
stroke	O
.	O
''	O

Hyoscine	other-medical
butylbromide	other-medical
,	O
also	O
known	O
as	O
scopolamine	other-medical
butylbromide	other-medical
and	O
sold	O
under	O
the	O
brandname	organization-company
Buscopan	organization-company
among	O
others	O
,	O
is	O
an	O
anticholinergic	O
medication	O
used	O
to	O
treat	O
crampy	other-disease
abdominal	other-disease
pain	other-disease
,	O
esophageal	other-disease
spasms	other-disease
,	O
renal	other-disease
colic	other-disease
,	O
and	O
bladder	other-disease
spasms	other-disease
.	O

In	O
arm	O
fractures	O
in	O
children	O
,	O
ibuprofen	other-medical
has	O
been	O
found	O
to	O
be	O
as	O
effective	O
as	O
a	O
combination	O
of	O
paracetamol	other-medical
and	O
codeine	other-medical
.	O

The	O
CDC	organization-other
,	O
the	O
IOM	organization-other
of	organization-other
the	organization-other
National	organization-other
Academy	organization-other
of	organization-other
Sciences	organization-other
,	O
Australia	location-GPE
's	O
Department	organization-other
of	organization-other
Health	organization-other
,	O
and	O
the	O
UK	organization-other
National	organization-other
Health	organization-other
Service	organization-other
have	O
all	O
concluded	O
that	O
there	O
is	O
no	O
evidence	O
of	O
a	O
link	O
between	O
the	O
MMR	other-medical
vaccine	other-medical
and	O
autism	other-disease
.	O

Similarly	O
to	O
most	O
other	O
opioids	O
,	O
oxycodone	other-medical
increases	O
prolactin	O
secretion	O
,	O
but	O
its	O
influence	O
on	O
testosterone	O
levels	O
is	O
unknown	O
.	O

Biotron	organization-company
's	O
lead	O
drug	O
,	O
BIT225	other-medical
,	O
is	O
in	O
clinical	O
development	O
for	O
treatment	O
of	O
both	O
HIV	other-biologything
and	O
Hepatitis	other-disease
C	other-disease
,	O
as	O
well	O
as	O
the	O
hard	O
to	O
treat	O
HIV	other-biologything
/	O
Hepatitis	other-disease
C	other-disease
co-infected	O
population	O
.	O

Some	O
research	O
suggests	O
that	O
lamivudine	other-medical
can	O
cross	O
the	O
blood–brain	O
barrier	O
.	O

Intravenously	O
injected	O
methylene	other-medical
blue	other-medical
is	O
readily	O
released	O
into	O
the	O
urine	O
and	O
thus	O
can	O
be	O
used	O
to	O
test	O
the	O
urinary	O
tract	O
for	O
leaks	O
or	O
fistulas	O
.	O

However	O
,	O
as	O
no	O
material	O
had	O
been	O
offered	O
to	O
indicate	O
that	O
the	O
beta	O
crystalline	O
form	O
of	O
imatinib	other-medical
mesylate	O

Palliative	other-medical
care	other-medical
should	O
be	O
involved	O
earlier	O
,	O
rather	O
than	O
later	O
in	O
the	O
disease	O
course	O
.	O

FITM2	other-biologything
has	O
been	O
identified	O
as	O
being	O
overexpressed	O
throughout	O
the	O
time	O
3T3-L1	other-biologything
(	O
from	O
the	O
adipocyte	other-biologything
cell	other-biologything
line	O
)	O
is	O
being	O
differentiated	O
which	O
shows	O
resemblance	O
to	O
the	O
peroxisome	other-medical
proliferator-activated	other-medical
receptor	other-medical
gamma	other-medical
(	O
PPAR	other-medical
γ	other-medical
)	O
at	O
a	O
specific	O
period	O
when	O
lipid	O
droplets	O
have	O
been	O
identified	O
to	O
build-up	O
which	O
results	O
in	O
the	O
adipocyte	other-biologything
phenotype	O
that	O
is	O
seen	O
in	O
the	O
3T3-L1	other-biologything
cells	other-biologything
.	O

Catatonia	other-disease
with	O
inability	O
to	O
speak	O
is	O
responsive	O
to	O
lorazepam	other-medical
.	O

Beal	person-other
also	O
continued	O
to	O
crusade	O
for	O
the	O
use	O
of	O
Ibogaine	other-medical
to	O
treat	O
heroin	other-chemicalthing
addicts	O
.	O

Skele-Gro	other-medical
is	O
a	O
medicinal	O
potion	O
that	O
can	O
regrow	O
missing	O
or	O
removed	O
bones	O
,	O
though	O
it	O
tastes	O
terrible	O
and	O
the	O
process	O
is	O
very	O
slow	O
and	O
extremely	O
painful	O
.	O

Tazarotene	other-medical
is	O
the	O
most	O
effective	O
and	O
expensive	O
topical	other-medical
retinoid	other-medical
but	O
is	O
not	O
as	O
well	O
tolerated	O
.	O

Enzalutamide	other-chemicalthing
was	O
the	O
first	O
new	O
AR	other-chemicalthing
antagonist	other-chemicalthing
to	O
be	O
approved	O
for	O
the	O
treatment	O
of	O
prostate	other-disease
cancer	other-disease
in	O
over	O
15	O
years	O
,	O
following	O
the	O
introduction	O
of	O
the	O
first-generation	O
NSAA	other-medical
bicalutamide	other-medical
in	O
1995	O
.	O

Ketamine	other-medical
infusions	O
are	O
used	O
for	O
the	O
acute	O
pain	O
treatment	O
in	O
emergency	O
departments	O
and	O
in	O
the	O
perioperative	O
period	O
in	O
individuals	O
with	O
refractory	O
pain	O
.	O

Loratadine	other-medical
,	O
another	O
non-sedating	O
antihistamine	O
,	O
is	O
the	O
prodrug	O
of	O
desloratadine	other-medical
,	O
which	O
is	O
largely	O
responsible	O
for	O
the	O
antihistaminergic	O
effects	O
of	O
the	O
parent	O
compound	O
.	O

Some	O
common	O
dose-dependent	O
adverse	O
effects	O
of	O
amlodipine	other-medical
include	O
vasodilatory	other-disease
effects	O
,	O
[	O
[	O
peripheral	other-disease
edema	other-disease
]	O
]	O
,	O
[	O
[	O
dizziness	other-disease
]	O
]	O
,	O
[	O
[	O
palpitations	other-disease
]	O
]	O
,	O
and	O
[	O
[	O
Flushing	other-disease
(	other-disease
physiology	other-disease
)	other-disease
|flushing	other-disease
]	O
]	O
.	O

While	O
Fisher	person-actor
was	O
in	O
Chicago	location-GPE
filming	O
the	O
movie	O
,	O
she	O
choked	O
on	O
a	O
Brussels	other-livingthing
sprout	other-livingthing
;	O
Dan	person-actor
Aykroyd	person-actor
performed	O
the	O
Heimlich	other-medical
maneuver	other-medical
and	O
``	O
saved	O
my	O
life	O
''	O
.	O

The	O
visual	other-medical
disturbance	other-medical
is	O
due	O
solely	O
to	O
the	O
forced	O
closure	O
of	O
the	O
eyelids	O
.	O

This	O
block	O
of	O
nucleotide	other-biologything
biosynthesis	O
is	O
more	O
toxic	O
to	O
rapidly	O
growing	O
cells	O
than	O
non-dividing	O
cells	O
,	O
since	O
a	O
rapidly	O
growing	O
cell	O
has	O
to	O
carry	O
out	O
DNA	other-biologything
replication	O
,	O
therefore	O
methotrexate	other-biologything
is	O
often	O
used	O
in	O
cancer	other-medical
chemotherapy	other-medical
.	O

Combretastatin	other-medical
and	O
pazopanib	other-medical
are	O
being	O
researched	O
in	O
combination	O
for	O
recurrent	O
ovarian	other-disease
cancer	other-disease
.	O

In	O
the	O
late	O
2000s	O
,	O
reports	O
in	O
the	O
Israeli	location-GPE
media	O
claimed	O
that	O
injections	O
of	O
long-acting	O
contraceptive	O
Depo-Provera	other-medical
had	O
been	O
forced	O
on	O
hundreds	O
of	O
Ethiopian-Jewish	O
immigrants	O
both	O
in	O
transit	O
camps	O
in	O
Ethiopia	location-GPE
and	O
after	O
their	O
arrival	O
in	O
Israel	location-GPE
.	O

The	O
(	other-chemicalthing
+	other-chemicalthing
)	other-chemicalthing
-isomer	other-chemicalthing
is	O
predominantly	O
active	O
as	O
an	O
opiate	other-medical
with	O
a	O
higher	O
affinity	O
for	O
the	O
µ-opiate	other-medical
receptor	O
(	O
20	O
times	O
higher	O
affinity	O
than	O
the	O
(	other-chemicalthing
-	other-chemicalthing
)	other-chemicalthing
-isomer	other-chemicalthing
)	O
.	O

It	O
has	O
a	O
reasonably	O
fast	O
rate	O
of	O
occupancy	O
of	O
dopamine	other-chemicalthing
transporters	O
in	O
the	O
brain	O
,	O
though	O
slower	O
than	O
that	O
of	O
cocaine	other-medical
itself	O
.	O

In	O
the	O
Nigro	person-other
protocol	O
,	O
the	O
patient	O
receives	O
30	O
Gy	O
(	O
3000	O
rads	O
)	O
of	O
radiation	O
over	O
a	O
three-week	O
period	O
,	O
as	O
well	O
as	O
continuous	O
administration	O
of	O
fluorouracil	other-medical
for	O
the	O
first	O
four	O
days	O
and	O
on	O
days	O
20–31	O
,	O
with	O
bolus	other-medical
mitomycin	other-medical
on	O
day	O
1	O
.	O

Flunitrazepam	other-medical
was	O
discovered	O
at	O
Roche	organization-company
as	O
part	O
of	O
the	O
benzodiazepine	O
work	O
led	O
by	O
Leo	person-other
Sternbach	person-other
;	O
the	O
patent	O
application	O
was	O
filed	O
in	O
1962	O
and	O
it	O
was	O
first	O
marketed	O
in	O
1974	O
.	O

``	O
Prototheca	other-biologything
zopfii	other-biologything
``	O
is	O
less	O
susceptible	O
or	O
completely	O
resistant	O
to	O
clotrimazole	other-medical
,	O
fluconazole	other-medical
,	O
econazole	other-medical
,	O
flucytosine	other-medical
,	O
cefoperazone	other-medical
,	O
cephalexin	other-medical
,	O
enrofloxacin	other-medical
,	O
lincomycin	other-medical
,	O
oxytetracycline	other-medical
,	O
miconazole	other-medical
,	O
colistin	other-medical
,	O
a	O
combination	O
of	O
amoxicillin	other-medical
with	O
clavulanic	other-medical
acid	other-medical
,	O
enrofloxacin	other-medical
,	O
amoxicillin	other-medical
,	O
tetracycline	other-medical
,	O
penicillin	other-medical
,	O
lincomycin	other-medical
,	O
and	O
novobiocin	other-medical
,	O
whereas	O
drugs	O
such	O
as	O
nystatin	other-medical
,	O
ketoconazole	other-medical
,	O
and	O
amphotericin	other-medical
B	other-medical
are	O
effective	O
against	O
algae	O
isolated	O
from	O
milk	O
of	O
mastitis-affected	other-medical
cows	other-livingthing
.	O

Thoracentesis	other-medical
and	O
an	O
indwelling	other-medical
catheter	other-medical
for	O
use	O
at	O
home	O
is	O
generally	O
used	O
to	O
drain	O
the	O
chylothorax	other-disease
.	O

Nystatin	other-medical
(	O
``	O
Streptomyces	other-medical
noursei	other-medical
``	O
)	O
,	O
amphotericin	other-medical
B	other-medical
(	O
``	O
Streptomyces	other-medical
nodosus	other-medical
``	O
)	O
,	O
and	O
natamycin	other-medical
(	O
``	O
Streptomyces	other-medical
natalensis	other-medical
``	O
)	O
are	O
antifungals	O
isolated	O
from	O
``	O
Streptomyces	other-biologything
``	O
.	O

By	O
suppressing	O
the	O
production	O
of	O
melatonin	other-medical
over	O
the	O
course	O
of	O
the	O
night	O
rats	O
showed	O
increased	O
rates	O
of	O
tumors	other-disease
over	O
the	O
course	O
of	O
a	O
four-week	O
period	O
.	O

Nodules	other-medical
that	O
grow	O
larger	O
or	O
produce	O
symptoms	O
may	O
eventually	O
need	O
medical	O
care	O
.	O

The	O
discovery	O
and	O
development	O
of	O
melatonin	other-medical
receptor	other-medical
agonists	other-medical
was	O
motivated	O
by	O
the	O
need	O
for	O
more	O
potent	O
analogues	O
than	O
melatonin	other-chemicalthing
,	O
with	O
better	O
pharmacokinetics	O
and	O
longer	O
half-life	O
.	O

The	O
Chinese	location-GPE
herbal	O
medicine	O
long-dan-xie-gan-tan	other-medical
(	O
LDGXT	other-medical
)	O
has	O
also	O
been	O
shown	O
to	O
have	O
a	O
similar	O
anti	O
inflammatory	O
effect	O
,	O
and	O
in	O
mild	O
cases	O
may	O
be	O
used	O
alone	O
to	O
relieve	O
symptoms	O
while	O
infection	O
resolves	O
itself	O
.	O

Pathogenesis	O
of	O
immune-mediated	O
HIT	other-disease
is	O
believed	O
to	O
be	O
caused	O
by	O
heparin	other-medical
-dependent	O
immunoglobulin	other-biologything
antibodies	other-biologything
binding	O
to	O
platelet	other-biologything
factor	O
4/	O
heparin	other-medical
complexes	O
on	O
platelets	other-biologything
,	O
leading	O
to	O
wide	O
spread	O
platelet	other-biologything
activation	O
.	O

Lesser	O
evidence	O
supports	O
topical	other-medical
metronidazole	other-medical
cream	O
and	O
tetracycline	other-medical
by	O
mouth	O
.	O

When	O
tamoxifen	other-medical
was	O
launched	O
as	O
a	O
drug	O
,	O
it	O
was	O
thought	O
that	O
tamoxifen	other-medical
would	O
act	O
as	O
an	O
ER	O
antagonist	O
in	O
all	O
tissue	O
,	O
including	O
bone	O
,	O
and	O
therefore	O
it	O
was	O
feared	O
that	O
it	O
would	O
contribute	O
to	O
osteoporosis	other-disease
.	O

An	O
orally	other-medical
disintegrating	other-medical
tablet	other-medical
or	O
orally	other-medical
dissolving	other-medical
tablet	other-medical
(	O
ODT	other-medical
)	O
is	O
a	O
drug	O
dosage	O
form	O
available	O
for	O
a	O
limited	O
range	O
of	O
over-the-counter	other-medical
(	O
OTC	other-medical
)	O
and	O
prescription	O
medications	O
.	O

Selank	other-medical
,	O
as	O
well	O
as	O
a	O
related	O
peptide	O
drug	O
,	O
Semax	other-medical
,	O
have	O
been	O
found	O
to	O
inhibit	O
enzymes	O
involved	O
in	O
the	O
degradation	O
of	O
enkephalins	O
and	O
other	O
endogenous	O
regulatory	O
peptides	O
,	O
and	O
this	O
action	O
may	O
be	O
involved	O
in	O
their	O
effects	O
.	O

Diphenhydramine	other-chemicalthing
is	O
the	O
primary	O
constituent	O
of	O
dimenhydrinate	other-medical
and	O
dictates	O
the	O
primary	O
effect	O
.	O

Compared	O
to	O
other	O
NSAIDs	other-medical
,	O
it	O
may	O
have	O
other	O
side	O
effects	O
such	O
as	O
gastrointestinal	O
bleeding	O
.	O

In	O
treating	O
high	O
blood	O
pressure	O
,	O
ACE	other-medical
inhibitors	other-medical
are	O
often	O
the	O
first	O
drug	O
choice	O
,	O
particularly	O
when	O
diabetes	O
is	O
present	O
,	O
but	O
age	O
can	O
lead	O
to	O
different	O
choices	O
and	O
it	O
is	O
common	O
to	O
need	O
more	O
than	O
one	O
drug	O
to	O
obtain	O
the	O
desired	O
improvement	O
.	O

Several	O
internal	O
documents	O
,	O
which	O
were	O
released	O
by	O
the	O
British	organization-media,newspaper
Medical	organization-media,newspaper
Journal	organization-media,newspaper
,	O
indicated	O
a	O
link	O
between	O
use	O
of	O
Prozac	other-medical
and	O
suicidal	O
or	O
violent	O
behavior	O
.	O

A	O
Cochrane	organization-media,newspaper
review	O
concluded	O
that	O
there	O
is	O
no	O
credible	O
link	O
between	O
the	O
MMR	other-medical
vaccine	other-medical
and	O
autism	other-disease
,	O
that	O
MMR	other-medical
has	O
prevented	O
diseases	O
that	O
still	O
carry	O
a	O
heavy	O
burden	O
of	O
death	O
and	O
complications	O
,	O
that	O
the	O
lack	O
of	O
confidence	O
in	O
MMR	other-medical
has	O
damaged	O
public	O
health	O
,	O
and	O
that	O
the	O
design	O
and	O
reporting	O
of	O
safety	O
outcomes	O
in	O
MMR	other-medical
vaccine	other-medical
studies	O
are	O
largely	O
inadequate	O
.	O

A	O
diuretic	other-medical
is	O
any	O
substance	O
that	O
promotes	O
the	O
production	O
of	O
urine	O
.	O

Catatonia	other-disease
due	O
to	O
abrupt	O
or	O
overly	O
rapid	O
withdrawal	O
from	O
benzodiazepines	other-medical
,	O
as	O
part	O
of	O
the	O
benzodiazepine	other-disease
withdrawal	other-disease
syndrome	other-disease
,	O
should	O
also	O
respond	O
to	O
lorazepam	other-medical
treatment	O
.	O

Due	O
to	O
disagreement	O
and	O
misconceptions	O
among	O
health	O
and	O
mental	O
health	O
professionals	O
,	O
cyclothymia	other-disease
is	O
often	O
diagnosed	O
as	O
``	O
bipolar	other-medical
not	other-medical
otherwise	other-medical
specified	other-medical
``	O
.	O

In	O
2011	O
,	O
their	O
son	O
Andrew	person-other
died	O
of	O
an	O
OxyContin	other-medical
overdose	O
at	O
the	O
now-closed	O
Sunset	location-road,railway,highway,transit
Plaza	location-road,railway,highway,transit
Drive	location-road,railway,highway,transit
sober	O
living	O
facility	O
in	O
California	location-GPE
.	O

Intermittent	other-medical
urinary	other-medical
catheterization	other-medical
is	O
used	O
to	O
relieve	O
the	O
bladder	O
in	O
people	O
with	O
urinary	other-disease
retention	other-disease
.	O

A	O
single	O
intramuscular	O
injection	O
of	O
20	O
to	O
30	O
mg	O
estradiol	other-chemicalthing
undecylate	other-chemicalthing
has	O
been	O
found	O
to	O
inhibit	O
ovulation	O
when	O
used	O
as	O
an	O
estrogen	other-biologything
-only	O
injectable	other-medical
contraceptive	other-medical
in	O
premenopausal	O
women	O
for	O
1	O
to	O
3	O
months	O
(	O
mean	O
1.7	O
months	O
)	O
as	O
well	O
.	O

Large	O
volume	O
pumps	other-chemicalthing
can	O
pump	O
fluid	O
replacement	O
such	O
as	O
saline	other-chemicalthing
solution	other-chemicalthing
,	O
medications	O
such	O
as	O
antibiotics	other-medical
or	O
nutrient	other-medical
solutions	other-medical
large	O
enough	O
to	O
feed	O
a	O
patient	O
.	O

This	O
technique	O
,	O
combined	O
with	O
PET	other-medical
imaging	other-medical
,	O
is	O
used	O
to	O
image	O
areas	O
of	O
plaque	O
deposits	O
in	O
those	O
with	O
Alzheimer	other-disease
's	other-disease
.	O

Ultrasound	other-medical
of	O
the	O
lung	O
may	O
also	O
be	O
able	O
to	O
detect	O
Kerley	O
lines	O
.	O

Sometimes	O
prednisone	other-medical
will	O
be	O
prescribed	O
to	O
prevent	O
a	O
possible	O
late	O
phase	O
Type	other-disease
I	other-disease
hypersensitivity	other-disease
reaction	other-disease
.	O

Their	O
simulations	O
suggested	O
that	O
drug	O
resistance	O
may	O
arise	O
from	O
disruption	O
of	O
the	O
binding	O
process	O
due	O
to	O
electrostatic	O
attraction	O
in	O
charged	O
neuraminidase	O
pathways	O
,	O
in	O
addition	O
to	O
disruption	O
of	O
Tamiflu	other-medical
's	other-medical
pentyl	O
sidegroup	O
.	O

Oral	O
colchicine	other-medical
had	O
been	O
used	O
for	O
many	O
years	O
as	O
an	O
unapproved	O
drug	O
with	O
no	O
FDA	organization-government,governmentagency
-approved	O
prescribing	O
information	O
,	O
dosage	O
recommendations	O
,	O
or	O
drug	O
interaction	O
warnings	O
.	O

As	O
with	O
other	O
opioids	O
,	O
chronic	O
use	O
of	O
oxycodone	other-medical
(	O
particularly	O
with	O
higher	O
doses	O
)	O
often	O
causes	O
concurrent	other-disease
hypogonadism	other-disease
(	O
low	O
sex	O
hormone	O
levels	O
)	O
.	O

In	O
addition	O
to	O
coining	O
the	O
term	O
``	O
pediatric	other-medical
psychology	other-medical
``	O
,	O
Wright	person-scholar
wrote	O
several	O
conceptual	O
papers	O
related	O
to	O
the	O
field	O
.	O

A	O
large	O
cohort	O
study	O
of	O
babies	O
born	O
to	O
Israeli	O
women	O
exposed	O
to	O
metoclopramide	other-medical
during	O
pregnancy	O
found	O
no	O
evidence	O
that	O
the	O
drug	O
increases	O
the	O
risk	O
of	O
congenital	O
malformations	O
,	O
low	O
birth	O
weight	O
,	O
preterm	O
birth	O
,	O
or	O
perinatal	O
mortality	O
.	O

The	O
Dependency	O
,	O
Emotional	O
,	O
Attachment	O
Programme	O
(	O
DEAP	O
)	O
is	O
another	O
abstinence	O
based	O
treatment	O
Acorn	other-medical
developed	O
which	O
incorporates	O
psychodynamic	O
therapy	O
,	O
Gestalt	other-medical
psychology	other-medical
,	other-medical
Cognitive	other-medical
behavioral	other-medical
therapy	other-medical
and	O
Rational	other-medical
Emotive	other-medical
Therapy	other-medical
in	O
a	O
12-	O
to	O
20-week	O
program	O
.	O

But	O
even	O
years	O
of	O
psychoanalysis	other-medical
accomplished	O
little	O
,	O
if	O
anything	O
,	O
in	O
curing	O
premature	other-disease
ejaculation	other-disease
.	O

As	O
GH	other-medical
is	O
a	O
large	O
peptide	O
molecule	O
,	O
it	O
must	O
be	O
injected	O
into	O
subcutaneous	O
tissue	O
or	O
muscle	O
to	O
get	O
it	O
into	O
the	O
blood	O
.	O

``	O
First	O
described	O
by	O
Arocha-Pinango	person-other
and	O
Layrisse	person-other
in	O
Venezuela	location-GPE
in	O
1967	O
,	O
the	O
hemorrhagic	other-disease
diathesis	other-disease
caused	O
in	O
humans	O
by	O
touching	O
the	O
``	O
Lonomia	other-livingthing
``	O
species	O
begins	O
with	O
inflammatory	O
changes	O
at	O
the	O
site	O
of	O
envenoming	O
,	O
followed	O
by	O
systemic	O
symptoms	O
such	O
as	O
headache	other-medical
,	O
fever	other-medical
,	O
vomiting	other-medical
,	O
and	O
malaise	other-medical
.	O

Because	O
borage	O
oil	O
can	O
theoretically	O
lower	O
the	O
seizure	O
threshold	O
due	O
to	O
its	O
GLA	other-chemicalthing
content	O
,	O
it	O
could	O
therefore	O
trigger	O
a	O
seizure	O
in	O
users	O
of	O
phenothiazines	other-medical
or	O
tricyclic	other-medical
antidepressants	other-medical
.	O

Methicillin	other-medical
-resistant	O
``	O
Staphylococcus	other-biologything
aureus	other-biologything
``	O
(	O
MRSA	other-biologything
)	O
was	O
first	O
detected	O
in	O
Britain	location-GPE
in	O
1961	O
,	O
and	O
is	O
now	O
``	O
quite	O
common	O
''	O
in	O
hospitals	O
.	O

The	O
U.S.	organization-other
Centers	organization-other
for	organization-other
Disease	organization-other
Control	organization-other
and	organization-other
Prevention	organization-other
recommends	O
the	O
use	O
of	O
oseltamivir	other-medical
(	O
Tamiflu	other-medical
)	O
or	O
zanamivir	other-medical
(	O
Relenza	other-medical
)	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
infection	O
with	O
swine	other-disease
influenza	other-disease
viruses	other-disease
;	O
however	O
,	O
the	O
majority	O
of	O
people	O
infected	O
with	O
the	O
virus	O
make	O
a	O
full	O
recovery	O
without	O
requiring	O
medical	O
attention	O
or	O
antiviral	O
drugs	O
.	O

Criteria	O
for	O
diagnosis	O
of	O
gestational	other-disease
diabetes	other-disease
,	O
using	O
the	O
100	O
gram	O
Glucose	other-medical
Tolerance	other-medical
Test	other-medical
,	O
according	O
to	O
Carpenter	O
and	O
Coustan	O
:	O

Retinol	other-medical
is	O
a	O
form	O
of	O
vitamin	other-medical
A	other-medical
that	O
has	O
similar	O
but	O
milder	O
effects	O
and	O
is	O
present	O
in	O
many	O
over-the-counter	O
moisturizers	O
and	O
other	O
topical	O
products	O
.	O

An	O
additional	O
aim	O
of	O
the	O
study	O
was	O
to	O
further	O
evaluate	O
the	O
cardiovascular	other-biologything
safety	O
of	O
rofecoxib	other-medical
.	O

Josef	person-other
Jadassohn	person-other
described	O
the	O
first	O
case	O
of	O
metal	other-disease
contact	other-disease
dermatitis	other-disease
in	O
1895	O
,	O
to	O
a	O
mercurial	other-chemicalthing
-based	O
therapeutic	O
cream	O
,	O
and	O
confirmed	O
the	O
cause	O
by	O
epi-cutaneous	other-medical
patch	other-medical
testing	other-medical
.	O

In	O
2005	O
,	O
she	O
was	O
found	O
guilty	O
of	O
pemoline	other-medical
doping	O
.	O

``	O
N.	other-medical
gonorrhoeae	other-medical
``	O
is	O
oxidase	other-biologything
positive	O
(	O
possessing	O
cytochrome	other-biologything
c	other-biologything
oxidase	other-biologything
)	O
and	O
catalase	other-biologything
positive	O
(	O
able	O
to	O
convert	O
hydrogen	other-medical
peroxide	other-medical
to	O
oxygen	O
)	O
.	O

On	O
November	O
14	O
,	O
it	O
was	O
revealed	O
that	O
the	O
DEA	organization-government,governmentagency
had	O
intercepted	O
a	O
package	O
of	O
fifty	O
HGH	other-medical
syringes	O
en	O
route	O
to	O
Guillén	person-athlete
's	O
house	O
.	O

Botulinum	other-medical
toxin	other-medical
type-A	other-medical
is	O
only	O
temporary	O
and	O
repeated	O
injections	O
need	O
to	O
take	O
place	O
in	O
order	O
to	O
feel	O
the	O
effects	O
.	O

From	O
1975	O
to	O
1984	O
,	O
he	O
was	O
one	O
of	O
the	O
main	O
ringleaders	O
of	O
a	O
US	other-currency
$	other-currency
1.65	O
billion	O
heroin	other-medical
trafficking	O
operation	O
,	O
known	O
as	O
the	O
Pizza	event-other
Connection	event-other
,	O
that	O
imported	O
heroin	other-medical
from	O
the	O
Middle	location-GPE
East	location-GPE
and	O
distributed	O
the	O
drugs	O
through	O
U.S	location-GPE
.	location-GPE
mid-western	O
pizzeria	O
store	O
fronts	O
.	O

Modafinil	other-medical
first	O
came	O
into	O
attention	O
when	O
world	O
champion	O
runner	O
Kelli	person-athlete
White	person-athlete
was	O
tested	O
positive	O
for	O
illegally	O
consuming	O
modafinil	O
in	O
the	O
Athletics	event-sportsevent
World	event-sportsevent
Championship	event-sportsevent
in	O
2003	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
her	O
two	O
gold	O
medals	O
.	O

Metronidazole	other-medical
is	O
less	O
effective	O
,	O
but	O
is	O
available	O
in	O
a	O
gel	O
and	O
can	O
be	O
applied	O
twice	O
daily	O
.	O

In	O
2013	O
,	O
the	O
FDA	organization-government,governmentagency
lifted	O
its	O
earlier	O
restrictions	O
on	O
rosiglitazone	other-medical
after	O
reviewing	O
the	O
results	O
of	O
a	O
2009	O
trial	O
which	O
failed	O
to	O
show	O
increased	O
heart	O
attack	O
risk	O
.	O

In	O
October	O
2001	O
,	O
a	O
9-month-old	O
girl	O
named	O
Tshepang	O
was	O
raped	O
by	O
an	O
HIV-positive	O
man	O
and	O
had	O
to	O
undergo	O
extensive	O
reconstructive	other-medical
surgery	other-medical
in	O
Cape	location-GPE
Town	location-GPE
.	O

Antihistamine	product-other
tablets	product-other
may	O
be	O
prescribed	O
to	O
provide	O
relief	O
from	O
the	O
itch	O
,	O
although	O
they	O
are	O
generally	O
considered	O
much	O
less	O
effective	O
than	O
corticosteroid	other-medical
treatments	other-medical
,	O
and	O
may	O
decrease	O
itching	O
through	O
blocking	other-medical
histamine	other-medical
release	O
as	O
well	O
as	O
improving	O
sleep	O
quality	O
.	O

Doctors	O
frequently	O
prescribed	O
morphine	other-medical
to	O
women	O
in	O
those	O
years	O
to	O
treat	O
a	O
variety	O
of	O
causes	O
,	O
and	O
researchers	O
believe	O
that	O
her	O
symptoms	O
could	O
have	O
been	O
from	O
morphine	other-medical
poisoning	O
.	O

A	O
physician	O
may	O
apply	O
cocaine	other-medical
in	O
the	O
few	O
countries	O
that	O
allow	O
it	O
for	O
medical	O
use	O
.	O

In	O
the	location-GPE
United	location-GPE
States	location-GPE
,	O
Vytorin	other-medical
featured	O
a	O
television	O
advertising	O
campaign	O
showing	O
a	O
series	O
of	O
split-screen	O
images	O
of	O
a	O
person	O
and	O
a	O
food	O
item	O
to	O
make	O
the	O
point	O
that	O
cholesterol	other-biologything
comes	O
from	O
two	O
sources	O
and	O
can	O
be	O
absorbed	O
from	O
food	O
or	O
manufactured	O
by	O
the	O
body	O
,	O
and	O
that	O
heredity	other-biologything
plays	O
a	O
role	O
in	O
the	O
latter	O
.	O

Whereas	O
other	O
TCAs	other-medical
are	O
useful	O
for	O
treating	O
insomnia	O
,	O
desipramine	O
can	O
cause	O
insomnia	other-disease
as	O
a	O
side	O
effect	O
due	O
to	O
its	O
activating	O
properties	O
.	O

Rabeprazole	other-medical
binds	O
to	O
cysteine	other-chemicalthing
813	other-chemicalthing
and	O
both	O
892	other-chemicalthing
and	O
321	other-chemicalthing
.	O

From	O
1972	O
to	O
1975	O
,	O
Niikawa	person-scholar
served	O
as	O
a	O
research	O
associate	O
in	O
the	O
embryology	other-medical
and	O
cytogenetics	O
laboratory	O
at	O
the	O
Department	organization-other
of	organization-other
Gynaecology	organization-other
and	organization-other
Obstetrics	organization-other
in	O
the	O
Cantonal	building-hospital
Hospital	building-hospital
,	O
Geneva	organization-education
University	organization-education
.	O

Diphtheria	other-medical
toxin	other-medical
is	O
a	O
single	O
polypeptide	O
chain	O
of	O
535	O
amino	other-biologything
acids	other-biologything
consisting	O
of	O
two	O
subunits	O
linked	O
by	O
disulfide	other-biologything
bridges	O
,	O
known	O
as	O
an	O
A-B	O
toxin	O
.	O

Among	O
the	O
first	O
technology	O
to	O
be	O
added	O
to	O
the	O
institute	O
,	O
was	O
equipment	O
for	O
in	O
vivo	O
NMR	other-medical
studies	O
(	O
which	O
nowadays	O
is	O
mainly	O
known	O
as	O
MRI	other-medical
)	O
for	O
animal	O
studies	O
.	O

Before	O
initiating	O
warfarin	other-medical
therapy	other-medical
,	O
a	O
few	O
days	O
of	O
therapeutic	other-medical
heparin	other-medical
may	O
be	O
administered	O
to	O
prevent	O
warfarin	other-disease
necrosis	other-disease
and	O
other	O
progressive	O
or	O
recurrent	O
thrombotic	O
complications	O
.	O

Topically	O
,	O
clotrimazole	other-medical
is	O
used	O
for	O
vulvovaginal	other-disease
candidiasis	other-disease
(	O
yeast	other-disease
infection	other-disease
)	O
or	O
yeast	other-disease
infections	other-disease
of	O
the	O
skin	O
.	O

There	O
has	O
been	O
suggested	O
that	O
4-MTA	other-medical
because	O
of	O
its	O
slow	O
onset	O
of	O
action	O
,	O
is	O
more	O
dangerous	O
than	O
other	O
designer	O
drugs	O
.	O

They	O
recommend	O
that	O
it	O
be	O
used	O
only	O
when	O
artemisinins	other-medical
are	O
not	O
available	O
.	O

Damage	other-medical
to	other-medical
the	other-medical
arcuate	other-medical
fasciculus	other-medical
is	O
implicated	O
as	O
a	O
possible	O
cause	O
of	O
specific	other-disease
language	other-disease
impairment	other-disease
,	O
however	O
further	O
data	O
is	O
required	O
to	O
validate	O
this	O
claim	O
.	O

Bevacizumab	other-medical
was	O
approved	O
in	O
the	O
United	location-GPE
States	location-GPE
in	O
February	O
2004	O
,	O
for	O
use	O
in	O
metastatic	O
colorectal	O
cancer	O
when	O
used	O
with	O
standard	O
chemotherapy	O
treatment	O
(	O
as	O
first-line	O
treatment	O
)	O
and	O
with	O
5-fluorouracil	other-medical
-based	O
therapy	O
for	O
second-line	O
metastatic	O
colorectal	O
cancer	O
.	O

PPIs	other-medical
have	O
a	O
half-life	O
in	O
human	O
blood	O
plasma	O
of	O
only	O
60–90	O
minutes	O
,	O
but	O
because	O
they	O
covalently	O
bind	O
to	O
the	O
pump	O
,	O
the	O
half-life	O
of	O
their	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
lasts	O
an	O
estimated	O
24	O
hours	O
.	O

NSAIDs	other-medical
have	O
also	O
been	O
found	O
to	O
fatally	O
interact	O
with	O
methotrexate	other-biologything
in	O
numerous	O
case	O
reports	O
.	O

However	O
,	O
in	O
this	O
case	O
the	O
parent	O
compound	O
does	O
not	O
have	O
the	O
side	O
effects	O
associated	O
with	O
terfenadine	O
,	O
and	O
so	O
both	O
loratadine	other-medical
and	O
its	O
active	O
metabolite	O
,	O
desloratadine	other-medical
,	O
are	O
currently	O
marketed	O
.	O

In	O
July	O
2008	O
,	O
Mr	O
.	O
Patel	person-other
designed	O
and	O
initiated	O
Synageva	organization-company
's	O
lead	O
program	O
,	O
Kanuma	other-medical
®	O
(	O
sebelipase	other-medical
alfa	other-medical
)	O
to	O
address	O
a	O
rare	O
and	O
devastating	O
disease	O
known	O
as	O
lysosomal	other-disease
acid	other-disease
lipase	other-disease
deficiency	other-disease
(	O
LAL	other-disease
Deficiency	other-disease
)	O
.	O

Because	O
pruritus	O
is	O
due	O
to	O
excessive	O
serum	other-biologything
histamine	other-biologything
levels	O
,	O
antihistamines	other-medical
such	O
as	O
diphenhydramine	other-medical
(	O
Benadryl	other-medical
)	O
are	O
often	O
co-administered	O
.	O

By	O
weight	O
,	O
dimenhydrinate	other-medical
is	O
between	O
53	O
%	O
to	O
55.5	O
%	O
diphenhydramine	other-chemicalthing
.	O

Weight	O
loss	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
pirfenidone	other-medical
.	O

Beyond	O
suggestions	O
that	O
PET	other-biologything
receptor	O
occupancy	O
must	O
not	O
be	O
used	O
routinely	O
to	O
cap	O
dosing	O
for	O
new	O
medical	O
indications	O
for	O
this	O
class	O
,	O
or	O
that	O
&	O
gt	O
;	O
99	O
%	O
human	O
receptor	O
occupancy	O
might	O
be	O
required	O
for	O
consistent	O
psycho-pharmacological	O
or	O
other	O
therapeutic	O
effects	O
,	O
critical	O
scientific	O
dissection	O
and	O
debate	O
of	O
the	O
above	O
data	O
might	O
be	O
needed	O
to	O
enable	O
aprepitant	other-medical
,	O
and	O
the	O
class	O
of	O
NK1	other-biologything
antagonists	O
as	O
a	O
whole	O
,	O
to	O
fulfill	O
preclinically	O
predicted	O
utilities	O
beyond	O
CINV	O
(	O
i.e.	O
,	O
for	O
other	O
psychiatric	O
disorders	O
,	O
addictions	O
,	O
neuropathic	other-medical
pain	other-medical
,	O
migraine	other-medical
,	O
osteoarthritis	other-medical
,	O
overactive	other-medical
bladder	other-medical
,	O
inflammatory	other-medical
bowel	other-medical
disease	other-medical
and	O
other	O
disorders	O
with	O
suspected	other-medical
inflammatory	other-medical
or	O
immunological	O
components	O
.	O

Protease	other-medical
inhibitors	other-medical
can	O
cause	O
a	O
syndrome	O
of	O
lipodystrophy	other-disease
,	O
hyperlipidemia	other-disease
,	O
diabetes	other-disease
mellitus	other-disease
type	other-disease
2	other-disease
,	O
and	O
kidney	other-disease
stones	other-disease
.	O

Pharmacological	O
studies	O
point	O
to	O
alterations	O
in	O
dopamine	other-medical
function	O
and	O
the	O
endocannabinoid	other-medical
system	O
.	O

Despite	O
this	O
,	O
heroin	other-medical
users	O
in	O
Australia	location-GPE
are	O
more	O
likely	O
to	O
fail	O
in	O
their	O
attempts	O
to	O
quit	O
abusing	O
the	O
substance	O
than	O
any	O
other	O
illicit	O
drug	O
.	O

In	O
August	O
2012	O
,	O
Johnson	person-other
&	person-other
amp	person-other
;	O
Johnson	person-other
agreed	O
to	O
pay	O
$	other-currency
181million	O
to	O
36	O
U.S	location-GPE
.	location-GPE
states	O
in	O
order	O
to	O
settle	O
claims	O
that	O
it	O
had	O
promoted	O
risperidone	other-medical
and	O
paliperidone	other-medical
for	O
off-label	O
uses	O
including	O
for	O
dementia	O
,	O
anger	O
management	O
,	O
and	O
anxiety	O
.	O

The	O
product	O
is	O
sold	O
globally	O
under	O
different	O
brand	O
names	O
such	O
as	O
Nicoderm	other-medical
in	O
the	O
US	location-GPE
,	O
Nicabate	other-medical
in	O
Australia	location-GPE
and	O
New	location-GPE
Zealand	location-GPE
and	O
NiQuitin	other-medical
CQ	other-medical
in	O
China	location-GPE
,	O
many	O
parts	O
of	O
Europe	location-GPE
and	O
South	location-GPE
America	location-GPE
.	O

At	O
23	O
May	O
2007	O
,	O
during	O
the	O
2007	O
Giro	event-sportsevent
d'Italia	event-sportsevent
,	O
Alessandro	person-athlete
Petacchi	person-athlete
was	O
found	O
guilty	O
of	O
using	O
salbutamol	other-medical
after	O
a	O
doping	O
control	O
.	O

Trientine	other-medical
dihydrochloride	other-medical
(	O
brand	O
name	O
Cufence	other-medical
)	O
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
European	organization-other
Union	organization-other
in	O
July	O
2019	O
.	O

It	O
is	O
not	O
yet	O
known	O
whether	O
imatinib	other-medical
has	O
an	O
effect	O
on	O
catalase	other-biologything
,	O
or	O
if	O
its	O
reversal	O
of	O
the	O
graying	O
process	O
is	O
due	O
to	O
something	O
else	O
.	O

In	O
humans	O
5-HTP	other-chemicalthing
has	O
never	O
been	O
clinically	O
associated	O
with	O
serotonin	other-disease
syndrome	other-disease
,	O
although	O
a	O
case	O
report	O
suggests	O
5-HTP	other-chemicalthing
can	O
precipitate	O
mania	O
when	O
added	O
to	O
an	O
MAOI	other-medical
.	O

Following	O
the	O
season	O
,	O
Ankiel	person-athlete
admitted	O
to	O
using	O
human	other-medical
growth	other-medical
hormone	other-medical
(	O
HGH	other-medical
)	O
,	O
but	O
said	O
he	O
was	O
following	O
doctor	O
's	O
orders	O
.	O

Because	O
the	O
R	O
value	O
on	O
the	O
TEG	other-medical
represents	O
the	O
time	O
it	O
takes	O
for	O
clot	O
formation	O
to	O
start	O
,	O
it	O
is	O
a	O
reflection	O
of	O
coagulation	O
factor	O
activity	O
.	O

Relative	O
to	O
other	O
SNRIs	other-medical
,	O
levomilnacipran	other-medical
,	O
as	O
well	O
as	O
milnacipran	other-medical
,	O
differ	O
in	O
that	O
they	O
are	O
much	O
more	O
balanced	O
reuptake	O
inhibitors	O
of	O
serotonin	O
and	O
norepinephrine	O
.	O

Severe	O
allergic	O
reactions	O
(	O
anaphalaxis	other-disease
)	O
may	O
require	O
treatment	O
with	O
an	O
epinephrine	other-medical
pen	other-medical
,	O
which	O
is	O
an	O
injection	O
device	O
designed	O
to	O
be	O
used	O
by	O
a	O
non-healthcare	O
professional	O
when	O
emergency	O
treatment	O
is	O
warranted	O
.	O

Despite	O
the	O
non-steroidal	O
nature	O
of	O
finerenone	other-medical
which	O
yields	O
a	O
different	O
lipophilicity	other-medical
and	O
polarity	O
profile	O
for	O
this	O
compound	O
,	O
finerenone	other-medical
's	O
affinity	O
toward	O
mineralocorticoid	other-medical
receptors	O
is	O
equal	O
to	O
that	O
of	O
spironolactone	other-medical
and	O
500	O
times	O
that	O
of	O
eplerenone	other-medical
,	O
hinting	O
that	O
the	O
steroidal	O
core	O
component	O
of	O
most	O
antimineralocorticoids	O
is	O
not	O
essential	O
for	O
mineralocorticoid	other-medical
receptor	O
affinity	O
.	O

Possible	O
side	O
effects	O
of	O
olanzapine	other-medical
/	O
fluoxetine	other-medical
include	O
all	O
those	O
of	O
the	O
two	O
component	O
drugs	O
:	O
olanzapine	other-medical
(	O
side	O
effects	O
)	O
and	O
fluoxetine	other-medical
(	O
side	O
effects	O
)	O
.	O

Strontium	other-medical
ranelate	other-medical
also	O
stimulates	O
osteoblasts	other-biologything
to	O
secrete	O
osteoprotegerin	O
in	O
inhibiting	other-biologything
osteoclasts	other-biologything
formed	O
from	O
pre-osteoclasts	O
in	O
relation	O
to	O
the	O
RANKL	other-biologything
system	O
,	O
which	O
leads	O
to	O
the	O
decrease	O
of	O
bone	O
resorption	O
.	O

Sodium	other-medical
oxybate	other-medical
is	O
approved	O
by	O
U.S.	organization-government,governmentagency
Food	organization-government,governmentagency
and	organization-government,governmentagency
Drug	organization-government,governmentagency
Administration	organization-government,governmentagency
for	O
the	O
treatment	O
of	O
cataplexy	other-disease
associated	O
with	O
narcolepsy	other-disease
and	O
excessive	other-disease
daytime	other-disease
sleepiness	other-disease
(	O
EDS	other-disease
)	O
associated	O
with	O
narcolepsy	other-disease
.	O

Additionally	O
,	O
dosing	O
naltrexone	other-medical
after	O
recent	O
opioid	other-medical
use	O
could	O
lead	O
to	O
precipitated	other-medical
withdrawal	other-medical
.	O

The	O
live	O
attenuated	O
BCG	other-medical
vaccine	O
developed	O
against	O
tuberculosis	other-disease
has	O
been	O
shown	O
to	O
have	O
strong	O
beneficial	O
effects	O
on	O
the	O
ability	O
to	O
combat	O
non-	O
tuberculosis	other-disease
infections	O
.	O

With	O
a	O
strong	O
,	O
dense	O
smell	O
,	O
ether	other-medical
causes	O
irritation	O
to	O
respiratory	O
mucosa	O
and	O
is	O
uncomfortable	O
to	O
breathe	O
,	O
and	O
in	O
overdose	O
triggering	other-medical
salivation	other-medical
,	O
vomiting	other-medical
,	O
coughing	O
or	O
spasms	other-medical
.	O

Naltrexone	other-medical
is	O
an	O
opioid	other-medical
receptor	other-medical
antagonist	other-medical
used	O
for	O
the	O
treatment	O
of	O
opioid	other-medical
addiction	other-medical
.	O

Targeting	other-medical
Hsp90	other-medical
with	O
drugs	O
has	O
shown	O
promising	O
effects	O
in	O
clinical	O
trials	O
.	O

The	O
analgesic	O
properties	O
of	O
the	O
plant	O
seem	O
to	O
be	O
related	O
to	O
its	O
effect	O
on	O
prostaglandin	other-medical
synthesis	other-medical
.	O

Gabapentin	other-medical
may	O
reduce	O
symptoms	O
associated	O
with	O
neuropathic	other-disease
pain	other-disease
or	O
fibromyalgia	other-disease
in	O
some	O
people	O
.	O

Small-volume	O
pumps	other-chemicalthing
infuse	O
hormones	O
,	O
such	O
as	O
insulin	other-chemicalthing
,	O
or	O
other	O
medicines	O
,	O
such	O
as	O
opiates	other-medical
.	O

Using	O
caffeine	other-medical
and	O
naps	O
before	O
night	O
shifts	O
can	O
decrease	O
sleepiness	O
.	O

14.7	O
%	O
of	O
the	O
patients	O
(	O
n	O
=	O
44	O
)	O
on	O
fluoxetine	other-medical
had	O
suicidal	O
events	O
,	O
compared	O
to	O
6.3	O
%	O
in	O
the	O
psychotherapy	O
group	O
and	O
8.4	O
%	O
from	O
the	O
combined	O
treatment	O
group	O
.	O

Lamivudine	other-medical
(	O
3TC	other-medical
)	O
significantly	O
inhibits	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	other-biologything
to	O
the	O
active	O
form	O
,	O
and	O
accordingly	O
the	O
drugs	O
should	O
not	O
be	O
administered	O
together	O
.	O

Clenbuterol	other-medical
is	O
a	O
sympathomimetic	O
amine	O
used	O
by	O
sufferers	O
of	O
breathing	other-disease
disorders	other-disease
as	O
a	O
decongestant	O
and	O
bronchodilator	O
.	O

Fentanyl	other-medical
intoxication	O
and	O
recent	O
methamphetamine	other-chemicalthing
use	O
might	O
have	O
increased	O
the	O
likelihood	O
of	O
death	O
.	O

Prodine	other-medical
(	O
trade	O
names	O
Prisilidine	other-medical
and	O
Nisentil	other-medical
)	O
is	O
an	O
opioid	O
analgesic	O
that	O
is	O
an	O
analog	O
of	O
pethidine	other-medical
(	O
meperidine	other-medical
)	O
.	O

Pentobarbital	other-medical
(	O
previously	O
known	O
as	O
pentobarbitone	other-medical
in	O
Britain	location-GPE
and	O
Australia	location-GPE
)	O
is	O
a	O
short-acting	O
barbiturate	O
typically	O
used	O
as	O
a	O
sedative	O
,	O
a	O
preanesthetic	O
,	O
and	O
to	O
control	O
convulsions	O
in	O
emergencies	O
.	O

His	O
paper	O
``	O
Severe	art-writtenart
Dopaminergic	art-writtenart
Neurotoxicity	art-writtenart
in	art-writtenart
Primates	art-writtenart
After	art-writtenart
a	art-writtenart
Common	art-writtenart
Recreational	art-writtenart
Dose	art-writtenart
Regimen	art-writtenart
of	art-writtenart
MDMA	art-writtenart
(	art-writtenart
'Ecstasy	art-writtenart
'	art-writtenart
)	art-writtenart
``	O
in	O
``	O
Science	art-writtenart
``	O
was	O
later	O
retracted	O
after	O
it	O
became	O
clear	O
that	O
the	O
monkeys	O
had	O
in	O
fact	O
been	O
injected	O
not	O
with	O
MDMA	other-medical
,	O
but	O
with	O
extremely	O
high	O
doses	O
of	O
methamphetamine	other-medical
.	O

Pregabalin	other-medical
and	O
gabapentin	other-medical
may	O
reduce	O
pain	O
associated	O
with	O
diabetic	other-disease
neuropathy	other-disease
.	O

Large	O
amounts	O
of	O
heroin	other-medical
are	O
also	O
smuggled	O
throughout	O
the	O
(	O
Golden	location-other
Triangle	location-other
)	O
.	O

Anaphylactic	other-disease
shock	other-disease
requires	O
advanced	O
medical	O
care	O
immediately	O
;	O
but	O
other	O
first	O
aid	O
measures	O
include	O
rescue	O
breathing	O
(	O
part	O
of	O
CPR	other-medical
)	O
and	O
administration	O
of	O
epinephrine	other-medical
using	O
an	O
EpiPen	other-medical
for	O
immediate	O
administration	O
of	O
epinephrine	other-medical
(	O
adrenaline	other-medical
)	O
to	O
reverse	O
swelling	O
and	O
to	O
keep	O
the	O
respiratory	O
airway	O
(	O
trachea	O
)	O
open	O
.	O

There	O
has	O
been	O
controversy	O
over	O
the	O
decision	O
by	O
NHS	organization-other
Greater	location-GPE
Glasgow	location-GPE
to	O
downgrade	O
facilities	O
at	O
the	O
local	O
Stobhill	building-hospital
Hospital	building-hospital
in	O
nearby	O
Springburn	location-GPE
to	O
an	O
Ambulatory	building-hospital
care	O
facility	O
,	O
which	O
will	O
result	O
in	O
the	O
nearest	O
Accident	building-hospital
and	building-hospital
Emergency	building-hospital
and	O
inpatient	O
facilities	O
being	O
located	O
at	O
the	O
Glasgow	building-hospital
Royal	building-hospital
Infirmary	building-hospital
in	O
the	O
city	O
centre	O
,	O
as	O
well	O
as	O
the	O
development	O
of	O
an	O
inpatient	O
Psychiatric	other-medical
hospital	O
at	O
the	O
site	O
.	O

HGH	other-medical
was	O
not	O
banned	O
by	O
Major	organization-sportsleague
League	organization-sportsleague
Baseball	organization-sportsleague
until	O
2005	O
.	O

The	O
virus	O
isolated	O
in	O
the	O
2009	O
outbreak	O
have	O
been	O
found	O
resistant	O
to	O
amantadine	other-medical
and	O
rimantadine	other-medical
.	O

In	O
people	O
with	O
suspected	O
ketosis-prone	other-disease
type	other-disease
2	other-disease
diabetes	other-disease
,	O
determination	O
of	O
antibodies	O
against	O
glutamic	other-biologything
acid	other-biologything
decarboxylase	other-biologything
and	O
islet	O
cells	O
may	O
aid	O
in	O
the	O
decision	O
whether	O
to	O
continue	O
insulin	other-medical
administration	O
long-term	O
(	O
if	O
antibodies	O
are	O
detected	O
)	O
,	O
or	O
whether	O
to	O
withdraw	O
insulin	other-medical
and	O
attempt	O
treatment	O
with	O
oral	O
medication	O
as	O
in	O
type	other-disease
2	other-disease
diabetes	other-disease
.	O

Approximately	O
10	O
percent	O
of	O
testosterone	other-medical
enanthate	other-medical
will	O
be	O
converted	O
to	O
dihydrotestosterone	other-biologything
in	O
normal	O
men	O
.	O

However	O
,	O
Tim	person-athlete
admitted	O
to	O
using	O
the	O
prescription	O
drug	O
Adderall	other-medical
five	O
days	O
prior	O
to	O
the	O
event	O
;	O
Adderall	other-medical
is	O
a	O
drug	O
banned	O
by	O
the	O
Nevada	organization-other
State	organization-other
Athletic	organization-other
Commission	organization-other
.	O

In	O
2007	O
,	O
and	O
again	O
during	O
the	O
2009	O
swine	other-disease
flu	other-disease
pandemic	other-disease
,	O
Carter	person-other
said	O
that	O
rintatolimod	other-medical
could	O
also	O
be	O
used	O
as	O
an	O
H1N1	other-biologything
flu	other-biologything
vaccine	O
booster	O
,	O
citing	O
``	O
in	O
vitro	O
''	O
studies	O
with	O
Ampligen	other-medical
and	O
neuraminidase	other-biologything
inhibitors	O
oseltamivir	other-medical
and	O
zanamivir	other-medical
(	O
brand	O
names	O
Tamiflu	other-medical
and	O
Relenza	other-medical
)	O
.	O

Botulinum	other-medical
toxin	other-medical
A	other-medical
is	O
used	O
to	O
treat	O
involuntary	other-disease
muscle	other-disease
contraction	other-disease
and	O
spasms	other-disease
.	O

The	O
biggest	O
controversy	O
of	O
the	O
2012	event-sportsevent
Breeders	event-sportsevent
'	event-sportsevent
Cup	event-sportsevent
related	O
to	O
the	O
use	O
of	O
the	O
anti-bleeding	O
medication	O
Furosemide	other-medical
(	O
Lasix	other-medical
)	O
,	O
commonly	O
used	O
in	O
North	location-GPE
America	location-GPE
but	O
not	O
permitted	O
elsewhere	O
.	O

The	O
MHA-TP	other-medical
test	O
is	O
rarely	O
used	O
any	O
more	O
.	O

A	O
study	O
done	O
in	O
wide	O
range	O
of	O
bacteria	O
and	O
different	O
classes	O
of	O
antibiotics	O
showed	O
that	O
``	O
Pseudomonas	other-biologything
aeruginosa	other-biologything
``	O
and	O
``	O
Stenotrophomonas	other-biologything
maltophilia	other-biologything
``	O
,	O
already	O
resistant	O
to	O
triclosan	other-medical
,	O
had	O
increased	O
resistance	O
against	O
antibiotics	O
tetracycline	other-chemicalthing
and	O
norfloxacin	other-chemicalthing
when	O
exposed	O
to	O
triclosan	other-chemicalthing
.	O

In	O
the	O
United	location-GPE
States	location-GPE
,	O
piracetam	other-medical
is	O
not	O
approved	O
by	O
the	O
Food	organization-government,governmentagency
and	organization-government,governmentagency
Drug	organization-government,governmentagency
Administration	organization-government,governmentagency
.	O

It	O
was	O
the	O
first	O
second-generation	O
NSAA	other-medical
to	O
be	O
introduced	O
.	O

Human	other-medical
PTRF	other-medical
mutations	other-medical
may	O
cause	O
secondary	other-disease
deficiency	other-disease
of	other-disease
caveolins	other-disease
,	O
resulting	O
in	O
generalized	O
lipodystrophy	other-medical
in	O
association	O
with	O
in	O
muscular	other-medical
dystrophy	other-medical
.	O

62	O
%	O
of	O
people	O
taking	O
gabapentin	other-medical
may	O
have	O
at	O
least	O
one	O
adverse	O
event	O
,	O
however	O
the	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
found	O
to	O
be	O
low	O
.	O

Though	O
slightly	O
less	O
potent	O
,	O
artesunate	other-medical
is	O
also	O
useful	O
in	O
human	O
fasciolosis	O
.	O

The	O
anti-cancer	O
drug	O
imatinib	other-medical
has	O
recently	O
been	O
shown	O
to	O
reverse	O
the	O
graying	O
process	O
.	O

The	O
term	O
``	O
gender	other-medical
identity	other-medical
disorder	other-medical
``	O
itself	O
introduced	O
in	O
DSM-III	art-writtenart
was	O
taken	O
from	O
Green	person-scholar
's	O
1974	O
work	O
.	O
Sexual	art-writtenart
Identity	art-writtenart
Conflict	art-writtenart
in	art-writtenart
Children	art-writtenart
and	art-writtenart
Adults	art-writtenart
.	O

If	O
there	O
is	O
resistance	O
or	O
use	O
of	O
amoxicillin	other-medical
in	O
the	O
last	O
30	O
days	O
then	O
amoxicillin-clavulanate	other-medical
or	O
another	O
penicillin	other-medical
derivative	O
plus	O
beta	O
lactamase	other-medical
inhibitor	other-medical
is	O
recommended	O
.	O

An	O
infusion	O
of	O
5-FU	other-medical
is	O
then	O
started	O
through	O
a	O
drip	O
or	O
pump	O
,	O
which	O
lasts	O
for	O
22	O
hours	O
.	O

Other	O
major	O
estradiol	other-biologything
esters	other-biologything
that	O
are	O
or	O
have	O
been	O
used	O
in	O
medicine	O
include	O
estradiol	other-biologything
acetate	other-biologything
,	O
estradiol	other-biologything
cypionate	other-biologything
,	O
estradiol	other-biologything
dipropionate	other-biologything
,	O
estradiol	other-biologything
enantate	other-biologything
,	O
estradiol	other-biologything
undecylate	other-biologything
,	O
and	O
polyestradiol	other-biologything
phosphate	other-biologything
(	O
an	O
estrogen	other-biologything
ester	other-biologything
polymer	other-biologything
)	O
,	O
as	O
well	O
as	O
the	O
nitrogen	other-medical
mustard	other-medical
alkylating	other-medical
antineoplastic	other-medical
agent	other-medical
estramustine	other-medical
phosphate	other-medical
(	O
estradiol	other-chemicalthing
normustine	other-chemicalthing
phosphate	other-chemicalthing
)	O
.	O

Probenecid	other-medical
inhibits	O
methotrexate	other-biologything
excretion	O
,	O
which	O
increases	O
the	O
risk	O
of	O
methotrexate	other-biologything
toxicity	O
.	O

Petacchi	person-athlete
had	O
a	O
certificate	O
to	O
use	O
salbutamol	other-medical
in	O
the	O
treatment	O
of	O
asthma	other-disease
,	O
but	O
his	O
level	O
of	O
salbutamol	other-medical
was	O
extremely	O
high	O
.	O

Propranolol	other-medical
is	O
a	O
blocker	O
for	O
the	O
beta-adrenergic	other-biologything
receptors	other-biologything
in	O
the	O
amygdala	O
which	O
usually	O
are	O
bound	O
to	O
by	O
stress	O
hormones	O
released	O
by	O
the	O
adrenal	other-biologything
gland-	other-biologything
epinephrine	other-biologything
and	O
norepinephrine	other-biologything
.	O

ADEP	other-medical
antibiotics	other-medical
can	O
be	O
used	O
to	O
defeat	O
resistant	O
bacterial	O
infections	O
.	O

Ativan	other-medical
would	O
cause	O
the	O
patient	O
to	O
have	O
slurred	O
speech	O
but	O
propofol	other-medical
would	O
not	O
,	O
it	O
is	O
``	O
quick	O
onset	O
,	O
quick	O
offset	O
.	O
''	O

Topical	other-medical
retinoids	other-medical
include	O
adapalene	other-medical
,	O
retinol	other-medical
,	O
tazarotene	other-medical
,	O
trifarotene	other-medical
,	O
and	O
tretinoin	other-medical
.	O

Prazosin	other-medical
has	O
been	O
established	O
as	O
an	O
effective	O
and	O
safe	O
centrally	O
active	O
alpha-1	other-medical
adrenergic	other-medical
receptor	other-medical
antagonist	other-medical
.	O

Because	O
armodafinil	other-medical
has	O
a	O
longer	O
half-life	O
than	O
modafinil	other-medical
does	O
,	O
it	O
may	O
be	O
more	O
effective	O
at	O
improving	O
wakefulness	O
in	O
patients	O
with	O
excessive	O
daytime	O
sleepiness	O
.	O

Injecting	O
potassium	other-medical
chloride	other-medical
into	O
the	O
heart	O
muscle	O
disrupts	O
the	O
signal	O
that	O
causes	O
the	O
heart	O
to	O
beat	O
.	O

Another	O
medication	O
formulated	O
as	O
an	O
injector	O
pen	O
to	O
ensure	O
quick	O
onset	O
of	O
action	O
is	O
glucagon	other-medical
for	O
hypoglycemia	other-disease
.	O

The	O
patient	O
may	O
need	O
it	O
monthly	O
(	O
Lupron	other-medical
Depot	other-medical
,	O
Lupron	other-medical
Depot-PED	other-medical
)	O
or	O
every	O
3	O
,	O
4	O
or	O
6	O
months	O
(	O
Lupron	other-medical
Depot	other-medical
-3	O
month	O
,	O
Lupron	other-medical
Depot-PED	other-medical
-3	O
month	O
,	O
Lupron	other-medical
Depot	other-medical
-4	O
month	O
,	O
Lupron	other-medical
Depot	other-medical
-6	O
month	O
)	O
.	O

The	O
overexpression	O
of	O
FITM2	other-biologything
was	O
also	O
displayed	O
when	O
the	O
3T3-L1	other-biologything
cells	other-biologything
were	O
combined	O
with	O
rosiglitazone	other-medical
(	O
a	O
PPAR	other-medical
γ	other-medical
agonist	other-medical
)	O
.	O

Chlomethiazole	other-medical
appears	O
to	O
also	O
have	O
another	O
mechanism	O
of	O
action	O
mediating	O
some	O
of	O
its	O
hypothermic	O
and	O
neuroprotective	O
effects	O
.	O

Salgia	person-scholar
is	O
the	O
Arthur	person-politician
&	person-politician
amp	person-politician
;	person-politician
Rosalie	person-politician
Kaplan	person-politician
Endowed	O
Chair	O
of	O
Medical	other-medical
Oncology	other-medical
at	O
City	organization-other
of	organization-other
Hope	organization-other
National	organization-other
Medical	organization-other
Center	organization-other
in	O
Duarte	location-GPE
,	O
California	location-GPE
.	O

Aticaprant	other-medical
is	O
a	O
potent	O
,	O
selective	O
,	O
short-acting	O
(	O
i.e.	O
,	O
non-	O
''	O
inactivating	O
''	O
)	O
antagonist	O
of	O
the	O
KOR	O
(	O
Ki	O
=	O
0.81	O
nM	O
vs.	O
24.0	O
nM	O
and	O
155	O
nM	O
for	O
the	O
μ-opioid	other-biologything
receptor	other-biologything
(	O
MOR	other-biologything
)	O
and	O
δ-opioid	other-biologything
receptor	other-biologything
(	O
DOR	other-biologything
)	O
,	O
respectively	O
;	O
approximately	O
30-fold	O
selectivity	O
for	O
the	O
KOR	other-biologything
)	O
.	O

In	O
some	O
cases	O
,	O
correction	O
of	O
a	O
dehydrated	O
state	O
is	O
accomplished	O
by	O
the	O
replenishment	O
of	O
necessary	O
water	O
and	O
electrolytes	O
(	O
through	O
oral	O
rehydration	other-medical
therapy	other-medical
or	O
fluid	O
replacement	O
by	O
i	O
ntravenous	other-medical
therapy	other-medical
)	O
.	O

Tretinoin	other-medical
is	O
the	O
least	O
expensive	O
of	O
the	O
topical	other-medical
retinoids	other-medical
and	O
is	O
the	O
most	O
irritating	O
to	O
the	O
skin	O
,	O
whereas	O
adapalene	other-medical
is	O
the	O
least	O
irritating	O
but	O
costs	O
significantly	O
more	O
.	O

Furthermore	O
,	O
edema	other-medical
in	other-medical
gastrocnemius	other-medical
muscle	other-medical
was	O
also	O
attenuated	O
.	O

CPA	other-medical
is	O
used	O
as	O
an	O
antiandrogen	O
to	O
treat	O
high	O
androgen	O
levels	O
and	O
associated	O
symptoms	O
such	O
as	O
masculinization	O
due	O
to	O
conditions	O
like	O
polycystic	other-disease
ovary	other-disease
syndrome	other-disease
(	O
PCOS	other-disease
)	O
and	O
congenital	other-disease
adrenal	other-disease
hyperplasia	other-disease
(	O
CAH	other-disease
)	O
in	O
women	O
.	O

Hypotonia	other-medical
is	O
common	O
(	O
75	O
%	O
)	O
,	O
as	O
is	O
an	O
unsteady	O
gait	O
.	O

Enoxaparin	other-medical
binds	O
to	O
and	O
potentiates	O
antithrombin	other-biologything
(	O
a	O
circulating	O
anticoagulant	O
)	O
to	O
form	O
a	O
complex	O
that	O
irreversibly	O
inactivates	O
clotting	other-biologything
factor	other-biologything
Xa	other-biologything
.	O

Consuming	O
an	O
adult	O
dose	O
of	O
10	O
oz	O
of	O
laxative	other-medical
syrup	other-medical
(	O
@	O
1.745	O
g/oz	O
)	O
implies	O
a	O
consumption	O
of	O
17.45	O
g	O
o	O
f	other-chemicalthing
magnesium	other-chemicalthing
citrate	other-chemicalthing
in	O
a	O
single	O
10	O
oz	O
dose	O
resulting	O
in	O
a	O
consumption	O
of	O
approximately	O
2.0	O
g	O
of	O
elemental	O
magnesium	other-chemicalthing
per	O
single	O
dose	O
.	O

Omeprazole	other-medical
reacts	O
with	O
cysteine	other-chemicalthing
813	other-chemicalthing
and	O
892	other-chemicalthing
.	O

In	O
December	O
2014	O
,	O
Boulle	person-other
's	O
company	O
Tendyne	organization-company
Holdings	organization-company
Inc	organization-company
.	O
announced	O
the	O
first	O
successful	O
human	O
Mitral	other-medical
Valve	other-medical
implant	other-medical
at	O
the	O
Royal	building-hospital
Brompton	building-hospital
Hospital	building-hospital
in	O
London	location-GPE
,	O
England	location-GPE
.	O

Both	O
diabetes	other-disease
mellitus	other-disease
type	other-disease
1	other-disease
and	O
diabetes	other-disease
mellitus	other-disease
type	other-disease
2	other-disease
are	O
marked	O
by	O
a	O
loss	other-medical
of	other-medical
pancreatic	other-medical
function	other-medical
,	O
though	O
to	O
differing	O
degrees	O
.	O

Thus	O
,	O
a	O
depressed	O
alpha	O
angle	O
could	O
be	O
treated	O
with	O
cryoprecipitate	other-medical
.	O

There	O
is	O
not	O
good	O
evidence	O
that	O
it	O
works	O
better	O
than	O
other	O
PPIs	other-medical
.	O

As	O
with	O
other	O
opioids	other-medical
,	O
chronic	O
use	O
of	O
oxycodone	other-medical
(	O
particularly	O
with	O
higher	O
doses	O
)	O
often	O
causes	O
concurrent	other-disease
hypogonadism	other-disease
(	O
low	O
sex	O
hormone	O
levels	O
)	O
.	O

Petacchi	person-athlete
was	O
then	O
absolved	O
by	O
the	O
FCI	organization-other
when	O
they	O
deemed	O
any	O
overuse	O
of	O
Salbutamol	other-medical
as	O
simple	O
human	O
error	O
.	O

Antitumor	O
drugs	O
targeting	O
this	O
section	O
of	O
Hsp90	other-biologything
include	O
the	O
antibiotics	O
geldanamycin	other-medical
,	O
herbimycin	other-medical
,	O
radicicol	other-medical
,	O
deguelin	other-medical
,	O
derrubone	other-medical
,	O
macbecin	other-medical
,	O
and	O
beta-lactams	other-medical
.	O

After	O
Townley	person-athlete
suffered	O
a	O
concussion	other-medical
at	O
Pocono	location-GPE
during	O
an	O
ARCA	O
race	O
,	O
Clint	person-athlete
Bowyer	person-athlete
drove	O
the	O
No	O
.	O

ErbB2	other-medical
overexpression	other-medical
can	O
occur	O
in	O
breast	O
,	O
ovarian	O
,	O
bladder	O
,	O
non-small-cell	O
lung	O
carcinoma	O
,	O
as	O
well	O
as	O
several	O
other	O
tumor	O
types	O
.	O

It	O
has	O
been	O
known	O
since	O
the	O
1980s	O
that	O
buprenorphine	other-medical
binds	O
to	O
at	O
high	O
affinity	O
and	O
antagonizes	O
the	O
KOR	other-medical
.	O

This	O
may	O
,	O
however	O
,	O
be	O
counter-productive	O
for	O
patients	O
who	O
are	O
also	O
taking	O
methotrexate	other-medical
,	O
which	O
is	O
a	O
folic	other-medical
acid	other-medical
inhibitor	other-medical
.	O

Doxepin	other-medical
is	O
a	O
tricyclic	other-chemicalthing
compound	other-chemicalthing
,	O
specifically	O
a	O
dibenzoxepin	other-chemicalthing
,	O
and	O
possesses	O
three	O
rings	O
fused	O
together	O
with	O
a	O
side	O
chain	O
attached	O
in	O
its	O
chemical	O
structure	O
.	O

Fentanyl	other-medical
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family	O
,	O
which	O
includes	O
sufentanil	other-medical
,	O
alfentanil	other-medical
,	O
remifentanil	other-medical
,	O
and	O
carfentanil	other-medical
.	O

Cognitive	other-medical
behavioral	other-medical
therapy	other-medical
may	O
improve	O
quality	O
of	O
life	O
,	O
asthma	other-disease
control	O
,	O
and	O
anxiety	O
levels	O
in	O
people	O
with	O
asthma	other-disease
.	O

H2	other-medical
antagonists	other-medical
require	O
doses	O
much	O
higher	O
than	O
other	O
species	O
to	O
block	O
acid	O
production	O
in	O
the	O
equine	O
stomach	O
,	O
possibly	O
because	O
so	O
little	O
histamine	other-chemicalthing
is	O
needed	O
to	O
produce	O
maximal	O
secretion	O
of	O
acid	O
.	O

Current	O
advances	O
in	O
further	O
treatments	O
include	O
evaluations	O
of	O
triazoles	O
such	O
as	O
itraconazole	other-medical
and	O
fluconazole	other-medical
``	O
as	O
therapeutic	O
options	O
in	O
ophthalmic	O
mycoses	O
.	O
''	O

Counterfeit	O
drugs	O
such	O
as	O
Profetamine	other-medical
(	O
a	O
generic	O
form	O
of	O
amphetamine	other-medical
sulfate	other-medical
)	O
appeared	O
,	O
aiming	O
to	O
circumvent	O
Alles	person-scholar
'	O
'weak	O
'	O
patent	O
.	O

Anticonvulsant	other-medical
medication	O
is	O
commonly	O
prescribed	O
for	O
migraine	other-disease
prevention	O
,	O
because	O
they	O
have	O
been	O
shown	O
in	O
placebo-controlled	O
double-blind	O
trials	O
to	O
be	O
effective	O
in	O
some	O
migraine	other-disease
sufferers	O
.	O

This	O
occurs	O
naturally	O
in	O
the	O
adrenal	O
cortex	O
and	O
during	O
first-pass	O
metabolism	O
in	O
the	O
liver	O
and	O
intestines	O
when	O
exogenous	other-medical
DHEA	other-medical
is	O
administered	O
orally	O
.	O

He	O
died	O
in	O
1989	O
of	O
a	O
suspected	O
accidental	O
valium	other-medical
overdose	O
,	O
while	O
attempting	O
to	O
resurrect	O
his	O
football	O
career	O
in	O
the	O
CFL	organization-other
,	O
and	O
while	O
fighting	O
alcoholism	O
.	O

There	O
has	O
never	O
been	O
an	O
adequately	O
large	O
randomized	O
controlled	O
trial	O
to	O
prove	O
definitively	O
that	O
HGH	other-medical
provides	O
significant	O
anti-aging	O
benefits	O
and	O
that	O
there	O
are	O
no	O
significant	O
adverse	O
drug	O
reactions	O
;	O
there	O
have	O
been	O
many	O
small	O
studies	O
which	O
are	O
described	O
below	O
.	O

Diagnosis	O
of	O
patients	O
with	O
even	O
mild	O
hirsutism	other-disease
should	O
include	O
assessment	O
of	O
ovulation	other-medical
and	O
ovarian	other-medical
ultrasound	other-medical
,	O
due	O
to	O
the	O
high	O
prevalence	O
of	O
polycystic	other-disease
ovary	other-disease
syndrome	other-disease
(	O
PCOS	other-disease
)	O
,	O
as	O
well	O
as	O
17α-hydroxyprogesterone	other-biologything
(	O
because	O
of	O
the	O
possibility	O
of	O
finding	O
nonclassic	O
21-hydroxylase	other-chemicalthing
deficiency	O
)	O
.	O

A	O
gene	O
knockout	O
experiment	O
of	O
the	O
mouse	O
homologue	O
of	O
ZDHHC13	other-biologything
showed	O
hair	other-medical
loss	other-medical
,	O
severe	other-medical
osteoporosis	other-medical
,	O
and	O
systemic	other-medical
amyloidosis	other-medical
,	O
both	O
of	O
AL	O
and	O
AA	O
depositions	O
.	O

Methylene	O
blue	O
is	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(	O
MAOI	other-medical
)	O
,	O
and	O
if	O
infused	O
intravenously	O
at	O
doses	O
exceeding	O
5	O
mg/kg	O
,	O
may	O
precipitate	O
serious	O
serotonin	O
toxicity	O
,	O
serotonin	O
syndrome	O
,	O
if	O
combined	O
with	O
any	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	other-medical
)	O
or	O
other	O
serotonin	O
reuptake	O
inhibitor	O
(	O
e.g.	O
,	O
duloxetine	O
,	O
sibutramine	O
,	O
venlafaxine	O
,	O
clomipramine	O
,	O
imipramine	O
)	O
.	O

There	O
are	O
also	O
nootropic	O
drugs	O
such	O
as	O
the	O
common	O
racetams	other-medical
Piracetam	other-medical
and	O
Noopept	other-medical
(	O
O	O
mberaceta	other-medical
m	O
)	O
along	O
with	O
the	O
neuroprotective	O
Semax	other-chemicalthing
,	O
and	O
N-Acetyl	other-chemicalthing
Semax	other-chemicalthing
.	O

Ketamine	other-medical
is	O
a	O
commonly	O
used	O
drug	O
that	O
can	O
cause	O
this	O
type	O
of	O
sedation	O
.	O

GHB	other-chemicalthing
is	O
the	O
active	O
ingredient	O
of	O
the	O
prescription	O
medication	O
sodium	other-medical
oxybate	other-medical
(	O
Xyrem	other-medical
)	O
.	O

A	O
study	O
observing	O
the	O
distribution	O
of	O
spermicide	O
containing	O
nonoxynol-9	other-medical
in	O
the	O
vaginal	O
tract	O
showed	O
“	O
After	O
10	O
min	O
the	O
gel	O
spread	O
within	O
the	O
vaginal	O
canal	O
providing	O
a	O
contiguous	O
covering	O
of	O
the	O
epithelium	O
of	O
variable	O
thickness.	O
”	O
The	O
sole	O
goal	O
of	O
spermicide	O
is	O
to	O
prevent	O
fertilization	O
.	O

Iobenguane	other-medical
I	other-medical
131	other-medical
,	O
marketed	O
under	O
the	O
trade	O
name	O
Azedra	other-medical
,	O
has	O
had	O
a	O
clinical	O
trial	O
as	O
a	O
treatment	O
for	O
malignant	O
,	O
recurrent	O
or	O
unresectable	O
pheochromocytoma	other-disease
and	O
paraganglioma	other-disease
,	O
and	O
the	O
FDA	organization-other
approved	O
it	O
on	O
July	O
30	O
,	O
2018	O
.	O

In	O
diabetes	other-disease
it	O
is	O
a	O
less	O
preferred	O
agent	O
compared	O
to	O
metformin	other-medical
.	O

Biostrophin	other-medical
is	O
being	O
manufactured	O
by	O
Asklepios	organization-company
BioPharmaceuticals	organization-company
,	organization-company
Inc	organization-company
.	organization-company
,	O
with	O
funding	O
provided	O
by	O
the	O
Muscular	organization-other
Dystrophy	organization-other
Association	organization-other
.	O

It	O
lasts	O
longer	O
than	O
lansoprazole	other-medical
,	O
to	O
which	O
it	O
is	O
chemically	O
related	O
,	O
and	O
needs	O
to	O
be	O
taken	O
less	O
often	O
.	O

Myocet	other-medical
has	O
similar	O
efficacy	O
as	O
conventional	O
doxorubicin	other-medical
,	O
while	O
significantly	O
reducing	O
cardiac	O
toxicity	O
.	O

Haloperidol	other-medical
is	O
excreted	O
in	O
breast	O
milk	O
.	O

West	person-artist,author
mentions	O
the	O
antidepressant	O
drug	O
Lexapro	other-medical
in	O
reference	O
to	O
his	O
issues	O
with	O
mental	O
health	O
,	O
a	O
subject	O
West	person-artist,author
mostly	O
touched	O
on	O
in	O
the	O
song	O
``	O
I	art-music
Feel	art-music
Like	art-music
That	art-music
``	O
from	O
the	O
end	O
of	O
his	O
and	O
Steve	person-artist,author
McQueen	person-artist,author
's	O
music	O
video	O
for	O
West	person-artist,author
's	O
2015	O
single	O
``	O
All	art-music
Day	art-music
``	O
.	O

The	O
MHA-TP	other-medical
test	O
detects	O
antibodies	O
to	O
the	O
bacteria	O
that	O
cause	O
syphilis	other-disease
and	O
can	O
be	O
used	O
to	O
detect	O
syphilis	other-disease
in	O
all	O
stages	O
,	O
except	O
during	O
the	O
first	O
3	O
to	O
4	O
weeks	O
.	O

Most	O
formulations	O
of	O
tretinoin	other-medical
are	O
incompatible	O
for	O
use	O
with	O
benzoyl	other-medical
peroxide	other-medical
.	O

This	O
same	O
amount	O
of	O
potassium	other-medical
chloride	other-medical
would	O
do	O
no	O
harm	O
if	O
taken	O
orally	O
and	O
not	O
injected	O
directly	O
into	O
the	O
blood	O
.	O

Advice	O
for	O
the	O
management	O
of	O
an	O
acute	O
overdose	O
of	O
ofloxacin	other-medical
is	O
emptying	O
of	O
the	O
stomach	O
,	O
along	O
with	O
close	O
observation	O
,	O
and	O
making	O
sure	O
that	O
the	O
patient	O
is	O
appropriately	O
hydrated	O
.	O

Acetazolamide	other-medical
also	O
helps	O
prevent	O
the	O
condition	O
.	O

Among	O
those	O
who	O
are	O
older	O
,	O
ofloxacin	other-medical
may	O
be	O
used	O
.	O

Lidocaine	other-medical
was	O
reported	O
to	O
be	O
much	O
less	O
effective	O
in	O
reducing	O
pain	O
in	O
another	O
study	O
of	O
humans	O
with	O
MC1R	other-biologything
mutations	O

Doxorubicin	other-medical
has	O
been	O
referred	O
to	O
frequently	O
as	O
a	O
highly-promising	O
anti-	O
cancer	other-disease
drug	O
that	O
is	O
also	O
being	O
utilized	O
in	O
chemotherapy	other-medical
treatments	O
;	O
however	O
,	O
as	O
with	O
nearly	O
all	O
chemotherapeutics	other-medical
,	O
the	O
issue	O
of	O
drug	O
resistance	O
remains	O
.	O

Vardenafil	other-medical
's	O
indications	O
and	O
contraindications	O
are	O
the	O
same	O
as	O
with	O
other	O
PDE5	other-medical
inhibitors	other-medical
;	O
it	O
is	O
closely	O
related	O
in	O
function	O
to	O
sildenafil	other-medical
citrate	other-medical
(	O
Viagra	other-medical
)	O
and	O
tadalafil	other-medical
(	O
Cialis	other-medical
)	O
.	O

Combined	O
use	O
of	O
clonazepam	other-medical
with	O
certain	O
antidepressants	O
,	O
anticonvulsants	O
(	O
such	O
as	O
phenobarbital	other-medical
,	O
phenytoin	other-medical
,	O
and	O
carbamazepine	other-medical
)	O
,	O
sedative	O
antihistamines	O
,	O
opiates	O
,	O
and	O
antipsychotics	O
,	O
nonbenzodiazepines	O
(	O
such	O
as	O
zolpidem	other-medical
)	O
,	O
and	O
alcohol	O
may	O
result	O
in	O
enhanced	O
sedative	O
effects	O
.	O

Low	O
volume	O
hyponatremia	O
is	O
typically	O
treated	O
with	O
intravenous	O
normal	other-medical
saline	other-medical
.	O

Day	O
1	O
:	O
Oxaliplatin	other-medical
85	O
mg/m2	O
intravenous	O
(	O
IV	O
)	O
infusion	O
in	O
250-500	O
mL	O
D5W	O
and	O
leucovorin	other-chemicalthing
200	O
mg/m2	O
IV	O
infusion	O
in	O
D5W	O
administered	O
concurrently	O
over	O
120	O
minutes	O
in	O
separate	O
bags	O
using	O
a	O
Y-line	O
,	O
followed	O
by	O
fluorouracil	other-medical
(	O
5-FU	other-medical
)	O
400	O
mg/m2	O
IV	O
bolus	O
given	O
over	O
2–4	O
minutes	O
,	O
followed	O
by	O
5-FU	other-medical
600	O
mg/m2	O
IV	O
infusion	O
in	O
500	O
mL	O
D5W	O
(	O
recommended	O
)	O
as	O
a	O
22-hour	O
continuous	O
infusion	O
.	O

These	O
treatments	O
were	O
finally	O
rendered	O
obsolete	O
by	O
the	O
discovery	O
of	O
penicillin	other-medical
,	O
and	O
its	O
widespread	O
manufacture	O
after	O
World	event-attack,battle,war,militaryconflict
War	event-attack,battle,war,militaryconflict
II	event-attack,battle,war,militaryconflict
allowed	O
syphilis	other-disease
to	O
be	O
effectively	O
and	O
reliably	O
cured	O
.	O

Side	O
effects	O
of	O
testosterone	other-medical
enanthate	other-medical
include	O
virilization	O
among	O
others	O
.	O

If	O
the	O
perioral	other-disease
dermatitis	other-disease
was	O
triggered	O
by	O
a	O
topical	O
steroid	O
then	O
pimecrolimus	other-medical
cream	O
has	O
been	O
suggested	O
as	O
effective	O
in	O
improving	O
symptoms	O
.	O

Cocaine	other-medical
is	O
the	O
only	O
local	O
anesthetic	O
that	O
also	O
produces	O
vasoconstriction	O
,	O
making	O
it	O
ideal	O
for	O
controlling	O
nosebleeds	O
.	O

Preparations	O
made	O
from	O
blistering	other-livingthing
beetles	other-livingthing
have	O
been	O
used	O
since	O
ancient	O
times	O
as	O
an	O
aphrodisiac	other-medical
,	O
possibly	O
because	O
their	O
physical	O
effects	O
were	O
perceived	O
to	O
mimic	O
those	O
of	O
sexual	O
arousal	O
,	O
and	O
because	O
they	O
can	O
cause	O
prolonged	O
erection	O
or	O
priapism	O
in	O
men	O
.	O

An	O
established	O
brain	O
stimulation	O
treatment	O
is	O
electroconvulsive	other-medical
therapy	other-medical
.	O

In	O
1996	O
,	O
the	O
U.S.	organization-government,governmentagency
Food	organization-government,governmentagency
and	organization-government,governmentagency
Drug	organization-government,governmentagency
Administration	organization-government,governmentagency
approved	O
Gemzar	other-medical
for	O
the	O
treatment	O
of	O
pancreatic	O
cancer	O
.	O

The	O
combination	O
of	O
paracetamol	other-medical
with	O
caffeine	other-medical
is	O
superior	O
to	O
paracetamol	other-medical
alone	O
for	O
the	O
treatment	O
of	O
common	O
pain	O
conditions	O
,	O
including	O
dental	O
pain	O
,	O
``	O
post	O
partum	O
''	O
pain	O
,	O
and	O
headache	O
.	O

Like	O
other	O
NSAIDs	other-medical
,	O
it	O
works	O
by	O
inhibiting	O
the	O
production	O
of	O
prostaglandins	O
by	O
decreasing	O
the	O
activity	O
of	O
the	O
enzyme	O
cyclooxygenase	O
(	O
COX	other-biologything
)	O
.	O

The	O
raceday	O
ban	O
on	O
Lasix	other-medical
would	O
eventually	O
be	O
removed	O
for	O
the	O
2014	O
event	O
.	O

On	O
June	O
30	O
,	O
2009	O
,	O
an	O
FDA	organization-other
advisory	organization-other
panel	organization-other
recommended	O
that	O
Vicodin	other-medical
and	O
another	O
painkiller	O
,	O
Percocet	other-medical
,	O
be	O
removed	O
from	O
the	O
market	O
because	O
they	O
have	O
allegedly	O
caused	O
over	O
400	O
deaths	O
a	O
year	O
.	O

Hence	O
tamoxifen	other-medical
's	O
tissue	O
selective	O
action	O
directly	O
led	O
to	O
the	O
formulation	O
of	O
the	O
concept	O
of	O
SERMs	other-medical
.	O

It	O
has	O
structural	O
and	O
pharmacodynamic	O
properties	O
similar	O
to	O
the	O
drugs	O
mescaline	other-medical
and	O
2C-T-2	other-medical
.	O

This	O
can	O
be	O
done	O
through	O
a	O
CT	other-medical
or	O
MRI	other-medical
or	O
the	O
brain	O
;	O
these	O
are	O
the	O
first	O
imaging	O
modality	O
of	O
choice	O
.	O

An	O
antihistamine	other-medical
such	O
as	O
diphenhydramine	other-medical
may	O
be	O
prescribed	O
.	O

In	O
the	O
Brugada	other-disease
syndrome	other-disease
,	O
changes	O
may	O
be	O
found	O
in	O
the	O
resting	O
ECG	other-medical
with	O
evidence	O
of	O
right	other-disease
bundle	other-disease
branch	other-disease
block	other-disease
(	O
RBBB	other-disease
)	O
and	O
ST	other-disease
elevation	other-disease
in	O
the	O
chest	O
leads	O
V1-V3	O
,	O
with	O
an	O
underlying	O
propensity	O
to	O
sudden	other-disease
cardiac	other-disease
death	other-disease
.	O

The	O
Royal	organization-other
London	organization-other
Hospital	organization-other
for	O
Integrated	O
Medicine	O
offers	O
clinical	O
services	O
including	O
complementary	other-medical
cancer	other-medical
treatments	other-medical
,	O
allergy	other-medical
services	other-medical
,	O
acupuncture	other-medical
,	O
homeopathy	other-medical
,	O
rheumatology	other-medical
,	O
weight	O
loss	O
management	O
,	O
sleep	O
management	O
,	O
musculoskeletal	O
medicine	other-chemicalthing
and	O
stress	O
management	O
,	O
and	O
has	O
access	O
to	O
conventional	O
medicine	O
.	O

Warfarin	other-medical
is	O
not	O
recommended	O
until	O
platelets	other-biologything
have	O
normalized	O
.	O

Lansoprazole	other-medical
reacts	O
with	O
cysteine	other-chemicalthing
813	other-chemicalthing
and	O
cysteine	other-chemicalthing
321	other-chemicalthing
,	O
whereas	O
pantoprazole	other-medical
and	O
tenatoprazole	other-medical
react	O
with	O
cysteine	other-chemicalthing
813	other-chemicalthing
and	O
822	other-chemicalthing
.	O

Gherasim	person-athlete
tested	O
positive	O
for	O
anabolic	other-medical
steroids	other-medical
at	O
the	O
Amsterdam	event-sportsevent
Marathon	event-sportsevent
in	O
2002	O
and	O
received	O
a	O
two-year	O
doping	O
ban	O
.	O

Recently	O
,	O
analeptics	O
have	O
been	O
turned	O
to	O
the	O
treatment	O
of	O
ADHD	other-disease
due	O
to	O
more	O
efficient	O
ways	O
to	O
treat	O
barbiturate	other-medical
overdoses	O
.	O

Transdermal	other-medical
estradiol	other-medical
patches	other-medical
are	O
described	O
as	O
delivering	O
a	O
fixed	O
amount	O
of	O
estradiol	other-chemicalthing
such	O
as	O
50	O
µg/day	O
or	O
100	O
µg/day	O
.	O

Coronary	other-medical
bypass	other-medical
surgery	other-medical
involves	O
bypassing	O
constricted	O
arteries	O
with	O
venous	O
grafts	O
.	O

Potassium	other-medical
chloride	other-medical
is	O
the	O
last	O
of	O
the	O
three	O
drugs	O
administered	O
and	O
actually	O
causes	O
death	O
.	O

For	O
instance	O
,	O
tamoxifen	other-medical
has	O
predominantly	O
antiestrogenic	O
effects	O
in	O
the	O
breasts	O
but	O
predominantly	O
estrogenic	O
effects	O
in	O
the	O
uterus	O
and	O
liver	O
.	O

Nonoxynol-9	other-medical
is	O
the	O
primary	O
chemical	O
in	O
spermicides	O
to	O
inhibit	O
sperm	O
motility	O
.	O

The	O
US	location-GPE
patent	O
for	O
Zoloft	other-medical
expired	O
in	O
2006	O
,	O
and	O
sertraline	O
is	O
available	O
in	O
generic	O
form	O
and	O
is	O
marketed	O
under	O
many	O
brand	O
names	O
worldwide	O
.	O

A	O
follow-on	O
drug	O
to	O
Inotersen	other-medical
is	O
being	O
developed	O
by	O
Ionis	organization-company
Pharmaceuticals	organization-company
and	O
under	O
license	O
to	O
Akcea	organization-company
Therapeutics	organization-company
for	O
hereditary	other-disease
transthyretin-mediated	other-disease
amyloidosis	other-disease
.	O

Shakur-Still	person-other
ran	O
the	O
WOMAN	other-medical
Trial	other-medical
which	O
looked	O
the	O
blood	O
clot	O
stabilising	O
drug	O
tranexamic	other-medical
acid	other-medical
for	O
post-delivery	other-disease
bleeding	other-disease
,	O
which	O
is	O
the	O
largest	O
cause	O
of	O
maternal	O
mortality	O
around	O
the	O
world	O
.	O

Bioavailability	O
:	O
Since	O
2013	O
a	O
company	O
named	O
Amorphical	organization-company
Ltd	organization-company
.	organization-company
sells	O
an	O
ACC	other-medical
dietary	O
supplement	O
.	O

Tamoxifen	other-medical
has	O
been	O
used	O
effectively	O
to	O
improve	O
blood	O
flow	O
,	O
reduce	O
uterine	O
contractility	O
and	O
pain	O
in	O
dysmenorrhea	other-disease
patients	O
.	O

These	O
substances	O
are	O
called	O
nootropics	other-medical
and	O
can	O
potentially	O
benefit	O
individuals	O
with	O
cognitive	O
decline	O
and	O
many	O
different	O
disorders	O
,	O
but	O
may	O
also	O
be	O
capable	O
of	O
yielding	O
results	O
in	O
cognitively	O
healthy	O
persons	O
.	O

Natalizumab	other-medical
is	O
considered	O
highly	O
effective	O
in	O
terms	O
of	O
relapse	O
rate	O
reduction	O
and	O
halting	O
disability	O
progression	O
,	O
however	O
,	O
it	O
is	O
considered	O
a	O
second-line	O
treatment	O
because	O
of	O
the	O
risk	O
of	O
adverse	O
side-effects	O
.	O

There	O
is	O
some	O
evidence	O
that	O
omeprazole	other-medical
and	O
esomeprazole	other-medical
,	O
two	O
medications	O
in	O
the	O
same	O
class	O
as	O
rabeprazole	other-medical
,	O
can	O
disturb	O
the	O
conversion	O
of	O
an	O
anticoagulant	O
medication	O
called	O
clopidogrel	other-medical
to	O
its	O
active	O
metabolite	O
.	O

Like	O
other	O
statins	O
,	O
atorvastatin	other-medical
also	O
reduces	O
blood	O
levels	O
of	O
triglycerides	other-chemicalthing
and	O
slightly	O
increases	O
levels	O
of	O
HDL-cholesterol	other-biologything
.	O

Another	O
Cochrane	O
Investigation	O
has	O
found	O
post-operative	other-medical
pain	other-medical
is	O
effectively	O
managed	O
with	O
either	O
ibuprofen	other-medical
,	O
or	O
ibuprofen	other-medical
in	O
combination	O
with	O
acetaminophen	other-medical
.	O

A	O
beneficial	O
side	O
effect	O
of	O
tamoxifen	other-medical
is	O
that	O
it	O
prevents	O
bone	O
loss	O
by	O
acting	O
as	O
an	O
ER	O
agonist	O
(	O
i.e.	O
,	O
mimicking	O
the	O
effects	O
of	O
estrogen	O
)	O
in	O
this	O
cell	O
type	O
.	O

A	O
cerebrospinal	other-biologything
fluid	other-biologything
sample	O
is	O
taken	O
by	O
lumbar	other-medical
puncture	other-medical
and	O
is	O
tested	O
for	O
leukocyte	other-biologything
levels	O
to	O
determine	O
if	O
there	O
is	O
an	O
infection	O
and	O
goes	O
on	O
to	O
further	O
testing	O
to	O
see	O
what	O
the	O
actual	O
cause	O
is	O
.	O

Creatine	other-medical
is	O
a	O
mass-produced	O
fitness	O
supplement	O
that	O
is	O
supposed	O
to	O
increase	O
the	O
user	O
's	O
muscle	O
mass	O
,	O
strength	O
and	O
power	O
.	O

The	O
FDA	organization-government,governmentagency
approved	O
reslizumab	O
(	O
US	location-GPE
trade	O
name	O
Cinqair	other-medical
)	O
for	O
use	O
with	O
other	O
asthma	other-medical
medicines	other-medical
for	O
the	O
maintenance	O
treatment	O
of	O
severe	O
asthma	other-disease
in	O
patients	O
aged	O
18	O
years	O
and	O
older	O
on	O
23	O
March	O
2016	O
.	O

Preclinical	O
usage	O
of	O
epigenetic	O
agents	O
like	O
5-azacytidine	other-medical
(	O
DNMT	other-medical
inhibitor	other-medical
)	O
and	O
romidepsin	other-medical
(	O
HDAC	other-medical
inhibitor	other-medical
)	O
sensitizes	O
cancer	other-biologything
cells	other-biologything
for	O
further	O
treatment	O
.	O

Testosterone	other-medical
enanthate	other-medical
can	O
also	O
be	O
converted	O
to	O
estradiol	other-biologything
by	O
aromatase	other-biologything
,	O
which	O
may	O
lead	O
to	O
gynecomastia	other-disease
in	O
males	O
.	O

Azithromycin	other-medical
appears	O
to	O
have	O
less	O
side	O
effects	O
than	O
either	O
high	O
dose	O
amoxicillin	other-medical
or	O
amoxicillin	other-medical
/	O
clavulanate	other-medical
.	O

One	O
of	O
the	O
most	O
popular	O
and	O
common	O
treatments	O
used	O
``	O
for	O
life-threatening	O
and	O
severe	O
ophthalmic	O
mycoses	O
''	O
is	O
amphotericin	other-medical
B	other-medical
which	O
is	O
a	O
specific	O
anti-fungal	O
drug	O
.	O

Nguyen	person-other
also	O
testified	O
that	O
Murray	person-other
never	O
mentioned	O
propofol	other-medical
.	O

This	O
is	O
also	O
true	O
for	O
omeprazole	other-medical
doses	O
,	O
especially	O
if	O
given	O
orally	O
.	O

Therapeutic	O
doses	O
of	O
fluoxetine	other-medical
have	O
been	O
shown	O
to	O
decrease	O
these	O
neuronal	O
fatigue	O
states	O
by	O
inhibiting	O
vesicle	O
release	O
and	O
thereby	O
preventing	O
synaptic	O
fatigue	O
in	O
hippocampal	other-biologything
neurons	other-biologything
.	O

A	O
pooled	O
analysis	O
of	O
randomized	O
,	O
controlled	O
studies	O
of	O
meloxicam	other-medical
therapy	O
of	O
up	O
to	O
60	O
days	O
duration	O
found	O
that	O
meloxicam	other-medical
was	O
associated	O
with	O
a	O
statistically	O
significantly	O
lower	O
number	O
of	O
thromboembolic	other-medical
complications	other-medical
than	O
the	O
NSAID	other-medical
diclofenac	other-medical
(	O
0.2	O
%	O
versus	O
0.8	O
%	O
respectively	O
)	O
but	O
a	O
similar	O
incidence	O
of	O
thromboembolic	other-medical
events	O
to	O
naproxen	other-medical
and	O
piroxicam	other-medical
.	O

Amesergide	other-medical
(	O
,	O
;	O
developmental	O
code	O
name	O
LY-237733	O
)	O
is	O
a	O
serotonin	O
receptor	O
antagonist	O
of	O
the	O
ergoline	O
and	O
lysergamide	O
families	O
related	O
to	O
methysergide	O
which	O
was	O
under	O
development	O
by	O
Eli	organization-company
Lilly	organization-company
and	organization-company
Company	organization-company
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
including	O
depression	other-disease
,	O
anxiety	other-disease
,	O
schizophrenia	other-disease
,	O
male	other-disease
sexual	other-disease
dysfunction	other-disease
,	O
migraine	other-disease
,	O
and	O
thrombosis	other-disease
but	O
was	O
never	O
marketed	O
.	O

The	O
history	O
of	O
opium	other-medical
in	O
China	location-GPE
began	O
with	O
the	O
use	O
of	O
opium	other-medical
for	O
medicinal	O
purposes	O
during	O
the	O
7th	O
century	O
.	O

Muhtar	person-scholar
studied	O
histology	O
in	O
Louis-Charles	person-scholar
Malassez	person-scholar
’	O
s	O
laboratory	O
and	O
pathological	other-medical
anatomy	other-medical
in	O
Hôpital	building-hospital
de	building-hospital
la	building-hospital
Charité	building-hospital
from	O
P.C.E	O
.	O

The	O
MicroMed	other-medical
DeBakey	other-medical
VAD	other-medical
is	O
an	O
axial-flow	O
ventricular	O
assist	O
device	O
and	O
is	O
known	O
as	O
a	O
second-generation	O
LVAD	other-medical
.	O

The	O
variety	O
shows	O
potential	O
for	O
medical	O
usage	O
,	O
especially	O
for	O
those	O
who	O
do	O
not	O
wish	O
to	O
experience	O
the	O
typical	O
high	O
of	O
recreational	O
marijuana	other-medical
use	O
.	O

These	O
mechanisms	O
of	O
STAT3-RANTES	other-biologything
autocrine	O
signaling	O
suggest	O
a	O
novel	O
strategy	O
for	O
management	O
of	O
patients	O
with	O
tamoxifen-resistant	other-medical
tumors	O
.	O

Tinnitus	other-disease
may	O
be	O
associated	O
with	O
vitamin	other-medical
B12	other-medical
deficiency	O
.	O

In	O
King	location-GPE
County	location-GPE
outcomes	O
of	O
attempted	O
out-of-hospital	O
resuscitations	O
are	O
recorded	O
,	O
following	O
the	O
Utstein	other-medical
uniform	O
reporting	O
guidelines	O
,	O
in	O
a	O
cardiac	O
arrest	O
registry	O
.	O

Prazosin	other-medical
is	O
commonly	O
used	O
as	O
an	O
anti-hypertensive	other-medical
,	O
but	O
because	O
alpha-1	other-medical
adrenergic	other-medical
activity	O
has	O
been	O
connected	O
to	O
fear	O
and	O
startle	O
responses	O
,	O
it	O
sees	O
use	O
as	O
a	O
PTSD	other-disease
treatment	O
.	O

The	O
disease	O
presents	O
as	O
a	O
bleeding	other-medical
disorder	other-medical
with	O
easy	other-medical
bruising	other-medical
,	O
mucosal	other-medical
bleeding	other-medical
,	O
such	O
as	O
nosebleeds	other-medical
,	O
and	O
mild	O
to	O
severe	other-medical
anemia	other-medical
.	O

Analgecine	other-medical
(	O
brand	O
name	O
AGC	other-medical
)	O
is	O
an	O
analgesic	O
extract	O
that	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
back	other-medical
pain	other-medical
and	O
neuralgia	other-medical
in	O
China	location-GPE
.	O

Severe	O
manifestations	O
are	O
often	O
treated	O
with	O
Cyclophosphamide	other-medical
or	O
Rituximab	other-medical
and	O
three	O
doses	O
of	O
methylprednisolone	other-medical
IV-pulse	O
treatment	O
(	O
as	O
recommended	O
by	O
ACR	O
guidelines	O
)	O
prior	O
to	O
switching	O
to	O
oral	O
prednisolone	O
and	O
azathioprine	O
for	O
maintenance	O
.	O

Fluoxetine	other-medical
was	O
developed	O
at	O
Eli	organization-company
Lilly	organization-company
and	organization-company
Company	organization-company
in	O
the	O
early	O
1970s	O
by	O
Bryan	person-other
Molloy	person-other
,	O
Klaus	person-other
Schmiegel	person-other
,	O
David	person-other
T.	person-other
Wong	person-other
and	O
others	O
.	O

The	O
discovery	O
and	O
development	O
of	O
this	O
first	O
sulfonamide	other-medical
drug	O
opened	O
a	O
new	O
era	O
in	O
medicine	O
.	O

Frequency	O
of	O
treatment-emergent	O
sexual	other-disease
dysfunction	other-disease
were	O
similar	O
for	O
duloxetine	other-medical
and	O
SSRIs	other-medical
when	O
compared	O
in	O
a	O
6-month	O
observational	O
study	O
in	O
depressed	other-disease
patients	O
.	O

Until	O
2010	O
paracetamol	other-medical
was	O
believed	O
safe	O
in	O
pregnancy	O
however	O
,	O
in	O
a	O
study	O
published	O
in	O
October	O
2010	O
it	O
has	O
been	O
linked	O
to	O
infertility	O
in	O
the	O
adult	O
life	O
of	O
the	O
unborn	O
.	O

Signs	O
and	O
symptoms	O
of	O
withdrawal	O
from	O
abrupt	O
cessation	O
of	O
an	O
SNRI	other-medical
include	O
dizziness	O
,	O
anxiety	O
,	O
insomnia	O
,	O
nausea	O
,	O
sweating	O
,	O
and	O
flu-like	O
symptoms	O
,	O
such	O
as	O
lethargy	O
and	O
malaise	O
.	O

Cymbalta	other-medical
generated	O
sales	O
of	O
nearly	O
in	O
2012	O
,	O
with	O
of	O
that	O
in	O
the	O
U.S	location-GPE
.	location-GPE
,	O
but	O
its	O
patent	O
protection	O
terminated	O
January	O
1	O
,	O
2014	O
.	O

A	O
high-quality	O
ELISA	other-medical
test	O
for	O
human	O
recombinant	O
erythropoietin	O
is	O
now	O
available	O
,	O
and	O
recently	O
the	O
first	O
Mass	other-medical
Spectral	other-medical
Confirmation	other-medical
method	O
to	O
detect	O
use	O
of	O
human	other-medical
recombinant	other-medical
erythropoietin	other-medical
(	O
rhEPO	other-medical
)	O
in	O
horses	O
or	O
any	O
species	O
was	O
developed	O
.	O

The	O
Neuropsychiatric	other-medical
EEG-Based	other-medical
Assessment	other-medical
Aid	other-medical
(	O
NEBA	other-medical
)	O
System	O
a	O
device	O
used	O
to	O
measure	O
the	O
Theta-to-Beta	O
ratio	O
was	O
approved	O
as	O
a	O
tool	O
to	O
assist	O
in	O
diagnosis	O
of	O
ADHD	other-disease
on	O
July	O
15	O
,	O
2013	O
.	O

Vigabatrin	other-medical
is	O
a	O
drug	O
that	O
is	O
irreparably	O
suppresses	O
GABA	other-biologything
transaminase	other-biologything
that	O
causes	O
increased	O
amount	O
of	O
GABA	other-biologything
in	O
the	O
brain	O
.	O

She	O
was	O
interested	O
in	O
the	O
Baháʼí	other-medical
Faith	other-medical
and	other-medical
Theosophy	other-medical
.	O

Dressler	other-disease
syndrome	O
is	O
best	O
treated	O
with	O
high	O
dose	O
aspirin	other-medical
.	O

Hydrocodone	other-medical
,	O
almost	O
as	O
potent	O
as	O
oxycodone	other-medical
,	O
in	O
combined	O
form	O
previously	O
allowed	O
refills	O
.	O

Ritonavir	other-medical
is	O
manufactured	O
as	O
Norvir	other-medical
by	O
AbbVie	organization-company
,	organization-company
Inc	organization-company
..	O

In	O
2008	O
Medic	O
One	O
's	O
survival	O
rate	O
for	O
witnessed	O
cardiac	other-medical
arrests	other-medical
due	O
to	O
heart	O
disease	O
prior	O
to	O
EMS	product-car
arrival	O
with	O
initial	O
rhythm	O
of	O
ventricular	other-medical
fibrillation	other-medical
or	O
ventricular	other-medical
tachycardia	other-medical
was	O
49	O
%	O
.	O

Opioid	other-medical
rotation	other-medical
is	O
one	O
method	O
suggested	O
to	O
minimise	O
the	O
impact	O
of	O
constipation	other-disease
in	O
long-term	O
users	O
.	O

One	O
NSAID	other-medical
in	O
particular	O
,	O
indomethacin	O
,	O
can	O
inhibit	O
new	O
collagen	O
deposition	O
,	O
thus	O
impairing	O
the	O
healing	O
process	O
for	O
the	O
infarcted	O
region	O
.	O

Isotopes	other-medical
commonly	O
used	O
in	O
the	O
treatment	O
of	O
bone	O
metastasis	O
are	O
radium-223	other-chemicalthing
,	O
strontium-89	other-chemicalthing
and	O
samarium	other-chemicalthing
(	O
153Sm	other-chemicalthing
)	O
lexidronam	other-chemicalthing
.	O

In	O
both	O
young	O
and	O
old	O
people	O
with	O
hypoglycemia	other-medical
,	O
the	O
brain	O
may	O
habituate	O
to	O
low	O
glucose	O
levels	O
,	O
with	O
a	O
reduction	O
of	O
noticeable	O
symptoms	O
despite	O
neuroglycopenic	other-medical
impairment	other-medical
.	O

Atropine	other-medical
blocks	O
acetylcholine	O
from	O
binding	O
with	O
muscarinic	O
receptors	O
,	O
which	O
reduces	O
the	O
pesticide	O
's	O
impact	O
.	O

The	O
sale	O
of	O
dextromethorphan	other-medical
in	O
its	O
pure	O
powder	O
form	O
may	O
incur	O
penalties	O
,	O
although	O
no	O
explicit	O
law	O
exists	O
prohibiting	O
its	O
sale	O
or	O
possession	O
,	O
other	O
than	O
in	O
Illinois	location-GPE
.	O

Oral	other-medical
iron	other-medical
tablets	other-medical
are	O
not	O
easily	O
tolerated	O
and	O
may	O
cause	O
nausea	O
,	O
vomiting	O
,	O
abdominal	other-disease
pain	other-disease
,	O
constipation	other-disease
and	O
diarrhoea	other-disease
.	O

This	O
can	O
be	O
seen	O
in	O
people	O
who	O
are	O
experiencing	O
the	O
classic	O
signs	O
of	O
pericarditis	other-disease
but	O
then	O
show	O
signs	O
of	O
relief	O
,	O
and	O
progress	O
to	O
show	O
signs	O
of	O
cardiac	O
tamponade	O
which	O
include	O
decreased	O
alertness	O
and	O
lethargy	O
,	O
pulsus	O
paradoxus	O
(	O
decrease	O
of	O
at	O
least	O
10	O
mmHg	O
of	O
the	O
systolic	O
blood	O
pressure	O
upon	O
inspiration	O
)	O
,	O
low	O
blood	O
pressure	O
(	O
due	O
to	O
decreased	O
cardiac	O
index	O
)	O
,	O
(	O
jugular	O
vein	O
distention	O
from	O
right	O
sided	O
heart	O
failure	O
and	O
fluid	O
overload	O
)	O
,	O
distant	O
heart	O
sounds	O
on	O
auscultation	O
,	O
and	O
equilibration	O
of	O
all	O
the	O
diastolic	O
blood	O
pressures	O
on	O
cardiac	other-medical
catheterization	other-medical
due	O
to	O
the	O
constriction	O
of	O
the	O
pericardium	other-disease
by	O
the	O
fluid	O
.	O

Since	O
then	O
,	O
FDA	organization-government,governmentagency
has	O
determined	O
that	O
other	O
types	O
of	O
nitrosamine	O
compounds	O
,	O
e.g.	O
,	O
N-Nitrosodiethylamine	other-chemicalthing
(	O
NDEA	other-chemicalthing
)	O
,	O
are	O
present	O
at	O
unacceptable	O
levels	O
in	O
APIs	other-medical
from	O
multiple	O
API	other-medical
producers	O
of	O
valsartan	other-medical
and	O
other	O
drugs	O
in	O
the	O
ARB	other-medical
class	O
.	O
''	O

Prontosil	other-medical
was	O
the	O
first	O
commercially	O
available	O
antibacterial	other-medical
antibiotic	other-medical
(	O
with	O
a	O
relatively	O
broad	O
effect	O
against	O
Gram-positive	other-biologything
cocci	other-biologything
.	O

In	O
March	O
2010	O
Health	organization-other
Canada	organization-other
advised	O
the	O
public	O
that	O
illegal	O
``	O
Herbal	product-other
Diet	product-other
Natural	product-other
``	O
had	O
been	O
found	O
on	O
the	O
market	O
,	O
containing	O
sibutramine	other-medical
,	O
which	O
is	O
a	O
prescription	O
drug	O
in	O
Canada	location-GPE
,	O
without	O
listing	O
sibutramine	other-medical
as	O
an	O
ingredient	O
.	O

When	O
laparoscopy	O
is	O
used	O
for	O
diagnosis	O
,	O
the	O
most	O
common	O
cause	O
of	O
dysmenorrhea	other-medical
is	O
endometriosis	other-disease
,	O
in	O
approximately	O
70	O
%	O
of	O
adolescents	O
.	O

The	O
non-steroidal	O
drug	O
Irosustat	other-medical
has	O
been	O
the	O
most	O
studied	O
to	O
date	O
.	O

Another	O
patient	O
,	O
in	O
whom	O
POIS	other-disease
was	O
suspected	O
to	O
be	O
caused	O
by	O
cytokine	O
release	O
,	O
was	O
successfully	O
treated	O
with	O
nonsteroidal	other-medical
anti-inflammatory	other-medical
drugs	other-medical
(	O
NSAIDs	other-medical
)	O
just	O
prior	O
to	O
and	O
for	O
a	O
day	O
or	O
two	O
after	O
ejaculation	O
.	O

Chemotherapy	other-medical
or	O
traditional	O
radiotherapy	other-medical
are	O
not	O
very	O
effective	O
for	O
most	O
chondrosarcomas	other-disease
,	O
although	O
proton	other-medical
therapy	other-medical
is	O
showing	O
promise	O
with	O
local	O
tumor	O
control	O
at	O
over	O
80	O
%	O
.	O

Prophylactic	O
use	O
of	O
both	O
omeprazole	other-medical
and	O
H2	other-medical
antagonists	other-medical
such	O
as	O
ranitidine	other-medical
,	O
cimetidine	other-medical
,	O
and	O
famotidine	other-medical
can	O
be	O
used	O
to	O
help	O
prevent	O
gastric	O
ulcer	O
formation	O
when	O
the	O
horse	O
will	O
be	O
placed	O
into	O
a	O
stressful	O
situation	O
,	O
such	O
as	O
travel	O
or	O
showing	O
.	O

Another	O
potentially	O
serious	O
complication	O
associated	O
with	O
heparin	other-medical
use	O
is	O
called	O
heparin-induced	other-disease
thrombocytopenia	other-disease
(	O
HIT	other-disease
)	O
.	O

For	O
many	O
opioid	other-medical
users	O
,	O
heroin	other-medical
was	O
cheaper	O
,	O
more	O
potent	O
,	O
and	O
often	O
easier	O
to	O
acquire	O
than	O
prescription	O
medications	O
.	O

According	O
to	O
the	O
RCM	product-other
,	O
the	O
causal	O
effect	O
of	O
your	O
taking	O
or	O
not	O
taking	O
aspirin	other-medical
one	O
hour	O
ago	O
is	O
the	O
difference	O
between	O
how	O
your	O
head	O
would	O
have	O
felt	O
in	O
case	O
1	O
(	O
taking	O
the	O
aspirin	other-medical
)	O
and	O
case	O
2	O
(	O
not	O
taking	O
the	O
aspirin	other-medical
)	O
.	O

Thyroid	other-medical
nodules	other-medical
are	O
nodules	other-medical
(	O
raised	O
areas	O
of	O
tissue	O
or	O
fluid	O
)	O
which	O
commonly	O
arise	O
within	O
an	O
otherwise	O
normal	O
thyroid	O
gland	O
.	O

Crofelemer	other-medical
(	O
USAN	other-medical
,	O
trade	O
name	O
Mytesi	other-medical
)	O
is	O
a	O
botanical	O
drug	O
for	O
the	O
treatment	O
of	O
diarrhea	O
associated	O
with	O
anti-	O
HIV	other-disease
drugs	O
such	O
as	O
nucleoside	O
analog	O
reverse	O
transcriptase	O
inhibitors	O
and	O
protease	O
inhibitors	O
.	O

Subsequent	O
RhoA	other-biologything
expression	O
decrease	O
has	O
also	O
been	O
associated	O
with	O
increased	O
sensitivity	O
to	O
doxorubicin	other-medical
and	O
the	O
complete	O
reversion	O
of	O
doxorubicin	other-medical
resistance	O
in	O
certain	O
cells	O
;	O
this	O
shows	O
the	O
resilience	O
of	O
RhoA	other-biologything
as	O
a	O
consistent	O
indicator	O
anti-	O
cancer	other-disease
activity	O
.	O

However	O
,	O
gossypol	other-medical
also	O
had	O
serious	O
flaws	O
.	O

``	O
C	other-biologything
.	other-biologything
``	O
``	O
tertium	other-biologything
``	O
is	O
commonly	O
(	O
but	O
not	O
universally	O
)	O
resistant	O
to	O
many	O
β-lactam	other-biologything
antibiotics	O
such	O
as	O
penicillin	other-medical
and	O
cephalosporin	other-medical
;	O
clindamycin	other-medical
;	O
and	O
metronidazole	other-medical
;	O
but	O
it	O
is	O
susceptible	O
to	O
vancomycin	other-medical
,	O
trimethoprim-sulfamethoxazole	other-medical
,	O
and	O
ciprofloxacin	other-medical
.	O

The	O
monoclonal	O
antibody	O
farletuzumab	other-medical
is	O
being	O
researched	O
as	O
an	O
adjuvant	O
to	O
traditional	O
chemotherapy	O
.	O

HLA-B15	other-biologything
allele	other-biologything
*	other-biologything
1502	other-biologything
is	O
associated	O
with	O
the	O
severe	O
skin	O
conditions	O
Stevens–Johnson	other-disease
syndrome	other-disease
(	O
SJS	other-disease
)	O
and	O
toxic	other-disease
epidermal	other-disease
necrolysis	other-disease
(	O
TEN	other-disease
)	O
caused	O
by	O
carbamazepine	other-medical
drug	O
sensitivity	O
in	O
East	location-GPE
Asians	location-GPE
.	O

It	O
was	O
used	O
to	O
treat	O
symptoms	O
associated	O
with	O
allergies	O
and	O
colds	O
such	O
as	O
itchy	other-medical
and	other-medical
watery	other-medical
eyes	other-medical
,	O
runny	other-medical
nose	other-medical
,	O
nasal	other-medical
and	other-medical
sinus	other-medical
congestion	other-medical
,	O
and	O
sneezing	other-medical
.	O

ABA	other-medical
-based	O
interventions	O
focus	O
on	O
teaching	O
tasks	O
one-on-one	O
using	O
the	O
behaviorist	O
principles	O
of	O
stimulus	O
,	O
response	O
and	O
reward	O
,	O
and	O
on	O
reliable	O
measurement	O
and	O
objective	O
evaluation	O
of	O
observed	O
behavior	O
.	O

Likewise	O
in	O
the	O
2000	O
US	location-GPE
APL	organization-other
study	O
,	O
the	O
survival	O
rates	O
in	O
those	O
receiving	O
ATRA	other-medical
maintenance	O
was	O
61	O
%	O
compared	O
to	O
just	O
36	O
%	O
without	O
ATRA	other-medical
maintenance	O
.	O

On	O
October	O
29	O
,	O
2014	O
Health	organization-government,governmentagency
Canada	organization-government,governmentagency
gave	O
the	O
permission	O
for	O
Sanofi	organization-company
to	O
resume	O
production	O
of	O
BCG	other-medical
.	O

A	O
new	O
model	O
has	O
recently	O
surfaced	O
in	O
the	O
literature	O
regarding	O
the	O
HPA	other-medical
axis	other-medical
(	O
structures	O
in	O
the	O
brain	O
that	O
get	O
activated	O
in	O
response	O
to	O
stress	O
)	O
and	O
its	O
involvement	O
with	O
dysthymia	other-medical
(	O
e.g	O
.	O

Of	O
the	O
drugs	O
that	O
cause	O
DIL	other-disease
,	O
hydralazine	other-medical
has	O
been	O
found	O
to	O
cause	O
a	O
higher	O
incidence	O
.	O

Upon	O
his	O
return	O
in	O
1951	O
,	O
Crosby	person-scholar
established	O
both	O
the	O
hematology	other-medical
and	O
oncology	other-medical
specialties	O
at	O
Walter	building-hospital
Reed	building-hospital
Army	building-hospital
Hospital	building-hospital
a	O
position	O
he	O
would	O
hold	O
until	O
1965	O
.	O

Guaifenesin	other-medical
is	O
used	O
to	O
try	O
to	O
help	O
with	O
coughing	O
up	O
thick	O
mucus	O
and	O
is	O
sometimes	O
combined	O
with	O
dextromethorphan	other-medical
,	O
an	O
antitussive	O
(	O
cough	other-medical
suppressant	other-medical
)	O
,	O
such	O
as	O
in	O
Mucinex	other-medical
DM	other-medical
or	O
Robitussin	other-medical
DM	other-medical
.	O

Oseltamivir	other-medical
(	O
Tamiflu	other-medical
)	O
a	O
prodrug	other-medical
,	O
Zanamivir	other-medical
(	O
Relenza	other-medical
)	O
,	O
Laninamivir	other-medical
(	O
Inavir	other-medical
)	O
,	O
and	O
Peramivir	other-medical
belong	O
to	O
this	O
class	O
.	O

Methylprednisolon	other-medical
e	O
dosage	O
and	O
administration	O
for	O
these	O
diseases	O
is	O
highly	O
variable	O
due	O
to	O
varied	O
pathophysiology	O
between	O
the	O
diseases	O
and	O
within	O
patients	O
diagnosed	O
with	O
a	O
given	O
disease	O
.	O

Doxepin	other-medical
is	O
a	O
mixture	O
of	O
(	other-chemicalthing
``	other-chemicalthing
E	other-chemicalthing
''	other-chemicalthing
)	other-chemicalthing
and	other-chemicalthing
(	other-chemicalthing
``	other-chemicalthing
Z	other-chemicalthing
''	other-chemicalthing
)	other-chemicalthing
stereoisomers	other-chemicalthing
(	O
the	O
latter	O
being	O
known	O
as	O
``	O
cidoxepin	O
''	O
or	O
``	O
cis	O
''	O
-doxepin	O
)	O
and	O
is	O
used	O
commercially	O
in	O
a	O
ratio	O
of	O
approximately	O
85:15	O
.	O

Cervarix	other-medical
had	O
been	O
used	O
routinely	O
in	O
young	O
females	O
from	O
its	O
introduction	O
in	O
2008	O
,	O
but	O
was	O
only	O
effective	O
against	O
the	O
high-risk	O
HPV	other-disease
types	other-disease
16	other-disease
and	O
18	other-disease
,	O
neither	O
of	O
which	O
typically	O
causes	O
warts	O
.	O

People	O
who	O
have	O
either	O
type	O
of	O
diabetes	O
are	O
at	O
risk	O
for	O
low	other-medical
and	other-medical
high	other-medical
blood	other-medical
sugar	other-medical
,	O
with	O
potentially	O
severe	O
consequences	O
.	O

They	O
are	O
used	O
to	O
treat	O
estrogen	O
receptor-sensitive	O
or	O
progesterone	O
receptor-sensitive	O
breast	O
cancer	O
,	O
along	O
with	O
older	O
classes	O
of	O
drugs	O
like	O
selective	other-medical
estrogen	other-medical
receptor	other-medical
modulators	other-medical
(	O
SERMs	other-medical
)	O
and	O
aromatase	other-medical
inhibitors	other-medical
.	O

A	O
large	O
cohort	O
study	O
in	O
Denmark	location-GPE
found	O
,	O
in	O
addition	O
,	O
no	O
association	O
between	O
metoclopramide	other-medical
exposure	O
and	O
miscarriage	O
.	O

She	O
is	O
shown	O
being	O
given	O
Electroconvulsive	other-medical
therapy	other-medical
(	O
ECT	other-medical
)	O
as	O
a	O
clinical	O
treatment	O
and	O
being	O
discussed	O
at	O
a	O
lecture	O
for	O
medical	O
students	O
.	O

2α-	other-medical
(	other-medical
Propanoyl	other-medical
)	other-medical
-3β-	other-medical
(	other-medical
2-	other-medical
(	other-medical
6-methoxynaphthyl	other-medical
)	other-medical
)	other-medical
-tropane	other-medical
or	O
WF-33	other-medical
is	O
a	O
cocaine	other-medical
analogue	O
.	O

Aspirin	other-medical
increases	O
prothrombin	other-biologything
time	O
and	O
can	O
result	O
in	O
post-operative	O
complications	O
,	O
such	O
as	O
excessive	O
bleeding	O
.	O

Ketoconazole	other-medical
has	O
activity	O
against	O
many	O
kinds	O
of	O
fungi	other-disease
that	O
may	O
cause	O
human	O
disease	O
,	O
such	O
as	O
``	O
Candida	other-disease
``	O
,	O
``	O
Histoplasma	other-disease
``	O
,	O
``	O
Coccidioides	other-disease
``	O
,	O
and	O
``	O
Blastomyces	other-disease
``	O
(	O
although	O
it	O
is	O
not	O
active	O
against	O
``	O
Aspergillus	other-disease
``	O
)	O
,	O
chromomycosis	other-disease
and	O
paracoccidioidomycosis	other-disease
.	O

Liraglutide	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Victoza	organization-company
among	O
others	O
,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
diabetes	other-disease
mellitus	other-disease
type	other-disease
2	other-disease
and	O
obesity	other-disease
.	O

Chloral	other-medical
hydrate	other-medical
has	O
not	O
been	O
approved	O
by	O
the	O
FDA	organization-other
in	O
the	O
United	location-GPE
States	location-GPE
or	O
the	O
EMA	organization-other
in	O
the	O
European	organization-government,governmentagency
Union	organization-government,governmentagency
for	O
any	O
medical	O
indication	O
and	O
is	O
on	O
the	O
FDA	organization-other
list	O
of	O
unapproved	O
drugs	O
that	O
are	O
still	O
prescribed	O
by	O
clinicians	O
.	O

A	O
formulation	O
of	O
MPA	other-medical
as	O
an	O
aqueous	O
suspension	O
for	O
subcutaneous	O
injection	O
is	O
also	O
available	O
in	O
the	O
United	location-GPE
States	location-GPE
under	O
the	O
brand	O
name	O
Depo-SubQ	other-medical
Provera	other-medical
104	other-medical
.	O

Radiation	other-medical
therapy	other-medical
is	O
generally	O
used	O
for	O
people	O
whose	O
tumors	O
are	O
not	O
completely	O
removed	O
by	O
surgery	O
,	O
for	O
people	O
who	O
are	O
not	O
good	O
candidates	O
for	O
surgery	O
because	O
of	O
other	O
health	O
problems	O
,	O
and	O
for	O
people	O
who	O
do	O
not	O
respond	O
adequately	O
to	O
surgery	O
and	O
medication	O
.	O

Between	O
1930	O
and	O
1960	O
synthetic	O
analeptics	O
such	O
as	O
nikethamide	other-medical
,	O
pentylenetetrazol	other-medical
,	O
bemegride	other-medical
,	O
amphetamine	other-medical
,	O
and	O
methylphenidate	other-medical
replaced	O
the	O
naturally	O
occurring	O
compounds	O
in	O
treating	O
barbiturate	other-medical
overdose	O
.	O

Lo	person-other
was	O
diagnosed	O
with	O
lung	other-medical
cancer	other-medical
in	O
September	O
2001	O
.	O

Acetamiprid	other-medical
is	O
an	O
insecticide	O
belonging	O
to	O
the	O
chloropyridinyl	O
neonicotinoids	O
,	O
this	O
family	O
of	O
insecticides	O
was	O
introduced	O
in	O
the	O
early	O
1990s	O
.	O

This	O
includes	O
epinephrine	other-medical
,	O
which	O
when	O
used	O
to	O
treat	O
anaphylaxis	other-disease
must	O
work	O
as	O
soon	O
as	O
possible	O
.	O

He	O
also	O
supported	O
the	O
idea	O
of	O
a	O
p24-	other-medical
vaccine	other-medical
without	O
gp120	other-medical
which	O
was	O
patented	O
by	O
Jonas	person-other
Salk	person-other
as	O
``	O
Remune	other-medical
``	O
.	O

It	O
,	O
along	O
with	O
WF-23	other-medical
the	O
other	O
``	O
2-naphthyl	other-medical
``	O
cocaine	other-medical
analogue	O
,	O
are	O
considered	O
the	O
more	O
potent	O
of	O
the	O
WF	other-medical
series	O
cocaine	other-medical
analogues	O
.	O

Different	O
strengths	O
,	O
doses	O
and	O
routes	O
of	O
administration	O
of	O
epinephrine	other-medical
are	O
used	O
.	O

In	O
Japan	location-GPE
,	O
Milnacipran	other-medical
is	O
used	O
in	O
the	O
treatment	O
of	O
Taijin	other-disease
kyofusho	other-disease
,	O
a	O
Japanese	location-GPE
variant	O
of	O
social	other-disease
anxiety	other-disease
disorder	other-disease
.	O

Fanapanel	other-medical
(	O
INN	other-medical
,	O
code	O
name	O
ZK-200775	O
)	O
,	O
also	O
known	O
as	O
MPQX	other-medical
,	O
is	O
a	O
quinoxalinedione	O
derivative	O
drug	O
which	O
acts	O
as	O
a	O
competitive	O
antagonist	O
of	O
the	O
AMPA	other-chemicalthing
receptor	O
.	O

He	O
is	O
also	O
credited	O
with	O
discovering	O
and	O
publishing	O
the	O
physiological	O
effects	O
of	O
amphetamine	other-medical
and	O
methylenedioxyamphetamine	other-medical
(	O
MDA	other-medical
)	O
.	O

He	O
also	O
completed	O
advanced	O
TMS	other-medical
Therapy	O
Fellowship	O
at	O
Duke	building-hospital
University	building-hospital
Medical	building-hospital
Center	building-hospital
in	O
2014	O
.	O

While	O
all	O
opioids	other-medical
cause	O
constipation	other-disease
,	O
there	O
are	O
some	O
differences	O
between	O
drugs	O
,	O
with	O
studies	O
suggesting	O
tramadol	other-medical
,	O
tapentadol	other-medical
,	O
methadone	other-medical
and	O
fentanyl	other-medical
may	O
cause	O
relatively	O
less	O
constipation	other-disease
,	O
while	O
with	O
codeine	other-medical
,	O
morphine	other-medical
,	O
oxycodone	other-medical
or	O
hydromorphone	other-medical
constipation	other-medical
may	O
be	O
comparatively	O
more	O
severe	O
.	O

Atypical	other-medical
antipsychotics	other-medical
can	O
be	O
used	O
to	O
stabilise	O
mood	O
and	O
control	O
aggression	O
,	O
especially	O
in	O
those	O
with	O
comorbid	O
ASD	other-disease
.	O

On	O
June	O
10	O
,	O
2014	O
the	O
UK	location-GPE
Advisory	organization-government,governmentagency
Council	organization-government,governmentagency
on	organization-government,governmentagency
the	organization-government,governmentagency
Misuse	organization-government,governmentagency
of	organization-government,governmentagency
Drugs	organization-government,governmentagency
(	O
ACMD	organization-government,governmentagency
)	O
recommended	O
that	O
LSZ	other-medical
be	O
specifically	O
named	O
in	O
the	O
UK	other-law
Misuse	other-law
of	other-law
Drugs	other-law
Act	other-law
as	O
a	O
class	O
A	O
drug	O
despite	O
not	O
identifying	O
any	O
harm	O
associated	O
with	O
its	O
use	O
.	O

It	O
is	O
thought	O
that	O
Ro15-4513	other-medical
antagonizes	O
the	O
effects	O
of	O
ethanol	other-chemicalthing
because	O
the	O
azido	other-biologything
group	other-biologything
at	O
the	O
8-	O
position	O
of	O
the	O
benzene	other-biologything
ring	other-biologything
blocks	O
the	O
binding	O
site	O
for	O
ethanol	other-chemicalthing
on	O
the	O
α5β3δ	other-biologything
subtype	other-biologything
of	O
the	O
GABAA	other-biologything
receptor	other-biologything
;	O
flumazenil	other-medical
,	O
which	O
has	O
a	O
fluorine	other-chemicalthing
at	O
this	O
position	O
,	O
does	O
not	O
block	O
this	O
binding	O
site	O
and	O
so	O
does	O
not	O
counteract	O
the	O
effects	O
of	O
ethanol	other-chemicalthing
.	O

The	O
drug	O
is	O
also	O
not	O
associated	O
with	O
weight	O
gain	O
,	O
in	O
contrast	O
to	O
many	O
other	O
TCAs	other-medical
.	O

San	location-GPE
Antonio	location-GPE
's	O
South	location-other
Texas	location-other
Medical	location-other
Center	location-other
facilities	O
rank	O
sixth	O
in	O
clinical	other-medical
medicine	other-medical
research	other-medical
impact	O
in	O
the	O
United	location-GPE
States	location-GPE
.	O

FKBP	other-chemicalthing
(	O
FKBP1A	other-chemicalthing
)	O
does	O
not	O
normally	O
form	O
a	O
dimer	O
but	O
will	O
dimerize	O
in	O
the	O
presence	O
of	O
FK1012	other-medical
,	O
a	O
derivative	O
of	O
the	O
drug	O
tacrolimus	other-medical
(	O
FK506	other-medical
)	O
.	O

The	O
oral	O
antifungal	O
drug	O
Diflucan	other-medical
(	O
fluconazole	O
)	O
,	O
which	O
had	O
been	O
discovered	O
at	O
the	O
Sandwich	building-other
site	building-other
,	O
was	O
launched	O
in	O
1988	O
.	O

Bevacizumab	other-medical
was	O
approved	O
in	O
the	location-GPE
United	location-GPE
States	location-GPE
in	O
February	O
2004	O
,	O
for	O
use	O
in	O
metastatic	other-disease
colorectal	other-disease
cancer	other-disease
when	O
used	O
with	O
standard	O
chemotherapy	O
treatment	O
(	O
as	O
first-line	O
treatment	O
)	O
and	O
with	O
5-fluorouracil-based	O
therapy	O
for	O
second-line	O
metastatic	other-disease
colorectal	other-disease
cancer	other-disease
.	O

Gemzar	other-medical
is	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
pancreatic	O
cancer	O
,	O
usually	O
in	O
coordination	O
with	O
5-FU	other-medical
chemotherapy	O
and	O
radiology	O
.	O

The	O
atypical	other-medical
antidepressants	other-medical
mirtazapine	other-medical
and	O
bupropion	other-medical
have	O
been	O
studied	O
for	O
the	O
treatment	O
of	O
social	other-disease
anxiety	other-disease
disorder	other-disease
,	O
and	O
rendered	O
mixed	O
results	O
.	O

Aromatase	other-biologything
inhibitors	O
can	O
help	O
to	O
prevent	O
the	O
estrogenic	O
activity	O
of	O
testosterone	other-medical
enanthate	other-medical
in	O
the	O
body	O
.	O

The	O
US	organization-other
National	organization-other
Institutes	organization-other
of	organization-other
Health	organization-other
lists	O
three	O
conditions	O
for	O
which	O
fish	other-medical
oil	other-medical
and	O
other	O
omega-3	other-medical
sources	O
are	O
most	O
highly	O
recommended	O
:	O
hypertriglyceridemia	other-disease
(	O
high	O
triglyceride	O
level	O
)	O
,	O
preventing	O
secondary	other-disease
cardiovascular	other-disease
disease	other-disease
,	O
and	O
hypertension	other-disease
(	O
high	O
blood	O
pressure	O
)	O
.	O

Paramedics	O
responded	O
and	O
injected	O
the	O
turtle	O
with	O
Valium	other-medical
after	O
the	O
turtle	O
refused	O
to	O
let	O
go	O
of	O
the	O
woman	O
's	O
lip	O
.	O

Nefiracetam	other-medical
is	O
able	O
to	O
reverse	O
the	O
amnesia	O
caused	O
by	O
the	O
GABAA	other-biologything
receptor	O
antagonists	O
picrotoxin	O
and	O
bicuculline	O
in	O
mice	O
,	O
although	O
it	O
failed	O
to	O
prevent	O
seizures	O
induced	O
by	O
these	O
drugs	O
.	O

Cardiac	O
arrest	O
may	O
occur	O
in	O
propranolol	other-medical
overdose	O
due	O
to	O
sudden	O
ventricular	O
arrhythmias	O
,	O
or	O
cardiogenic	O
shock	O
which	O
may	O
ultimately	O
culminate	O
in	O
bradycardic	O
PEA	O
.	O

As	O
with	O
other	O
statins	other-medical
,	O
atorvastatin	other-medical
is	O
a	O
competitive	O
inhibitor	O
of	O
HMG-CoA	other-biologything
reductase	other-biologything
.	O

When	O
incubated	O
with	O
the	O
carbohydrates	other-biologything
lactose	other-biologything
,	O
maltose	other-biologything
,	O
sucrose	other-biologything
,	O
and	O
glucose	other-biologything
,	O
``	O
N.	other-medical
gonorrhoeae	other-medical
``	O
will	O
oxidize	O
only	O
the	O
glucose	other-biologything
.	O

Via	O
activation	O
of	O
the	O
KOR	O
,	O
levomethorphan	other-medical
can	O
produce	O
dysphoria	O
and	O
psychotomimetic	O
effects	O
such	O
as	O
dissociation	O
and	O
hallucinations	O
.	O

It	O
has	O
been	O
shown	O
that	O
phosphorylation	O
of	O
STAT3	other-biologything
and	O
RANTES	other-biologything
expression	O
are	O
increased	O
in	O
response	O
to	O
tamoxifen	other-medical
in	O
human	O
breast	other-disease
cancer	other-disease
cells	O
.	O

Electrosurgery	other-medical
is	O
defined	O
as	O
“	O
the	O
intentional	O
passage	O
of	O
high	O
frequency	O
waveforms	O
or	O
currents	O
through	O
tissues	O
of	O
the	O
body	O
to	O
achieve	O
a	O
controllable	O
surgical	O
effect	O
”	O
and	O
has	O
been	O
used	O
for	O
over	O
50	O
years	O
in	O
dentistry	O
.	O

Hydrocodone	other-medical
with	O
paracetamol	other-medical
has	O
also	O
gained	O
favor	O
.	O

This	O
was	O
considered	O
an	O
acceptable	O
risk	O
because	O
the	O
malaria	other-disease
could	O
later	O
be	O
treated	O
with	O
quinine	other-medical
,	O
which	O
was	O
available	O
at	O
that	O
time	O
.	O

In	O
the	O
UK	location-GPE
,	O
Gardasil	other-medical
replaced	O
Cervarix	other-medical
in	O
September	O
2012	O
for	O
reasons	O
unrelated	O
to	O
safety	O
.	O

Talley	person-scholar
's	person-scholar
research	O
interests	O
are	O
in	O
neurogastroenterology	other-medical
;	O
including	O
the	O
treatment	O
,	O
pathophysiology	O
and	O
epidemiology	O
of	O
functional	other-disease
dyspepsia	other-disease
and	O
irritable	other-disease
bowel	other-disease
syndrome	other-disease
;	O
he	O
is	O
considered	O
an	O
international	O
authority	O
in	O
the	O
field	O
.	O

The	O
crew	O
conducted	O
the	O
first	O
intravenous	other-medical
saline	other-medical
solution	O
injection	O
in	O
space	O
as	O
part	O
of	O
an	O
experiment	O
to	O
study	O
the	O
human	O
body	O
's	O
response	O
to	O
direct	O
fluid	O
replacement	O
as	O
a	O
countermeasure	O
for	O
amounts	O
lost	O
during	O
space	O
flight	O
.	O

She	O
also	O
likened	O
his	O
calm	O
political	O
style	O
and	O
persona	O
to	O
the	O
calming	O
effect	O
of	O
Valium	other-medical
,	O
telling	O
a	O
reporter	O
,	O
``	O
If	O
you	O
chopped	O
(	O
him	O
)	O
into	O
little	O
pieces	O
,	O
you	O
could	O
sell	O
him	O
as	O
Valium	other-medical
tablets	O
.	O
''	O

In	O
one	O
patient	O
,	O
all	O
of	O
whose	O
routine	O
laboratory	O
tests	O
were	O
normal	O
,	O
the	O
following	O
were	O
attempted	O
,	O
all	O
without	O
success	O
:	O
ibuprofen	other-medical
,	O
400	O
mg	O
on	O
demand	O
;	O
tramadol	other-medical
50	O
mg	O
one	O
hour	O
pre-coitally	O
;	O
and	O
escitalopram	other-medical
10	O
mg	O
daily	O
at	O
bedtime	O
for	O
3	O
months	O
.	O

Diazepam	other-medical
has	O
been	O
studied	O
as	O
an	O
anti-convulsive	O
on	O
the	O
GABA	other-biologything
system	O
,	O
and	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
anisatin	other-chemicalthing
-induced	O
convulsions	O
.	O

Folic	other-medical
acid	other-medical
might	O
also	O
be	O
counter-productive	O
for	O
patients	O
taking	O
6-MP	other-medical
and	O
related	O
drugs	O
that	O
inhibit	O
all	O
cell	O
division	O
.	O

Salbutamol	other-medical
,	O
also	O
known	O
as	O
albuterol	O
and	O
marketed	O
as	O
Ventolin	other-medical
among	O
other	O
brand	O
names	O
,	O
is	O
a	O
medication	O
that	O
opens	O
up	O
the	O
medium	O
and	O
large	O
airways	O
in	O
the	O
lungs	O
.	O

Ether	other-medical
causes	O
a	O
very	O
long	O
excitation	O
stage	O
prior	O
to	O
blacking	O
out	O
.	O

NSAIDs	other-medical
may	O
also	O
be	O
illegal	O
in	O
competition	O
,	O
so	O
it	O
may	O
be	O
necessary	O
to	O
stop	O
treatment	O
with	O
NSAIDs	other-medical
several	O
days	O
before	O
the	O
horse	O
competes	O
.	O

Second-line	O
therapy	O
for	O
adults	O
is	O
phenytoin	other-medical
or	O
fosphenytoin	other-medical
and	O
phenobarbital	other-medical
for	O
children	O
.	O

In	O
2007	O
,	O
as	O
part	O
of	O
a	O
six-member	O
committee	O
,	O
he	O
helped	O
to	O
negotiate	O
a	O
$	other-currency
4.85	O
billion	O
settlement	O
between	O
Merck	organization-company
and	O
nearly	O
27,000	O
patients	O
who	O
suffered	O
medical	O
problems	O
while	O
taking	O
Vioxx	other-medical
.	O

Salbutamol	other-medical
is	O
usually	O
used	O
with	O
an	O
inhaler	O
or	O
nebulizer	O
,	O
but	O
it	O
is	O
also	O
available	O
in	O
a	O
pill	O
,	O
liquid	O
,	O
and	O
intravenous	O
solution	O
.	O

In	O
infants	O
,	O
the	O
Apt	other-medical
test	O
can	O
be	O
used	O
to	O
distinguish	O
fetal	O
hemoglobin	other-biologything
from	O
maternal	O
blood	O
based	O
on	O
the	O
differences	O
in	O
composition	O
of	O
fetal	O
hemoglobin	other-biologything
as	O
compared	O
to	O
the	O
hemoglobin	other-biologything
found	O
in	O
adults	O
.	O

One	O
reason	O
hypoglycemia	other-medical
due	O
to	O
excessive	O
insulin	O
can	O
be	O
more	O
dangerous	O
is	O
that	O
insulin	O
lowers	O
the	O
available	O
amounts	O
of	O
most	O
alternate	O
brain	O
fuels	O
,	O
such	O
as	O
ketones	other-medical
.	O

Other	O
NSAIDs	other-medical
,	O
though	O
once	O
used	O
to	O
treat	O
Dressler	other-disease
syndrome	O
,	O
are	O
less	O
advocated	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
ischemic	O
heart	O
disease	O
.	O

Fluvoxamine	other-medical
was	O
the	O
first	O
SSRI	other-medical
to	O
be	O
approved	O
in	O
Japan	O
(	O
1999	O
)	O
sertraline	other-medical
received	O
approval	O
in	O
April	O
2006	O
,	O
having	O
been	O
pending	O
approval	O
for	O
over	O
15	O
years	O
.	O

Cirrhosis	other-disease
is	O
a	O
late	O
stage	O
of	O
serious	O
liver	O
disease	O
marked	O
by	O
inflammation	other-medical
(	O
swelling	other-medical
)	O
,	O
fibrosis	other-medical
(	O
cellular	other-medical
hardening	other-medical
)	O
and	O
damaged	other-medical
membranes	other-medical
preventing	O
detoxification	O
of	O
chemicals	O
in	O
the	O
body	O
,	O
ending	O
in	O
scarring	other-medical
and	O
necrosis	other-medical
(	O
cell	other-medical
death	other-medical
)	O
.	O

Many	O
users	O
of	O
dissociatives	O
have	O
been	O
concerned	O
about	O
the	O
possibility	O
of	O
NMDA	other-medical
antagonist	other-medical
neurotoxicity	other-medical
(	O
NAN	other-medical
)	O
.	O

Methylprednisolone	other-medical
is	O
used	O
to	O
treat	O
several	O
rheumatic	O
diseases	O
,	O
such	O
as	O
Systemic	other-disease
Lupus	other-disease
Erythematosus	other-disease
(	O
SLE	other-disease
)	O
and	O
Rheumatoid	other-disease
Arthritis	other-disease
(	O
RA	other-disease
)	O
.	O

The	O
cutaneous	O
symptoms	O
vary	O
,	O
and	O
range	O
from	O
rashes	other-medical
and	O
noduli	other-medical
(	O
small	O
bumps	O
)	O
to	O
erythema	other-medical
nodosum	other-medical
,	O
granuloma	other-medical
annulare	other-medical
,	O
or	O
lupus	other-medical
pernio	other-medical
.	O

Exposure	O
to	O
light	O
during	O
the	O
hours	O
of	O
melatonin	other-medical
production	O
reduces	O
melatonin	other-medical
production	O
.	O

The	O
degree	O
of	O
tolerance	O
is	O
more	O
pronounced	O
with	O
clonazepam	other-medical
than	O
with	O
chlordiazepoxide	other-medical
.	O

The	O
patient	O
took	O
diclofenac	other-medical
75	O
mg	O
1	O
to	O
2	O
hours	O
prior	O
to	O
sexual	O
activity	O
with	O
orgasm	O
,	O
and	O
continued	O
twice	O
daily	O
for	O
24	O
to	O
48	O
hours	O
.	O

A	O
number	O
of	O
the	O
endogenous	O
compounds	O
have	O
been	O
reported	O
to	O
be	O
affected	O
by	O
ofloxacin	other-medical
as	O
inhibitors	O
,	O
alteraters	O
,	O
and	O
depletors	O
.	O

Influvac	other-medical
is	O
a	O
subunit	O
vaccine	O
produced	O
and	O
marketed	O
by	O
Mylan	organization-company
.	O

Colchicine	other-medical
in	O
combination	O
with	O
probenecid	other-medical
has	O
been	O
FDA	organization-government,governmentagency
-approved	O
prior	O
to	O
1982	O
.	O

There	O
are	O
commercially	O
available	O
immunohistochemical	O
tests	O
,	O
Dako	other-medical
HercepTest	other-medical
,	O
Leica	other-medical
Biosystems	other-medical
Oracle	other-medical
and	O
Ventana	other-medical
Pathway	other-medical
.	O

The	O
acute	O
administration	O
of	O
stimulants	O
such	O
as	O
amphetamines	other-medical
typically	O
produces	O
hyperglycemia	O
;	O
chronic	O
use	O
,	O
however	O
,	O
produces	O
hypoglycemia	O
.	O

Somatostatin	other-medical
and	O
octreotide	other-medical
,	O
while	O
recommended	O
for	O
varicial	other-disease
bleeding	other-disease
,	O
have	O
not	O
been	O
found	O
to	O
be	O
of	O
general	O
use	O
for	O
non	other-disease
variceal	other-disease
bleeds	other-disease
.	O

Nodular	other-disease
vasculitis	other-disease
is	O
a	O
skin	O
condition	O
characterized	O
by	O
crops	O
of	O
small	O
,	O
tender	O
,	O
erythematous	other-medical
nodules	other-medical
on	O
the	O
legs	O
,	O
mostly	O
on	O
the	O
calves	O
and	O
shins	O
.	O

Doctors	O
may	O
search	O
for	O
Thyroid	other-medical
peroxidase	other-medical
Antibodies	other-medical
(	O
TPOAb	other-medical
)	O
when	O
a	O
person	O
has	O
symptoms	O
of	O
hypothyroidism	O
,	O
or	O
when	O
a	O
person	O
will	O
be	O
started	O
on	O
a	O
drug	O
therapy	O
associated	O
with	O
risks	O
of	O
developing	O
hypothyroidism	O
,	O
such	O
as	O
lithium	other-medical
or	O
Interferon	other-medical
alfa	other-medical
.	O

Insulin	other-medical
resistance	O
reduces	O
the	O
body	O
's	O
sensitivity	O
to	O
insulin	other-medical
.	O

Of	O
the	O
344	O
wounded	O
that	O
were	O
admitted	O
to	O
the	O
Tripler	building-hospital
Army	building-hospital
Hospital	building-hospital
,	O
only	O
13	O
did	O
not	O
survive	O
,	O
and	O
it	O
is	O
unlikely	O
that	O
thiopentone	other-medical
overdose	O
was	O
responsible	O
for	O
more	O
than	O
a	O
few	O
of	O
these	O
.	O

Testimony	O
then	O
turned	O
to	O
the	O
use	O
of	O
flumazenil	other-medical
(	O
a	O
benzodiazepine	other-medical
antagonist	O
)	O
as	O
an	O
antidote	O
to	O
Ativan	other-medical
.	O

The	O
only	O
time	O
heparin	other-medical
could	O
be	O
used	O
with	O
pericarditis	O
is	O
with	O
coexisting	O
acute	O
MI	other-disease
,	O
in	O
order	O
to	O
prevent	O
further	O
thrombus	O
formation	O
.	O

By	O
the	O
mid-1980s	O
,	O
Tylenol	other-medical
had	O
rebounded	O
completely	O
.	O

Polythiazide	other-medical
is	O
a	O
thiazide	other-medical
diuretic	other-medical
.	O

Testosterone	other-medical
enanthate	other-medical
can	O
also	O
lead	O
to	O
an	O
increase	O
in	O
igf-1	other-biologything
and	O
igf-bp	other-biologything
.	O

Flupamesone	other-medical
(	O
brand	O
name	O
Flutenal	other-medical
)	O
,	O
also	O
known	O
as	O
triamcinolone	other-medical
acetonide	other-medical
metembonate	other-medical
,	O
is	O
a	O
synthetic	O
glucocorticoid	other-biologything
corticosteroid	other-biologything
which	O
is	O
marketed	O
in	O
Spain	location-GPE
.	O

Contrary	O
to	O
most	O
other	O
injector	O
pens	O
,	O
epinephrine	other-medical
injector	O
pens	O
are	O
designed	O
to	O
administer	O
the	O
medication	O
via	O
intramuscular	O
injection	O
.	O

On	O
July	O
30	O
,	O
2009	O
the	O
FDA	organization-government,governmentagency
approved	O
colchicine	other-medical
as	O
a	O
monotherapy	O
for	O
the	O
treatment	O
of	O
three	O
different	O
indications	O
(	O
familial	O
Mediterranean	O
fever	O
,	O
acute	O
gout	O
flares	O
,	O
and	O
for	O
the	O
prophylaxis	O
of	O
gout	O
flares	O
)	O
,	O
and	O
gave	O
URL	organization-company
Pharma	organization-company
a	O
three-year	O
marketing	O
exclusivity	O
agreement	O
in	O
exchange	O
for	O
URL	organization-company
Pharma	organization-company
doing	O
17	O
new	O
studies	O
and	O
investing	O
$	other-currency
100	O
million	O
into	O
the	O
product	O
,	O
of	O
which	O
$	other-currency
45	O
million	O
went	O
to	O
the	O
FDA	organization-government,governmentagency
for	O
the	O
application	O
fee	O
.	O

Oral	other-medical
iron	other-medical
supplementations	other-medical
are	O
the	O
first	O
line	O
of	O
care	O
for	O
iron	other-disease
deficiency	other-disease
and	O
iron	other-disease
deficiency	other-disease
anaemia	other-disease
.	O

Niacin	other-medical
has	O
also	O
been	O
used	O
and	O
tested	O
for	O
the	O
purpose	O
of	O
enhancing	O
detoxification	other-medical
by	O
removing	O
skin	O
lipid-stored	O
xenobiotics	other-medical
.	O

In	O
1980	O
,	O
9.7	O
%	O
of	O
the	O
dialysis	O
population	O
was	O
on	O
home	other-medical
hemodialysis	other-medical
but	O
by	O
1987	O
the	O
proportion	O
had	O
dropped	O
to	O
3.6	O
%	O
.	O

Dillard-Nalle	O
then	O
began	O
selling	O
their	O
Dellard	other-medical
's	other-medical
Aspergum	other-medical
in	O
the	O
United	location-GPE
States	location-GPE
in	O
1928.	O
it	O
was	O
an	O
early	O
example	O
of	O
a	O
functional	O
gum	O
–	O
chewing	O
gum	O
as	O
a	O
drug	O
delivery	O
system	O
.	O

Henry	person-politician
Wellcome	person-politician
's	O
interest	O
was	O
the	O
history	O
of	O
medicine	O
in	O
a	O
broad	O
sense	O
and	O
included	O
subjects	O
such	O
as	O
alchemy	O
or	O
witchcraft	O
,	O
but	O
also	O
anthropology	other-medical
and	O
ethnography	other-medical
.	O

Furosemide	other-medical
should	O
be	O
used	O
with	O
caution	O
when	O
combined	O
with	O
corticosteroids	other-medical
(	O
as	O
this	O
increases	O
the	O
risk	O
of	O
electrolyte	other-disease
imbalance	other-disease
)	O
,	O
aminoglycoside	other-medical
antibiotics	other-medical
(	O
increases	O
risk	O
of	O
kidney	O
or	O
ear	O
damage	O
)	O
,	O
and	O
trimethoprim	other-medical
sulfa	other-medical
(	O
causes	O
decreased	other-disease
platelet	other-disease
count	other-disease
)	O
.	O

Some	O
states	O
and	O
store	O
chains	O
have	O
implemented	O
restrictions	O
,	O
such	O
as	O
requiring	O
signatures	O
for	O
DXM	other-medical
sale	O
,	O
limiting	O
quantities	O
allowable	O
for	O
purchase	O
,	O
and	O
requiring	O
that	O
purchasers	O
be	O
over	O
the	O
age	O
of	O
majority	O
in	O
their	O
state	O
.	O

Hyperventilation	other-medical
may	O
occur	O
and	O
is	O
sometimes	O
followed	O
by	O
apnea	other-medical
and	O
cyanosis	other-medical
.	O

Bevacizumab	other-medical
,	O
another	O
medication	O
for	O
the	O
same	O
purpose	O
,	O
resulted	O
in	O
an	O
incidence	O
between	O
0.09	O
%	O
and	O
0.4	O
%	O
.	O

While	O
there	O
is	O
good	O
evidence	O
for	O
the	O
efficacy	O
of	O
opioid	other-medical
rotation	O
as	O
a	O
treatment	O
approach	O
in	O
general	O
,	O
there	O
is	O
less	O
evidence	O
for	O
what	O
particular	O
opioid	other-medical
analgesics	O
are	O
most	O
suitable	O
,	O
and	O
in	O
practice	O
the	O
choice	O
of	O
opioid	other-medical
drugs	O
used	O
depends	O
on	O
many	O
factors	O
such	O
as	O
patient	O
characteristics	O
,	O
prescriber	O
preferences	O
and	O
safety	O
.	O

Treatment	O
may	O
include	O
a	O
direct	other-medical
thrombin	other-medical
inhibitor	other-medical
,	O
such	O
as	O
lepirudin	other-medical
or	O
argatroban	other-medical
.	O

Generally	O
speaking	O
,	O
nootropics	other-medical
are	O
said	O
to	O
be	O
effective	O
for	O
enhancing	O
focus	O
,	O
learning	O
,	O
memory	O
function	O
,	O
mood	O
,	O
and	O
in	O
some	O
cases	O
,	O
physical	O
brain	O
development	O
.	O

Alles	O
first	O
reported	O
the	O
physiological	O
properties	O
of	O
amphetamine	other-medical
as	O
a	O
synthetic	O
analog	O
of	O
ephedrine	other-medical
,	O
and	O
therefore	O
received	O
credit	O
for	O
this	O
discovery	O
.	O

Oxazepam	other-medical
when	O
taken	O
during	O
the	O
third	O
trimester	O
,	O
causes	O
a	O
definite	O
risk	O
to	O
the	O
neonate	O
including	O
a	O
severe	O
benzodiazepine	other-disease
withdrawal	other-disease
syndrome	other-disease
including	O
hypotonia	other-medical
,	O
and	O
reluctance	O
to	O
suck	O
,	O
to	O
apnoeic	other-medical
spells	other-medical
,	O
cyanosis	other-medical
,	O
and	O
impaired	other-medical
metabolic	other-medical
responses	other-medical
to	O
cold	O
stress	O
.	O

As	O
a	O
pharmaceutical	O
drug	O
it	O
is	O
called	O
cholecalciferol	other-medical
(	O
USAN	other-medical
)	O
or	O
colecalciferol	other-medical
(	O
INN	other-medical
,	O
BAN	other-medical
)	O
.	O

Ranitidine	other-medical
has	O
been	O
shown	O
to	O
reduce	O
ulceration	O
when	O
given	O
concurrently	O
during	O
feed	O
deprivation	O
trials	O
.	O

Use	O
is	O
widespread	O
among	O
amphetamine	other-medical
users	O
,	O
with	O
those	O
that	O
use	O
amphetamines	other-medical
and	O
benzodiazepines	other-medical
having	O
greater	O
levels	O
of	O
mental	O
health	O
problems	O
and	O
social	O
deterioration	O
.	O

A	O
number	O
of	O
high-profile	O
infant	O
rapes	O
appeared	O
since	O
2001	O
(	O
including	O
the	O
fact	O
that	O
they	O
required	O
extensive	O
reconstructive	other-medical
surgery	other-medical
to	O
rebuild	O
urinary	O
,	O
genital	O
,	O
abdominal	O
,	O
or	O
tracheal	O
systems	O
)	O
.	O

Loratadine	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Claritin	other-medical
among	O
others	O
,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
allergies	other-disease
.	O

AAV-DC-CTL	other-medical
:	O
A	O
clinical	O
trial	O
is	O
currently	O
in	O
Phase	O
I	O
investigation	O
of	O
Oncolytic	other-disease
AAV	other-disease
treatments	O
for	O
stage	O
IV	O
gastric	other-disease
cancer	other-disease
in	O
China	location-GPE
.	O

In	O
2005	O
,	O
the	O
withdrawal	O
of	O
the	O
painkiller	other-medical
Vioxx	other-medical
was	O
followed	O
by	O
an	O
investigation	O
by	O
Deer	person-other
into	O
the	O
people	O
responsible	O
for	O
the	O
drug	O
's	O
introduction	O
.	O

Pharmacologically	O
,	O
it	O
is	O
of	O
interest	O
as	O
an	O
acetylcholinesterase	other-medical
inhibitor	other-medical
and	O
accordingly	O
as	O
possibly	O
relevant	O
to	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
.	O

IVF	other-medical
is	O
available	O
for	O
women	O
aged	O
18	O
to	O
45	O
.	O

Cryotherapy	other-medical
may	O
be	O
used	O
to	O
treat	O
a	O
variety	O
of	O
tissue	O
lesions	O
.	O

In	O
November	O
2009	O
,	O
Mencia	person-actor
began	O
appearing	O
in	O
commercials	O
for	O
a	O
weight-loss	O
product	O
called	O
Belly	other-medical
Burner	other-medical
,	O
which	O
he	O
has	O
claimed	O
to	O
have	O
used	O
personally	O
.	O

Gardasil	other-medical
protects	O
against	O
strains	O
6	O
,	O
11	O
,	O
16	O
,	O
and	O
18	O
,	O
and	O
Cervarix	other-medical
protects	O
against	O
16	O
and	O
18	O
,	O
whereas	O
plantar	O
warts	O
are	O
caused	O
by	O
strains	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
63	O
.	O

Taking	O
equal	O
doses	O
of	O
vitamin	other-medical
C	other-medical
and	O
aspirin	other-medical
may	O
decrease	O
the	O
amount	O
of	O
stomach	O
damage	O
that	O
occurs	O
compared	O
to	O
taking	O
aspirin	other-medical
alone	O
.	O

The	O
main	O
suppliers	O
of	O
heroin	other-medical
to	O
the	O
US	location-GPE
have	O
been	O
Mexican	location-GPE
transnational	O
criminal	O
organizations	O
.	O

Ro15-4513	other-medical
was	O
somewhat	O
less	O
effective	O
than	O
flumazenil	other-medical
at	O
blocking	O
the	O
effects	O
of	O
benzodiazepines	other-medical
,	O
but	O
instead	O
selectively	O
blocked	O
the	O
effects	O
of	O
ethanol	other-chemicalthing
.	O

There	O
is	O
tentative	O
evidence	O
of	O
benefit	O
for	O
tranexamic	other-medical
acid	other-medical
which	O
inhibits	O
clot	O
breakdown	O
.	O

Carfecillin	other-medical
is	O
a	O
beta-lactam	other-medical
antibiotic	other-medical
.	O

Acyclovir	other-medical
,	O
favipiravir	other-medical
,	O
and	O
remdesivir	other-medical
have	O
been	O
assessed	O
as	O
potential	O
antivirals	O
against	O
Nipah	other-biologything
virus	other-biologything
.	O

The	O
WHO	organization-other
announced	O
it	O
was	O
developing	O
a	O
COVID-19	other-medical
virus	other-medical
treatment	O
master	O
plan	O
.	O

Unlike	O
morphine	other-medical
,	O
oxycodone	other-medical
lacks	O
immunosuppressive	O
activity	O
(	O
measured	O
by	O
natural	O
killer	O
cell	O
activity	O
and	O
interleukin	O
2	O
production	O
``	O
in	O
vitro	O
''	O
)	O
;	O
the	O
clinical	O
relevance	O
of	O
this	O
has	O
not	O
been	O
clarified	O
.	O

However	O
,	O
there	O
are	O
two	O
possible	O
causes	O
of	O
the	O
corneal	other-disease
inflammatory	other-disease
response	other-disease
:	O
an	O
infection	O
and/or	O
an	O
immunological	other-medical
response	other-medical
,	O
such	O
as	O
a	O
hypersensitivity	other-medical
type	other-medical
reaction	other-medical
,	O
or	O
(	O
rarely	O
)	O
Cogan	other-disease
syndrome	other-disease
.	O

However	O
,	O
chloral	other-medical
hydrate	other-medical
products	O
,	O
licensed	O
for	O
short-term	O
management	O
of	O
severe	other-disease
insomnia	other-disease
,	O
are	O
available	O
in	O
the	O
United	location-GPE
Kingdom	location-GPE
.	O

An	O
elevated	O
EPL	O
or	O
LY30	O
suggests	O
fibrinolysis	O
and	O
may	O
be	O
treated	O
with	O
an	O
antifibrinolytic	O
,	O
such	O
as	O
tranexamic	other-medical
acid	other-medical
or	O
aminocaproic	other-medical
acid	other-medical
,	O
in	O
the	O
appropriate	O
clinical	O
setting	O
.	O

For	O
dental	O
procedures	O
,	O
the	O
American	location-GPE
protocol	O
in	O
2017	O
called	O
for	O
the	O
prescription	O
of	O
amoxicillin	other-medical
or	O
ampicillin	other-medical
.	O

It	O
also	O
lists	O
possible	O
safety	O
concerns	O
:	O
``	O
Intake	O
of	O
3	O
grams	O
per	O
day	O
or	O
greater	O
of	O
omega-3	other-medical
fatty	O
acids	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
,	O
although	O
there	O
is	O
little	O
evidence	O
of	O
significant	O
bleeding	O
risk	O
at	O
lower	O
doses	O
.	O

If	O
your	O
headache	O
would	O
remain	O
without	O
aspirin	O
but	O
disappear	O
if	O
you	O
took	O
aspirin	other-medical
,	O
then	O
the	O
causal	O
effect	O
of	O
taking	O
aspirin	other-medical
is	O
headache	O
relief	O
.	O

If	O
a	O
malignant	other-disease
neoplastic	other-disease
chylothorax	other-disease
is	O
present	O
,	O
then	O
treatment	O
with	O
radiotherapy	other-medical
and/or	O
chemotherapy	other-medical
is	O
warranted	O
.	O

Levels	O
of	O
anti-GM1	other-medical
antibodies	O
are	O
elevated	O
in	O
patients	O
with	O
various	O
forms	O
of	O
dementia	O
.	O

in	O
2008	O
16	O
Anadin	other-medical
Paracetamol	other-medical
tablets	other-medical
each	O
containing	O
500	O
mg	O
of	O
paracetamol	O
cost	O
around	O
£2.09	other-currency
while	O
non-branded	O
equivalents	O
retailed	O
for	O
around	O
£0.35	other-currency
)	O
.	O

Unlike	O
α2	other-biologything
adrenoceptor	other-biologything
agonists	O
such	O
as	O
guanfacine	other-medical
and	O
clonidine	other-medical
,	O
atomoxetine	other-medical
's	O
use	O
can	O
be	O
abruptly	O
stopped	O
without	O
significant	O
discontinuation	O
effects	O
being	O
seen	O
.	O

Piracetam	other-medical
has	O
been	O
found	O
to	O
diminish	O
erythrocyte	O
adhesion	O
to	O
vascular	O
wall	O
endothelium	O
,	O
making	O
any	O
vasospasm	O
in	O
the	O
capillary	O
less	O
severe	O
.	O

Stereotactic	other-medical
radiation	other-medical
therapy	other-medical
,	O
also	O
called	O
stereotactic	other-medical
external-beam	other-medical
radiation	other-medical
therapy	other-medical
and	O
stereotaxic	other-medical
radiation	other-medical
therapy	other-medical
,	O
is	O
a	O
type	O
of	O
external	O
radiation	O
therapy	O
that	O
uses	O
special	O
equipment	O
to	O
position	O
the	O
patient	O
and	O
precisely	O
deliver	O
radiation	O
to	O
a	O
tumor	O
.	O

Conversely	O
,	O
naltrexone	other-medical
antagonism	O
at	O
the	O
opioid	other-biologything
receptor	other-biologything
can	O
be	O
overcome	O
with	O
higher	O
doses	O
of	O
opioids	O
.	O

BAT	other-medical
is	O
the	O
only	O
product	O
available	O
for	O
treating	O
botulism	other-disease
in	O
adults	O
,	O
and	O
for	O
botulism	other-disease
in	O
infants	O
caused	O
by	O
botulinum	other-biologything
toxins	other-biologything
other	O
than	O
types	O
A	O
and	O
B	O
.	O

Treatments	O
for	O
angina	other-disease
are	O
balloon	other-medical
angioplasty	other-medical
,	O
in	O
which	O
the	O
balloon	other-medical
is	O
inserted	O
at	O
the	O
end	O
of	O
a	O
catheter	other-medical
and	O
inflated	O
to	O
widen	O
the	O
arterial	O
lumen	O
.	O

The	O
mode	O
of	O
delivery	O
is	O
also	O
important	O
,	O
with	O
a	O
planned	O
Caesarian	other-medical
section	other-medical
having	O
a	O
lower	O
risk	O
than	O
vaginal	O
delivery	O
or	O
emergency	O
Caesarian	other-medical
section	other-medical
.	O

Caffeine	other-medical
is	O
a	O
substrate	O
for	O
CYP1A2	other-biologything
,	O
and	O
interacts	O
with	O
many	O
substances	O
through	O
this	O
and	O
other	O
mechanisms	O
.	O

Hypoventilation	other-medical
exists	O
when	O
the	O
ratio	O
of	O
carbon	other-chemicalthing
dioxide	other-chemicalthing
production	O
to	O
alveolar	O
ventilation	O
increases	O
above	O
normal	O
values	O
–	O
greater	O
than	O
45mmHg	O
.	O

In	O
the	O
17th	O
century	O
the	O
practice	O
of	O
mixing	O
opium	other-medical
with	O
tobacco	other-medical
for	O
smoking	O
spread	O
from	O
Southeast	location-GPE
Asia	location-GPE
,	O
creating	O
a	O
far	O
greater	O
demand	O
.	O

Similarly	O
,	O
lamotrigine	other-medical
treats	O
multiple	other-disease
seizure	other-disease
types	other-disease
including	O
partial	other-disease
seizures	other-disease
and	O
generalized	other-disease
seizures	other-disease
,	O
therefore	O
it	O
is	O
also	O
an	O
option	O
for	O
patients	O
with	O
multiple	other-disease
seizure	other-disease
types	other-disease
.	O

Quinine	other-medical
is	O
also	O
used	O
to	O
treat	O
lupus	other-disease
and	O
arthritis	other-disease
.	O

Medications	O
with	O
good	O
evidence	O
include	O
topical	other-medical
ivermectin	other-medical
and	O
azelaic	other-medical
acid	other-medical
creams	O
and	O
brimonidine	other-medical
,	O
and	O
doxycycline	other-medical
and	O
isotretinoin	other-medical
by	O
mouth	O
.	O

Trastuzumab	other-medical
or	O
Herceptin	other-medical
inhibits	O
downstream	O
signal	O
cascades	O
by	O
selectively	O
binding	O
to	O
the	O
extracellular	O
domain	O
of	O
ErbB-2	other-medical
receptors	other-medical
to	O
inhibit	O
it	O
.	O

Malaria	other-disease
as	O
a	O
treatment	O
for	O
syphilis	O
was	O
usually	O
reserved	O
for	O
late	O
disease	O
,	O
especially	O
neurosyphilis	other-disease
,	O
and	O
then	O
followed	O
by	O
either	O
Salvarsan	other-medical
or	O
Neosalvarsan	other-medical
as	O
adjuvant	O
therapy	O
.	O

Flu	O
drugs	O
Tamiflu	other-medical
and	O
Relenza	other-medical
work	O
by	O
inhibiting	O
some	O
strains	O
of	O
neuraminidase	other-biologything
.	O

The	O
two	O
contraindications	O
to	O
taking	O
ezetimibe	other-medical
are	O
a	O
previous	O
allergic	O
reaction	O
to	O
it	O
,	O
including	O
symptoms	O
of	O
rash	O
,	O
angioedema	other-disease
,	O
and	O
anaphylaxis	other-disease
,	O
and	O
severe	O
liver	O
disease	O
,	O
especially	O
when	O
taken	O
with	O
a	O
statin	O
.	O

Muscle	other-medical
relaxants	other-medical
are	O
typically	O
used	O
for	O
and	O
are	O
helpful	O
with	O
acute	other-medical
post-traumatic	other-medical
TTH	other-medical
rather	O
than	O
ETTH	other-medical
.	O

In	O
addition	O
he	O
had	O
signs	O
of	O
Balint	other-disease
's	other-disease
syndrome	other-disease
(	O
mild	other-medical
simultanagnosia	other-medical
,	O
optic	other-medical
ataxia	other-medical
,	O
and	O
optic	other-medical
apraxia	other-medical
)	O
.	O

Of	O
the	O
other	O
dose-dependent	O
side	O
effects	O
,	O
palpitations	other-disease
(	O
4.5	O
%	O
at	O
10	O
mg	O
vs.	O
0.6	O
%	O
in	O
placebos	other-medical
)	O
and	O
flushing	other-disease
(	O
2.6	O
%	O
vs.	O
0	O
%	O
)	O
occurred	O
more	O
often	O
in	O
women	O
;	O
dizziness	other-disease
(	O
3.4	O
%	O
vs.	O
1.5	O
%	O
)	O
had	O
no	O
sex	O
bias	O
.	O

First-generation	O
antihistamines	other-medical
include	O
diphenhydramine	other-medical
(	O
Benadryl	other-medical
)	O
,	O
carbinoxamine	other-medical
(	O
Clistin	other-medical
)	O
,	O
clemastine	other-medical
(	O
Tavist	other-medical
)	O
,	O
chlorpheniramine	other-medical
(	O
Chlor-Trimeton	other-medical
)	O
,	O
and	O

Mitoxantrone	other-medical
is	O
also	O
highly	O
useful	O
to	O
reduce	O
attacks	O
and	O
disability	O
,	O
but	O
it	O
is	O
generally	O
not	O
considered	O
as	O
a	O
long-term	O
therapy	O
due	O
to	O
its	O
severe	O
cardiac	O
toxicity	O
.	O

Botulinum	other-medical
toxin	other-medical
is	O
used	O
to	O
treat	O
a	O
number	O
of	O
therapeutic	O
indications	O
,	O
many	O
of	O
which	O
are	O
not	O
part	O
of	O
the	O
approved	O
drug	O
label	O
.	O

Cauterization	other-medical
methods	O
include	O
burning	O
the	O
affected	O
area	O
with	O
acid	O
,	O
hot	O
metal	O
,	O
or	O
lasers	O
.	O

Formulations	O
containing	O
high	O
concentrations	O
of	O
aspirin	other-medical
often	O
smell	O
like	O
vinegar	O
because	O
aspirin	other-medical
can	O
decompose	O
through	O
hydrolysis	O
in	O
moist	O
conditions	O
,	O
yielding	O
salicylic	other-chemicalthing
and	O
acetic	other-chemicalthing
acids	other-chemicalthing
.	O

Daunorubicin	other-medical
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	location-GPE
States	location-GPE
in	O
1979	O
.	O

Since	O
the	O
1960s	O
,	O
when	O
she	O
first	O
joined	O
the	O
university	O
,	O
Wohl	person-scholar
specialized	O
in	O
the	O
respiratory	other-medical
diseases	O
of	O
children	O
and	O
was	O
a	O
leader	O
in	O
the	O
field	O
of	O
clinical	O
research	O
on	O
Cystic	other-disease
fibrosis	other-disease
.	O

Proton-pump	O
inhibitors	O
such	O
as	O
omeprazole	other-chemicalthing
and	O
the	O
anticonvulsant	other-chemicalthing
valproate	other-chemicalthing
have	O
been	O
found	O
to	O
increase	O
the	O
plasma	O
concentrations	O
of	O
methotrexate	other-biologything
,	O
as	O
have	O
nephrotoxic	O
agents	O
such	O
as	O
cisplatin	other-medical
,	O
the	O
GI	other-medical
drug	other-medical
colestyramine	other-medical
,	O
and	O
dantrolene	other-medical
.	O

A	O
systematic	O
review	O
and	O
meta	O
analysis	O
conducted	O
in	O
2014	O
,	O
demonstrated	O
that	O
the	O
BCG	other-medical
vaccine	other-medical
reduced	O
infections	O
by	O
19–27	O
%	O
and	O
reduced	O
progression	O
to	O
active	other-disease
TB	other-disease
by	O
71	O
%	O
.	O

A	O
subsequent	O
double-blind	O
RCT	product-other
,	O
that	O
treated	O
patients	O
who	O
self-poisoned	O
,	O
found	O
no	O
benefit	O
of	O
pralidoxime	other-medical
,	O
including	O
specifically	O
in	O
chlorpyrifos	O
patients	O
.	O

Strontium	other-medical
ranelate	other-medical
stimulates	O
the	O
calcium-sensing	O
receptors	O
and	O
leads	O
to	O
the	O
differentiation	O
of	O
pre-osteoblast	O
to	O
osteoblast	other-biologything
which	O
increases	O
the	O
bone	O
formation	O
.	O

BAT	other-medical
has	O
been	O
used	O
to	O
treat	O
a	O
case	O
of	O
type	O
F	O
infant	O
botulism	other-disease
and	O
,	O
on	O
a	O
case-by-case	O
basis	O
,	O
may	O
be	O
used	O
for	O
future	O
cases	O
of	O
non-type	O
A	O
and	O
non-type	O
B	O
infant	O
botulism	other-disease
.	O

The	O
label	O
states	O
,	O
``	O
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Zestril	other-medical
as	O
soon	O
as	O
possible	O
.	O
''	O

He	O
is	O
credited	O
with	O
the	O
invention	O
of	O
transcutaneous	other-medical
electrical	other-medical
nerve	other-medical
stimulator	other-medical
,	O
spinal	other-medical
cord	other-medical
stimulator	other-medical
,	O
and	O
radiofrequency	other-medical
ablation	other-medical
for	O
back	O
pain	O
arising	O
from	O
facet	other-disease
arthropathy	other-disease
.	O

Naltrexone	other-medical
is	O
not	O
as	O
widely	O
used	O
as	O
buprenorphine	other-medical
or	O
methadone	other-medical
for	O
OUD	other-disease
due	O
to	O
low	O
rates	O
of	O
patient	O
acceptance	O
,	O
non-adherence	O
due	O
to	O
daily	O
dosing	O
,	O
and	O
difficulty	O
achieving	O
abstinence	O
from	O
opioids	other-medical
before	O
beginning	O
treatment	O
.	O

A	O
Cochrane	O
Systematic	O
Review	O
showed	O
that	O
trifluridine	other-medical
and	O
aciclovir	other-medical
were	O
a	O
more	O
effective	O
treatment	O
than	O
idoxuridine	other-medical
or	O
vidarabine	other-medical
,	O
significantly	O
increasing	O
the	O
relative	O
number	O
of	O
successfully	O
healed	O
eyes	O
in	O
one	O
to	O
two	O
weeks	O
.	O

Increasing	O
prescription	O
of	O
opioids	other-medical
fueled	O
a	O
growing	O
black	O
market	O
for	O
heroin	other-medical
.	O

Treponema	other-medical
pallidum	other-medical
particle	other-medical
agglutination	other-medical
assay	other-medical
(	O
TP-PA	other-medical
)	O
and	O
the	O
Toluidine	other-medical
red	other-medical
unheated	other-medical
serum	other-medical
test	other-medical
(	O
TRUST	other-medical
)	O
,	O
which	O
may	O
be	O
used	O
to	O
confirm	O
a	O
positive	O
VDRL	other-medical
result	O
,	O
are	O
more	O
specific	O
for	O
syphilis	other-disease
than	O
non-treponemal	O
tests	O
and	O
in	O
the	O
presence	O
of	O
a	O
positive	O
test	O
,	O
more	O
likely	O
indicate	O
active	O
infection	O
.	O

Velneperit	other-medical
(	O
S-2367	O
)	O
is	O
a	O
drug	O
developed	O
by	O
Shionogi	organization-company
,	O
which	O
acts	O
as	O
a	O
potent	O
and	O
selective	O
antagonist	O
for	O
the	O
Neuropeptide	other-chemicalthing
Y	other-chemicalthing
receptor	other-chemicalthing
Y5	other-chemicalthing
.	O

Lamivudine	other-medical
treatment	O
has	O
been	O
shown	O
to	O
restore	O
zidovudine	other-medical
sensitivity	O
of	O
previously	O
resistant	O
HIV	other-biologything
.	O

Chlorpromazine	other-medical
may	O
be	O
used	O
as	O
an	O
antiemetic	O
in	O
dogs	O
and	O
cats	O
,	O
or	O
,	O
less	O
often	O
,	O
as	O
sedative	other-medical
prior	O
to	O
anesthesia	other-medical
.	O

A	O
meta-analysis	O
of	O
53	O
clinical	O
trials	O
has	O
shown	O
that	O
all	O
triptans	other-medical
are	O
effective	O
for	O
treating	O
migraine	O
at	O
marketed	O
doses	O
and	O
that	O
naratriptan	other-medical
,	O
although	O
less	O
effective	O
than	O
sumatriptan	other-medical
and	O
rizatriptan	other-medical
was	O
more	O
effective	O
than	O
placebo	O
in	O
reducing	O
migraine	other-disease
symptoms	O
at	O
two	O
hours	O
and	O
efficacy	O
was	O
demonstrated	O
in	O
almost	O
two	O
thirds	O
of	O
subjects	O
after	O
four	O
hours	O
of	O
treatment	O
.	O

Many	O
Psychostimulant	other-disease
drugs	O
are	O
known	O
to	O
interact	O
with	O
VMAT	other-medical
,	O
including	O
Amphetamine	other-medical
analogs	O
such	O
as	O
Methamphetamine	other-medical
(	O
METH	other-medical
)	O
,	O
Cocaine	other-medical
,	O
and	O
Ecstasy	other-medical
(	O
MDMA	other-medical
)	O
.	O

Anemia	other-medical
is	O
a	O
condition	O
in	O
which	O
there	O
is	O
an	O
insufficient	O
number	O
of	O
red	O
blood	O
cells	O
to	O
carry	O
adequate	O
levels	O
of	O
oxygen	O
to	O
the	O
body	O
's	O
tissues	O
.	O

Amiodarone	other-medical
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
ventricular	other-disease
tachycardia	other-disease
in	O
certain	O
instances	O
.	O

In	O
about	O
10	O
%	O
of	O
cases	O
the	O
blood	other-medical
sugar	other-medical
is	O
not	O
significantly	O
elevated	O
(	O
``	O
euglycemic	other-disease
diabetic	other-disease
ketoacidosis	other-disease
``	O
)	O
.	O

Tadalafil	other-medical
is	O
structurally	O
different	O
from	O
both	O
sildenafil	other-medical
and	O
vardenafil	other-medical
.	O

It	O
may	O
have	O
potential	O
as	O
a	O
broad	O
spectrum	O
antibiotic	other-medical
,	O
as	O
demonstrated	O
in	O
tests	O
against	O
``	O
Staphylococcus	other-medical
aureus	other-medical
``	O
,	O
``	O
Bacillus	other-medical
subtilis	other-medical
``	O
,	O
``	O
Pseudomonas	other-medical
aeruginosa	other-medical
``	O
,	O
and	O
``	O
Escherichia	other-medical
coli	other-medical
``	O
.	O

Scopolamine	other-medical
(	O
Hyoscine	other-medical
)	O
has	O
anti-emetic	O
activity	O
and	O
is	O
,	O
therefore	O
,	O
used	O
to	O
treat	O
motion	O
sickness	O
.	O

When	O
international	O
vaccine	O
care	O
standards	O
were	O
being	O
designed	O
in	O
the	O
1970s	O
,	O
the	O
manuals	O
typically	O
generalized	O
from	O
the	O
needs	O
of	O
care	O
for	O
the	O
oral	other-medical
polio	other-medical
vaccine	other-medical
since	O
that	O
was	O
the	O
most	O
delicate	O
vaccine	O
in	O
wide	O
use	O
.	O

Recent	O
challenges	O
in	O
drug	O
testing	O
include	O
the	O
development	O
of	O
effective	O
regulatory	O
methods	O
for	O
the	O
newer	O
hormonal	O
products	O
such	O
as	O
the	O
various	O
human	other-medical
recombinant	other-medical
erythropoietin	other-medical
products	other-medical
and	O
variants	O
and	O
growth	other-medical
hormones	other-medical
.	O

Miglustat	other-medical
is	O
indicated	O
to	O
treat	O
adults	O
with	O
mild	O
to	O
moderate	O
type	O
I	O
Gaucher	other-disease
disease	O
for	O
whom	O
enzyme	O
replacement	O
therapy	O
is	O
unsuitable	O
.	O

Growth	other-medical
hormone	other-medical
deficiency	O
is	O
treated	O
by	O
replacing	O
GH	other-medical
.	O

Most	O
subjects	O
recovered	O
after	O
stopping	O
treatment	O
and	O
taking	O
potassium	other-medical
supplements	other-medical
.	O

Wright	person-scholar
had	O
open	O
heart	O
surgery	O
in	O
1983	O
,	O
spurring	O
an	O
interest	O
in	O
health	O
psychology	O
,	O
especially	O
in	O
the	O
relationship	O
between	O
Type	O
A	O
personality	O
and	O
cardiac	other-medical
rehabilitation	other-medical
.	O

Sarin	other-medical
acts	O
on	O
acetylcholinesterase	other-medical
by	O
forming	O
a	O
covalent	O
bond	O
with	O
the	O
particular	O
serine	other-biologything
residue	O
at	O
the	O
active	O
site	O
.	O

Substance	O
abuse	O
is	O
attributed	O
to	O
the	O
previously	O
damaged	O
relationship	O
between	O
Ward	person-artist,author
and	O
Bonz	person-artist,author
,	O
who	O
often	O
mentioned	O
marijuana	other-medical
in	O
the	O
band	O
's	O
live	O
shows	O
.	O

Chemotherapy	other-medical
for	O
ALL	other-disease
consists	O
of	O
three	O
phases	O
:	O
remission	O
induction	O
,	O
intensification	O
,	O
and	O
maintenance	O
therapy	O
.	O

Dihydrotestosterone	other-biologything
also	O
plays	O
an	O
important	O
role	O
in	O
male	O
sexual	O
function	O
and	O
may	O
also	O
be	O
a	O
contributing	O
factor	O
of	O
ischemic	other-disease
priapism	other-disease
in	O
males	O
as	O
shown	O
in	O
a	O
study	O
conducted	O
on	O
the	O
use	O
of	O
finasteride	other-medical
to	O
treat	O
ischemic	other-disease
priapism	other-disease
in	O
males	O
.	O

Carbamazepine	other-medical
is	O
relatively	O
slowly	O
but	O
well	O
absorbed	O
after	O
oral	O
administration	O
.	O

To	O
move	O
towards	O
international	O
standards	O
,	O
the	O
Breeders	organization-other
'	organization-other
Cup	organization-other
decided	O
to	O
eliminate	O
the	O
use	O
of	O
Lasix	other-medical
in	O
the	O
Juvenile	O
races	O
,	O
with	O
the	O
intention	O
of	O
extending	O
the	O
ban	O
to	O
other	O
races	O
in	O
subsequent	O
years	O
.	O

Enasidenib	other-medical
is	O
used	O
to	O
treat	O
relapsed	other-disease
or	other-disease
refractory	other-disease
acute	other-disease
myeloid	other-disease
leukemia	other-disease
in	other-disease
people	other-disease
with	other-disease
specific	other-disease
mutations	other-disease
of	other-disease
the	other-disease
IDH2	other-disease
gene	other-disease
,	other-disease
determined	O
by	O
an	O
FDA-	organization-other
approved	O
IDH2	O
companion	O
diagnostic	O
test	O
.	O

Propofol	other-medical
is	O
only	O
to	O
be	O
used	O
in	O
a	O
hospital	O
,	O
``	O
not	O
just	O
any	O
hospital	O
room	O
,	O
but	O
only	O
in	O
an	O
intensive	O
care	O
unit	O
or	O
procedure	O
room	O
,	O
by	O
specialist	O
personnel	O
''	O
(	O
an	O
anesthesiologist	O
present	O
throughout	O
its	O
use	O
)	O
.	O

Imatinib	other-medical
is	O
used	O
to	O
treat	O
chronic	other-disease
myelogenous	other-disease
leukemia	other-disease
(	O
CML	other-disease
)	O
,	O
gastrointestinal	other-disease
stromal	other-disease
tumors	other-disease
(	O
GISTs	other-disease
)	O
and	O
a	O
number	O
of	O
other	O
malignancies	O
.	O

Generally	O
speaking	O
,	O
routine	O
measurement	O
of	O
C-peptide	other-biologything
as	O
a	O
measure	O
of	O
insulin	other-medical
production	O
is	O
not	O
recommended	O
unless	O
there	O
is	O
genuine	O
doubt	O
as	O
to	O
whether	O
someone	O
has	O
type	O
1	O
or	O
type	other-disease
2	other-disease
diabetes	other-disease
.	O

Certain	O
medications	O
increase	O
the	O
risk	O
of	O
hyperglycemia	O
,	O
including	O
:	O
corticosteroids	other-medical
,	O
octreotide	other-medical
,	O
beta	other-medical
blockers	other-medical
,	O
epinephrine	other-medical
,	O
thiazide	other-medical
diuretics	other-medical
,	O
statins	other-medical
,	O
niacin	other-medical
,	O
pentamidine	other-medical
,	O
protease	other-medical
inhibitors	other-medical
,	O
L-asparaginase	other-medical
,	O
and	O
antipsychotics	other-medical
.	O

The	O
Australian	location-GPE
biotech	O
company	O
Giaconda	organization-company
combines	O
bezafibrate	other-chemicalthing
with	O
chenodeoxycholic	other-chemicalthing
acid	other-chemicalthing
in	O
an	O
anti-hepatitis	O
C	O
drug	O
combination	O
called	O
Hepaconda	other-medical
.	O

Blockade	O
of	O
COX-1	O
by	O
aspirin	other-medical
apparently	O
results	O
in	O
the	O
upregulation	O
of	O
COX-2	O
as	O
part	O
of	O
a	O
gastric	O
defense	O
and	O
that	O
taking	O
COX-2	O
inhibitors	O
concurrently	O
with	O
aspirin	other-medical
increases	O
the	O
gastric	O
mucosal	O
erosion	O
.	O

Taking	O
it	O
with	O
vitamin	other-medical
C	other-medical
has	O
been	O
investigated	O
as	O
a	O
method	O
of	O
protecting	O
the	O
stomach	O
lining	O
.	O

Patients	O
on	O
high	O
dose	O
sulfasalazine	other-medical
require	O
folic	other-medical
supplementation	O
(	O
1	O
mg/day	O
)	O
(	O
1000	O
µg/day	O
)	O
to	O
maintain	O
normal	O
cell	O
division	O
.	O

Fomivirsen	other-medical
(	O
brand	O
name	O
Vitravene	other-medical
)	O
is	O
an	O
antisense	O
antiviral	O
drug	O
that	O
was	O
used	O
in	O
the	O
treatment	O
of	O
cytomegalovirus	other-disease
retinitis	other-disease
(	O
CMV	other-disease
)	O
in	O
immunocompromised	O
patients	O
,	O
including	O
those	O
with	O
AIDS	other-disease
.	O